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Summary 
 
 
Alzheimer’s disease (AD) is a neurodegenerative disease that leads to progress cognitive 
loss and eventually to the complete loss of all daily functions. Described by its distinct 
neuropathological hallmarks - extracellular deposits of amyloid plaques and intracellular 
neurofibrillary tangles - the cause of sporadic Alzheimer’s disease remains to be fully 
understood. The misfolding, accumulation and deposition of β-amyloid, however, has 
emerged as a central component of the disease. Amyloid-lowering therapies are currently, 
therefore, undergoing wide investigation as a treatment strategy for Alzheimer’s disease. 
Other underlying molecular and cellular mechanisms are likely to be identified as key 
mediators or causative factors of disease, providing not only better understanding into the 
pathogenesis and progression of AD, but also drug discovery.  
 
Here we have investigated the therapeutic potential of anti-TNF and amyloid-lowering 
treatment approaches in transgenic mouse models of brain amyloidosis. In the first study we 
administered etanercept anti-TNF treatment either directly within the brain by 
intracerebroventricular (icv) infusion using ALZET osmotic minipumps, or systemically via 4 
weekly intraperitoneal injections. Infliximab and PBS treated mice served as controls, along 
with, non-treated transgenic and wildtype mice. Cognitive assessment of mice demonstrated 
a treatment dependent improvement in cognitive performance in two hippocampus-
dependent cognitive tests. Results from the biochemical analyses indicate that the 
improvement in cognition was not associated with changes in soluble brain Abeta levels but 
rather a decrease in formic acid insoluble Abeta levels. Histological analysis using Thioflavin 
S demonstrated a treatment-induced lowering of plaque number and the percentage area 
covered by plaques. Upon further histological investigations, etanercept icv-treated mice 
were further shown to display increased cerebral amyloid angiophathy (CAA) amyloid 
pathology, as compared to controls, suggesting a redistribution of parenchymal plaques 
towards the vasculature. The increase in CAA-pathology did not show signs of increased 
occurrence of micro-bleeds, however, with time, it remains unknown, if these vessels might 
deteriorate, lose their integrity and begin to bleed. Anti-TNF treatment was further shown to 
induce a reduction in astrocytosis and increase microglia activation. Our results support 
clinical findings that TNF-directed immunotherapy may successfully reverse cognitive deficits 
and provide further evidence into the underlying therapeutic mechanism.  
 
In a second study, we describe the selection of Aβ-specific designed ankyrin repeat proteins 
(DARPins) as a novel class of therapeutics for Alzheimer’s disease. DARPins are small and 
highly stable proteins with a compact modular architecture ideal for high-affinity protein-
protein interactions. Having identified a lead Aβ-specific DARPin candidate (D23) we were 
able to characterize in great detail the binding affinity, Aβ epitope recognition and binding 
kinetics of mono- and trivalent D23. We further showed their in vitro ability to delay Aβ 
aggregation and prevent Aβ-mediated neurotoxicity. To demonstrate their in vivo therapeutic 
potential we infused intracerebroventricularly D23 and 3xD23 into brains of 11 months old 
Tg2576 mice over four weeks. Both D23 and 3xD23 treatment were shown to result in 
improved cognitive performance and reduced soluble Aβ levels. Collectively, our findings 
provide proof-of-principle that Aβ-specific DARPins maybe used for the treatment of 
Alzheimer’s disease.   
 
To study the effects of the E693Δ APP mutation on Aβ accumulation and deposition in vivo, 
we generated a novel transgenic mouse model that overexpresses the human APP695 
isoform containing the “Swedish” (K670N+M671L) and E693Δ mutations under the control of 
the mouse PrP promoter. These newly developed E22ΔAβ mice were compared to the well-
established Tg2576 mouse line harboring the “Swedish” double mutation alone, and the 
ArcAβ mice, a mouse model recently developed in our laboratory that overexpresses the 
	  	  
	  
Swedish mutation and the Arctic (E693G) intra-Aβ APP mutation. All transgenic mouse lines 
and their respective littermate controls underwent extensive cognitive-behavioral 
assessments at three different ages before they were sacrificed for further biochemical and 
histopathological analyses. All three transgenic mouse lines, including the E22ΔAβ mice, 
showed early cognitive impairments in a panel of hippocampus-dependent cognitive tasks. 
As expected, ArcAβ and Tg2576 mice showed an age-dependent increase in amyloid plaque 
deposition that was associated with an increase of Aβ in SDS insoluble protein fractions. In 
contrast, histopathological and biochemical analyses in 15 month-old E22ΔAβ mice revealed 
a complete absence of extracellular amyloid deposition that was accompanied by prominent 
accumulation of intraneuronal Aβ species and early decreases in soluble Aβ levels. However, 
at 24 months of age, prominent vascular amyloid deposits were observed in cortical and – 
more pronounced – cerebellar leptomeningeal vessels of E22ΔAβ mice. Additional in vitro 
experiments with recombinant E22Δ Aβ peptides clearly demonstrated a strong propensity of 
the mutated Aβ species to form amyloid fibrils. Moreover, E22Δ Aβ42 showed a unique 
aggregation kinetics lacking exponential fibril growth and poor seeding effects on wildtype Aβ 
aggregation. These results provide a possible explanation for the recessive trait of 
inheritance of the E693Δ APP mutation and place this mutation on the list of other 
“vasculotropic” intra-Aβ APP mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	  	  
	  
Zusammenfassung 
 
 
Die Alzheimer-Krankheit ist die häufigste neurodegenerative Erkrankung und klinisch 
mit einer progredienten Abnahme kognitiver Fähigkeiten und im Verlauf 
vollständigem Verlust von Alltagsfunktionen sowie Selbständigkeit assoziiert. Obwohl 
die neuropathologischen Charakteristika der Erkrankung, extrazelluläre 
Ablagerungen von Amyloid-Plaques und intrazelluläre Anhäufungen von 
neurofibrillären Bündeln, bereits seit nunmehr über 100 Jahren bekannt sind, sind die 
Ursachen der weit verbreiteten sporadischen Form der Alzheimer-Krankheit immer 
noch unzureichend verstanden und weiterhin Gegenstand intensiver Forschung. Die 
Fehlfaltung, Akkumulierung und Ablagerung von beta-Amyloid wird heute von den 
meisten Wissenschaftlern als eine zentrale pathogenetische Komponente der 
Erkrankung angesehen. Verfahren, die darauf abzielen, beta-Amyloid im Hirn zu 
reduzieren, gehören daher zu den wichtigsten therapeutischen Strategien gegen die 
Alzheimer-Krankheit. Daneben ist jedoch davon auszugehen, dass sich mit der 
laufenden Identifizierung weiterer pathogenetisch wichtiger Krankheitsfaktoren 
diverse weitere (nicht Amyloid-basierte) Therapieansätze in absehbarer Zeit ergeben 
könnten.  
 
Im Rahmen dieser Doktorarbeit haben wir die Wirksamkeit zweier unterschiedlicher 
therapeutischer Ansätze in APP-transgenen Mausmodellen der Alzheimer-Krankheit 
studiert. In einer ersten Studie wurden die Effekte einer anti-TNF-Behandlung mit 
Etanercept untersucht, das 4 Wochen lang entweder kontinuierlich 
intracerebroventrikulär (icv) über ALZET osmotische Minipumpen oder systemisch 
durch wöchentliche intraperitoneale (ip) Applikationen (ebenfalls 4 Wochen lang) 
verabreicht wurde. Infliximab- und PBS-Vehikel-behandelte Mäuse sowie 
unbehandelte und nicht-transgene Mäuse wurden hierbei als Kontrollen 
herangezogen. Verhaltensanalysen ergaben therapieabhängige positive Effekte in 
zwei hippokampusabhängigen kognitiven Tests. In der biochemischen Analyse 
zeigte sich eine Abnahme von Detergens-unlöslichem beta-Amyloid, allerdings 
unveränderte lösliche beta-Amyloid-Spiegel. Die histologische Analyse ergab eine 
therapieabhängige Reduktion der Amyloid-Plaque-Zahl sowie des Gesamt-Amyloid-
Loads. Darüber hinaus zeigten die APP-transgenen Mäuse, die icv mit Etanercept 
behandelt worden waren, im Vergleich zu den Kontrollmäusen eine Zunahme von 
vaskulärem Amyloid (CAA). Letzteres ist ein möglicher Hinweis darauf, dass die 
Behandlung mit Etanercept zu einer Umverteilung von Amyloid von parenchymalen 
Plaques zum Gefässamyloid geführt haben dürfte. Die Zunahme von CAA in den 
behandelten Mäusen war allerdings nicht mit einer Zunahme von Mikroblutungen 
assoziiert. Desweiteren war die Behandlung mit Etanercept mit einer Abnahme der 
Astrogliose und einer Zunahme der Mikrogliaaktivierung assoziiert. 
Zusammengefasst unterstützen die Resultate dieser Studie die aktuellen klinischen 
Befunde, wonach anti-TNF-basierte Immuntherapien einen günstigen Effekt auf die 
Kognition bei Patienten mit einer Alzheimer-Krankheit haben können; sie liefern 
darüber hinaus Einblicke in mögliche zugrundeliegende therapeutische 
Mechanismen.  
 
In einer zweiten Studie haben wir die therapeutische Wirksamkeit von beta-Amyloid-
spezifischen „Designed Ankyrin Repeat Proteins“ (DARPins) in einem Mausmodel 
	  	  
	  
der Alzheimer-Krankheit untersucht. DARPins gehören zu einer neuartigen Klasse 
von Therapeutika mit verschiedenen vorteilhaften biochemischen Eigenschaften, zu 
denen neben der relativ kleinen Molekülgrösse und der hohen Stabilität auch der 
modulare Molekülaufbau gehört, der für die hochaffine Protein-Protein-Interaktion 
verantwortlich ist. Im Rahmen unserer Experimente haben wir das beta-Amyloid-
spezifische DARPin D23 identifiziert, haben dessen Bindungsaffinität, die Abeta-
Erkennungsdomäne sowie die Bindungskinetiken von monovalentem D23 versus 
trivalentem D23 beschrieben. In vitro-Analysen konnten einen inhibitorischen Effekt 
von D23 auf die Abeta-Aggregation und Abeta-vermittelte Neurotoxizität zeigen. Um 
das therapeutische Potential von Abeta-spezifischen DARPins in vivo zu 
untersuchen, wurden APP-transgene Tg2576-Mäuse 4 Wochen lang mit 
monovalentem (D23) und trivalentem DARPin (3XD23) icv behandelt. Dabei führte 
sowohl die Behandlung mit D23 als auch die Behandlung mit 3XD23 zu einer 
signifikanten Verbesserung der kognitiven Defizite, was mit reduzierten Spiegeln von 
Detergens-löslichem Abeta einherging. Diese Experimente belegen erstmals in vivo 
den potentiellen therapeutischen Nutzen von Abeta-spezifischen DARPins in der 
Behandlung der zerebralen Beta-Amyloidose.  
 
Im Rahmen unseres dritten Projekts haben wir die Effekte der erst kürzlich 
entdeckten familiären APP-Mutation E693Δ auf die Akkumulierung und die 
Ablagerung von beta-Amyloid in vivo untersucht. Dazu haben wir ein neues APP-
transgenes Mausmodell generiert, das die humane APP695-Isoform mit der E693Δ-
Mutation sowie der Schwedischen (K670N+M671L) Doppelmutation unter der 
Kontrolle des Maus-PrP-Promotors überexprimiert. Diese neu generierten E22ΔAβ-
Mäuse wurden mit dem etablierten Tg2576-Mausmodell, das die Schwedische 
Mutation allein exprimiert, und dem in unserem Labor entwickelten arcAβ-
Mausmodell (Expression von Schwedischer Mutation + „Arctic“ intra-Abeta-APP-
Mutation (E693G)) verglichen. Alle drei transgenen Linien, einschliesslich den 
E22ΔAβ-Mäusen, zeigten frühe kognitive Beeinträchtigungen in einem Panel von 
hippokampus-abhängigen kognitiven Tests. Wie zu erwarten war, zeigten arcAβ- und 
Tg2576-Mäuse eine altersabhängige Anhäufung von Amyloid-Plaques, die mit einem 
Anstieg von Detergens-unlöslichem beta-Amyloid im Hirn korrelierte. Dagegen 
konnten bei den E22ΔAβ-Mäusen bis zu einem Alter von 15 Monaten überhaupt 
keine extrazellulären Amyloid-Ablagerungen nachgewiesen werden, dagegen eine 
frühe Akkumulierung von intrazellulärem Abeta und reduzierte lösliche Abeta-
Spiegel. Im Alter von 24 Monaten waren allerdings auch bei den E22ΔAβ-Mäusen 
prominente extrazelluläre Amyloid-Ablagerungen in Form kortikaler und v. a. 
cerebellärer leptomeningealer vaskulärer Ablagerungen nachweisbar. Zusätzliche in 
vitro-Experimente konnten zudem zeigen, dass E22Δ-mutierte Aβ-Spezies in der Tat 
eine hohe Aggregationsbereitschaft und Fähigkeit zur Amyloid-Fibrillenbildung 
aufweisen. Darüber hinaus konnte bei E22Δ Aβ42 eine einzigartige 
Aggregationskinetik dokumentiert werden, die u. a. durch ein Fehlen der 
exponentiellen Wachstumsphase und schlechte „Seeding“-Eigenschaften 
charakterisiert ist, was eine mögliche Erklärung für das späte Auftreten von 
extrazellulären Amyloid-Ablagerungen und die rezessive Vererbung der E693Δ-
Mutation darstellen könnte.  
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1 Introduction 
 
 
1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that results in 
dementia. The neuropathological hallmarks of AD include β-amyloid plaques, 
composed of extracellular deposits of the 4 kDa Aβ40 and the more amyloidogenic 
Aβ42, as well as neurofibrillary tangles (NFT), consisting of intraneuronal filaments of 
hyperphosphorylated tau protein, as well as, pronounced astrocytosis and activated 
microglia (Figure 1).  These pathological hallmarks were first described in 1906 by 
the German psychiatrist Alois Alzheimer, following detailed pre-mortem clinical 
observations and post-mortem neuropathological examination of his patient Auguste 
Deter. The next major breakthrough in understanding AD pathology came 70 years 
later when it was discovered that the brains of AD patients demonstrated reduced 
levels of acetylcholine (for review see, Schliebs et al., 2010). These discoveries lead 
to the first ever treatment for AD with Tacrine and other cholinesterase inhibitors 
(Rivastigmine, Donepezil and Galantamine). It was later determined biochemically 
that beta-amyloid (Aβ) was the pathologic protein constituting extracellular amyloid 
plaques, leading to the so-called amyloid cascade hypothesis in which amyloid-beta 
serves a central role in AD pathogenesis (for review see Aguzzi and O’Connor 2010; 
Hardy et al., 2002).  
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Figure 1. Histopathological hallmarks of AD. A) Photomicrograph depicting extracellular aggregates of 
β-amyloid in brain parenchyma tissue and B) the intracellular accumulation of hyperphosporylated 
microtubule associated protein tau as neurofibrillary tangles (NFT) (modified from: Aguzzi and O’ 
Connor, 2010) 
 
Aβ is derived from the amyloid precursor protein (APP), a membrane-spanning 
protein, by two sequential secretase activities, γ- and β-secretase (Figure 2). In both 
in vitro and in vivo experiments, it has been widely shown that synthetic, as well as, 
naturally derived Aβ peptides can inhibit hippocampal long-term potentiation (LTP) 
and facilitate long-term depression (Li et al., 2009; Townsend et al., 2006; Walsh et 
al., 2002), impair memory in animal models (Clearly et al., 2005; Lesne et al., 2006; 
Shankar et al., 2008) and disrupt synaptic function and structure (Lacor et al., 2007).  
The most compelling evidence to support the amyloid cascade hypothesis, however, 
has come from genetic studies in which rare familial early onset autosomal dominant 
forms of AD (FAD) have been linked to missense mutations in the amyloid beta-
peptide precursor protein (APP) or the presenilin (PS1 and PS2) genes (for review 
see, Bertram et al, 2008; Bertram et al., 2010; Rademakers et al., 2009). All of these 
FAD mutations were shown to invariably increase the production of Aβ42, the longer 
and more toxic variant of the Aβ peptide which readily forms amyloid aggregates. 
The Swedish double mutation (K670N/M671L), for example, located upstream from 
the Aβ N-terminus adjacent to the β-cleavage site, results in an increased production 
of both Aβ40 and Aβ42 species, whereas mutations located at the γ-cleavage site of 
APP cause an increase of the Aβ42/Aβ40 ratio and, as a consequence of this, result 
in increased Aβ aggregation and deposition (Bertram et al, 2008; Bertram et al., 
2010; Rademakers et al., 2009). The recently discovered E22Δ (E693Δ) mutation 
(Tomiyama et al., 2008) is one of the six so-called “intra-Aβ” mutations clustered 
around the hydrophobic core of the Aβ sequence (at position 22±1). Position 22 
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seems to be a critical site involved in pathogenic aggregate formation since 
mutations at or (±1) around this site including the Dutch (E22Q) (Levy et al., 1990), 
Flemish (A21G) (Hendriks et al., 1992), Italian (E22K) (Miravalle et al., 2000), Iowa 
(D23N) (Grabowski et al., 2001) and Arctic (E22G) (Nilsberth et al., 2001) mutations 
have been reported to result in an increase in total Aβ production (Haass et al., 1994) 
and – with the exception of the Flemish mutation – enhance Aβ aggregation and 
toxicity (Fraser et al., 1992; Murakami et al., 2003).  
 
Figure 2. Amyloid-β formation. A) Amyloid-β (Aβ) peptide is generated following the serial proteolytic cleavage of 
the amyloid precursor protein (APP) by β- and γ-secretases. B) The non-amyloidogenic pathway results in the 
formation of secreted APP (APPsα) and internalized C83 following α-secretases cleavage, in which subsequently 
γ-cleavage takes place and the formation of p3 and APP intracellular domain (AICD) occurs (modified from: 
Aguzzi and O’ Connor, 2010). C) Proposed mechanisms leading to Aβ fibrillization, in which following the 
proteolytic cleavage of APP, soluble Aβ peptides begin to form abnormal β-sheet conformations which increase 
their likelihood of forming more structured dimer aggregates and small oligomers, these aggregates then act as 
seeds promoting the formation of protofibrils and fibrils and the eventual formation of insoluble extracellular 
amyloid plaques. 
 
1.2 Brain aging and neurodegeneration  
Aging is a major risk factor for the development of Alzheimer’s disease, as well as 
other neurodegenerative disease including, Parkinson’s disease, amyotrophic 
laterals sclerosis and others. Because the prevalence of both genetic and sporadic 
forms of most neurodegenerative diseases increases with age, factors associated 
with senescence are involved in their etiologies. An emerging body of evidence 
indicates that immune senescence plays an important role in modulating age-
associated changes in neuronal function. Immune senescence results in 
progressively impaired functions of innate and adaptive immunity, but also in 
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decreased tolerance, chronic inflammation, and accelerated inflammatory-stress 
responses. Dysfunctional senescent microglia up-regulate pro-inflammatory 
cytokines maintaining low-grade inflammation within brain and reactive astrocytosis 
impairs neurovascular coupling and synaptic regulation. As a result, the expression in 
the central nervous system of genes related to stress, oxidative damage and 
inflammatory response pathways increase with progressive aging (Lu et al., 2004; 
Yanker et al., 2008).  
The aging brain is further challenged by progressive DNA damage (McKinnon, 2009), 
mitochondrial dysfunction (DiMauro et al., 2008), oxidative stress (Barnham et al., 
2004), environmental and stress-induced epigenetic changes, altered gene and 
regulatory RNA expression (Bushati et al., 2008; Nelson et al., 2008; Yanker et al., 
2008), impaired protein degradation processes (autophagy and proteasome 
pathways) (Rubinsztein, 2006) and the accumulation of iron, among others. In short, 
age-dependent accumulation of mitochondrial DNA mutations has been associated 
with mitochondrial dysfunction, ATP/energy deficits, oxidative stress, impaired Ca2+ 
homeostasis, brain aging and neurodegeneration (Lin et al., 2006: Reeve et al., 
2008).  Moreover, with age iron accumulates progressively within the brain and in 
Parkinson’s disease, Alzheimer’s disease and other neurodegenerative diseases, 
iron promotes inflammation, oxidative stress, neuronal dysfunction and the 
production and aggregation of misfolded proteins (Zecca et al., 2004). Protein-
degradation activities, including, autophagy (macroautophagy, microautophagy and 
chaperone-mediated autophagy) and ubiquitin-proteasome pathways, decrease with 
age and are commonly associated with neurodegenerative diseases, including 
Alzheimer’s disease, Parkinson’s disease, and Huntingtin’s disease (Rubinsztein, 
2006; Wong et al., 2010). These compromised protein-degradation pathways result 
in the accumulation of misfolded aggregation-prone proteins, intracellular aggregates 
and cell death (Martinez-Vicente et al., 2007). Lastly, the role of misfolded protein 
aggregates in neurodegenerative disease has long been postulated, with some of the 
first neuropathological descriptions of intracellular inclusion bodies and extracellular 
plaques being described in postmortem brains of neurodegenerative patients over a 
century ago.  Extensive molecular, cellular and genetic evidence has since 
accumulated to support the role of misfolded aggregation-prone proteins with 
neurotoxic properties in neurodegenerative diseases (Aguzzi et al., 2010; Forman et 
al., 2004; Haass et al., 2007), including β-amyloid in Alzheimer’s disease (AD); tau in 
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AD, frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), Pick’s 
disease and other tauopathies; α-synuclein in Parkinson’s disease (PD) Lewy body 
dementia (LBD) and Multiple Systems Atrophy (MSA); huntington in Huntington’s 
disease; and superoxide dismutase in Amyotrophic lateral sclerosis; among others.  
 
1.3 Immune Senescence and neurodegeneration 
With progressive aging, the production of naïve lymphocytes decreases, thymic 
involution occurs, peripheral lymphoid tissues shrink in volume and the accumulation 
of incompetent memory lymphocytes increases resulting in reduced adaptive 
immunity, poor vaccination response and greater susceptibility to infection and 
disease (Nikolich-Zugich, 2008).  Compromised B and T cell functions can also lower 
the immune system’s ability to differentiate ‘self’ from ‘foreign’ antigens, thus leading 
to the development of ‘destructive’ autoimmune responses. Alternatively, these 
changes in B and T cell function may lead to decreased ‘protective’ autoimmunity, 
with less B-cell and T-cell reactions against brain antigen and reduced naturally-
occurring human conformation-specific antibodies (Szabo et al 2008; Neff et al., 
2008, Kellner et al., 2009) reacting with pathology aggregates of misfolded proteins 
with toxic properties and thus impaired protection against the development of 
neurodegenerative diseases (Bhat et al., 2009; Diamond et al., 2009).  
In addition to reduced adaptive immunity, progressive aging is associated with 
impaired innate immunity and a low-grade chronic inflammatory state (Shaw et al., 
2010). Senescence of brain-to-immune communication pathways activate the 
hypothalamus-pituitary-adrenal axis and increase glucocorticoids to neurotoxic 
concentrations resulting in neuronal damage, hippocampal atrophy, cognitive decline, 
depressive episodes and the risk of developing neurodegenerative diseases, such as 
AD (Sorrells et al., 2007; Sotiropoulos et al., 2008). Furthermore, age-related 
changes in microglia function can promote low-grade inflammation, exaggerate 
cognitive liabilities following inflammatory responses and promote neurodegeneration 
(Block et al., 2007; Fiala et al., 2007). Indeed, chronic low-grade inflammation during 
aging has been associated with increased mortality, cognitive decline and 
neurodegeneration, with numerous results indicating increased levels of such pro-
inflammatory cytokines as IL-1, IL-6 and TNF, chemokines and acute phase proteins, 
in serum, plasma and CSF of elderly subjects (Alvarez et al., 2007; Bermejo et al., 
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2008; Schram et al., 2007; Gimeno et al., 2008; Reuben et al., 2002). Not 
surprisingly, systemic immune and inflammatory alterations have been described in 
Alzheimer’s disease and ALS (Mantovani et al., 2009; Zhang et al., 2005) among 
others, with acute systemic immune challenges often reported as the main cause of 
delirium in elderly populations (Perry et al., 2007). Immune interventions that target 
these age-associated immunological components are of therapeutic importance for 
neurodegenerative diseases and currently the subject of considerable investigation 
(Dorshkind et al., 2009; Popovich et al., 2008; Weksler et al., 2009). 
 
1.4 Role of glial cell-related immunosenescence in neurodegeneration  
Glial cells are essential for normal brain development and function; they actively 
participate in neuronal plasticity and repair (Halassa et al., 2007), neurotrophic 
support, myelination, neurovascular coupling and the formation of the blood-brain 
barrier (BBB) (Zlokovic, 2008) and immune surveillance (Bains et al., 2007; Barres, 
2008; Allen et al., 2009). During disease states, however, compromised glial cell 
function can have detrimental consequences on brain function and cognition. Age-
related changes in glial function can also impair neuronal function, exaggerate 
inflammatory responses following infection or CNS injury and contribute to 
neurodegeneration (Jimenez et al., 2008; Solano et al., 2008).  Microglia serve 
multiple functions as resident macrophages within the CNS that express Fc receptors 
for IgG uptake, MHC glycoproteins, complement components and scavenger 
receptors, as well as, the secretion of cytokine and chemokine (Barres, 2008; 
Ransohoff et al., 2009). Evidence strongly supports the important role of microglial in 
immune surveillance, phagocytosis and immunological defense against pathogens 
and environmental insults within the CNS (Graeber, 2010; Hanisch et al., 2007; 
Kettenmann, 2007). In health, during ‘resting’ and ‘surveying’ states, microglia 
display neuroprotective properties, release growth factors, repair local 
microenvironment damage and continuously monitor their surroundings by extending 
and retracting their processes. However, following injury or immune activation, 
‘activated’ microglia become highly mobile and migrate to areas of injury, where they 
participate in phagocytosis and repair. Activated microglia also exert inflammatory 
responses characterized by the upregulation and secretion of pro-inflammatory 
cytokines (IL-1, IL-6 and TNF), chemokines and reactive oxygen species. Age-related 
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changes in microglia structure and phenotype (Figure 3) include spheroidal swelling, 
beaded or deramified processes (Streit, 2006; Streit et al., 2008), and associated 
impairment in phagocytic functions, heightened inflammatory responses and 
decreased production of neurotrophic factors (Jimenez et al., 2008).  
 
 
 
Figure 3. Microglial structure and phenotypes. Resident microglia can become activated to adopt one of many 
diverse phenotypes throughout aging, stage of disease and many other variables.  The first phase of the microglial 
life cycle during stage 1 involves acquisition of the HLA-DR-positive phenotype. There are two possible pathways: 
HLA-DR-positive perivascular cells differentiate to become HLA-DR-positive ramified microglia and/or HLA-DR-
negative microglia become HLA-DR-positive. Trans-differentiation of perivascular cells into ramified microglia is likely 
to be a minor pathway. During stage 2, ramified HLA-DR-positive microglia begin to show dystrophic changes by 
developing spheroidal swellings and beaded or deramified processes. They might also aggregate to form rod cells or 
other multi-cellular aggregates. During stage 3, degenerative changes such as fragmentation (cytorrhexis), loss of 
processes (atrophy) and apoptosis can occur. The exact sequence of this progression has not yet been determined. 
Adopted from Streit, 2006. 
 
Given the essential role microglia-mediated phagocytosis serves in clearance of 
cellular debris and triggering repair following injury, impaired phagocytosis has 
profound implications for the accumulation of abnormal deposits of misfolded 
proteins associated with neurodegenerative diseases (Neumann et al., 2009: Perry et 
al., 2010).  In a mouse model of brain amyloidosis newly formed beta-amyloid 
plaques recruit microglia to the site and induce microglia activation (Meyer-
Luehmann et al., 2008). Microglia-mediated clearance of beta-amyloid is strongly 
activated in the presence of specific IgG antibodies allowing for substrate recognition 
and Fc-mediated phagocytosis (Bard et al., 2000). Indeed, following the 
administration of immunotherapy in both humans and mice, microglia have been 
demonstrated to participate in the phagocytosis of Abeta (Wisniewski et al., 2008). 
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Moreover, immunization may alter phagocyte functions, enabling microglia to 
efficiently phagocytose Abeta through both Fc-mediated phagocytosis and Fc-
independent mechanisms (Boche et al., 2008; Brody et al., 2008; Koenigsknecht-
Talboo et al., 2008). Finally, evidence indicates that the trafficking of peripheral 
monocytes into the brain promotes the clearance of Abeta, provides neuroprotective 
support and delays the progression of AD (El Khoury et al., 2008; El Khoury et al., 
2007; Simard et al., 2006); however some experimental confounds have been raised 
(see Davoust et al., 2008; Ransohoff, 2007; Ransohoff and Perry, 2009). 
In the presence of toxic misfolded forms of Abeta, aged microglia react with 
exaggerated inflammatory responses, increased reactive oxygen species production 
and neurotoxicity, as compared to young microglia (Leung et al., 2009).  In support of 
these findings, a clinical study by Edison et al (2008), demonstrated using PiB-PET 
and [11C](R)PK11195-PET that microglial activation was associated with increased 
beta-amyloid plaque load and cognitive dysfunction. Taken together, these findings 
suggest that while there are roles of microglia in surveying the brain for, and clearing 
of, toxic misfolded proteins, their age-related changes predispose them for 
overshooting responses to misfolded proteins with detrimental downstream 
consequences for neuronal function and integrity. Impaired phagocytosis, chronic 
inflammation and microglia-mediated neurotoxicity might therefore represent three 
aspects of age-dependent changes in microglia function that result in accumulation of 
misfolded proteins and neurodegeneration (Block et al., 2007; Fiala et al., 2007). 
However the involvement of microglia in the formation, maintenance and clearance of 
misfolded protein monomers, higher-order aggregates and plaques remains to be 
fully understood (Grathwohl et al., 2009; Mandrekar et al., 2009; Ransohoff and 
Perry, 2009).  
Similarly, astrocyte functions can deteriorate during aging, leading to compromised 
BBB function, impaired neurovascular coupling, decreased neurotrophic support, 
excitotoxicity and compromised neuronal transmission and synaptic regulation (Wang 
et al., 2008). Astrocytes are the most abundant glial cell in the brain and have been 
widely recognized to serve several physiological functions that are necessary for 
brain development, function and repair (see Wang et al., 2008 for a review). Besides 
their roles in neuronal processing, synaptic integration, synaptogenesis, synaptic 
plasticity (Bains et al., 2007; Halassa et al., 2007; Turrigiano, 2006), astrocytes also 
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serve a key role in CNS innate immunity and inflammatory responses, by expressing 
Toll-like receptors involved in pathogen recognition and participating in phagocytosis 
(Farina et al., 2007: Wyss-Coray et al., 2003). Indeed, under pathophysiological 
conditions such as infection, injury and neurodegeneration, reactive astrocytes can 
exert immune and inflammatory responses by expressing and secreting a wide range 
of immunological factors, such as, complement factors, acute phase reactants, 
adhesion molecules, major histocompatibility complex (MHC) class I and II 
glycoproteins, cytokines and chemokines. Reactive astrocytes can also aid the 
recruitment of immune cells from the periphery by modifying BBB permeability. 
Finally, astrocytes serve an important role in neuronal survival and regeneration by 
providing neurotrophic support with growth factors, such as NGF, BDNF, GDNF and 
IGF-1. Loss of neurotrophic support can induce DR6-mediated axonal self 
destruction and neuronal death (Nikolaev et al., 2009); at least during 
neurodevelopment.  More specifically, neurotrophic deprivation triggers the release of 
N-APP, a 35kDa APP fragment generated from sAPPbeta by an unknown 
mechanism, following the cleavage of APP by beta-secretase. N-APP then binds 
DR6 to induce axonal self destruction via caspase 6 and neuronal death via caspase 
3). 
 
1.5 Role of inflammatory cytokines in physiology and neurodegeneration 
1.5.1 Cytokines, synaptic plasticity and cognitive function 
Immune signalling factors including cytokines, chemokines, complement proteins and 
other immune molecules serve essential roles within the brain such as neuronal 
development and synaptic plasticity (Di Filippo et al., 2008; McAfoose et al., 2009; 
Yanamadala et al., 2010). Chemokines, in particular, exert neuromodulator 
properties (Rostene et al., 2007) and cytokines, namely IL-1, IL-6 and TNF, under 
non-immune challenged conditions participate in several forms of synaptic plasticity 
such as, Hebbian plasticity (Malenka et al., 2004), synaptic scaling (Burrone et al., 
2003; Perez-Otano et al., 2005; Turrigiano, 2007), and adult neurogenesis (Bruel-
Jungerman et al., 2007a; Bruel-Jungerman et al., 2007b), that promote memory 
consolidation and cognition; for review see (Di Filippo et al., 2008; McAfoose et al., 
2009).  
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For example, growing evidence (Balschun et al., 2004; Li et al., 1997; Tancredi et al., 
2000; Jankowsky et al., 2000; Avital et al., 2003; Schneider et al., 1998; Spulber et 
al., 2009) suggests that IL-1 and IL-6 participates in long-term potentiation (LTP), a 
form of Hebbian synaptic plasticity, and memory consolidation processes. Essentially 
this process can be divided into three stages (Figure 4). In stage 1, the simultaneous 
neuronal activity (firing) of both pre-synaptic and post-synaptic neurons results in the 
induction of LTP. This induction of LTP, in stage 2, can lead to the production of both 
IL-1 and IL-6 (Jankowsky et al., 2000). Finally in stage 3, LTP maintenance is fine-
tuned by the overall level or net expression of both IL-1 and IL-6. More specifically, 
evidence (Schneider et al., 1998; Coogan et al., 1999; Ross et al., 2003) suggests 
that increased local production of IL-1 in the hippocampus facilitates LTP 
maintenance, whereas, IL-6 blocks LTP maintenance by opposing, in a negative 
feed-back fashion, the effects of IL-1 on LTP maintenance (Balschun et al., 2004). 
Collectively, these processes interact to influence memory consolidation and learning 
processes.  
Indeed, cognitive-behavioural research in mice and rats has demonstrated that IL-1 
and IL-6, under physiological conditions, participates in hippocampal-dependent 
memory processes (Brennan et al., 2003; Yirmiya et al., 2002; Hryniewicz et al., 
2007; Baier et al., 2009), with evidence (Avital et al., 2003) to support the link 
between synaptic plasticity and memory function. However, during stress, aging and 
disease, increased levels of IL-1 and IL-6 appear to elicit memory impairment 
(Godbout et al., 2004; Pugh et al., 2001), suggesting that deviations in physiological 
IL-1 and IL-6 concentrations result in impaired memory (Goshen et al., 2007; Avital et 
al., 2003).  
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Figure 4. Schematic showing the involvement of IL-1 and IL-6 in long-term potentiation (LTP) synaptic 
plasticity. In short, the simultaneous neuronal activity (firing) of both pre-synaptic and post-synaptic 
neurons results in the induction of LTP. This induction of LTP leads to the production of both IL-1 and 
IL-6, which according to the overall level of expression of both IL-1 and IL-6 will either facilitate or inhibit 
the maintenance of LTP, respectively. This fine-tuning of LTP by IL-1 and IL-6 ultimately influences the 
consolidation of learning and memory. Adapted from McAfoose & Baune, 2009. 
 
Tumor necrosis factor alpha (TNF) also exerts multiple biological functions within the 
brain, including, neuromodulation (Szelenyi, 2001; Vitkovic et al., 2000a; Vitkovic et 
al., 2000b), glutamate transmission (Pickering et al., 2005), dendritic branching 
(Neumann et al., 2002) and both Hebbian and non-Hebbian (synaptic scaling) 
synaptic plasticity (Albensi et al., 2000; Beattie et al., 2002; Stellwagen et al., 2005; 
Stellwagen et al., 2006). In particular, TNF participates in synaptic scaling, a non-
Hebbian form of synaptic plasticity which has been shown to stabilize the activity of 
neurons and networks (Bains et al., 2007; Stellwagen et al., 2006; Turrigiano, 2007) 
(Figure 5). In short, during prolonged neuronal inactivity, which leads to a decrease in 
synaptic strength, the release of TNF by astrocytes is induced by glial-neuronal 
communication processes (Stellwagen et al., 2006). In a hemeostatic fashion, the 
released TNF by astrocytes increases post-synaptic neuron activity, thus, increasing 
or scaling-up the synaptic strength of the post-synaptic neuron. Collectively, this 
helps to maintain neuronal activity and learning and memory functions.  
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Figure 5. Schematic showing the involvement of TNF in synaptic scaling. In brief, a prolonged period of 
neuronal inactivity leads to a decrease in synaptic strength, which triggers, via glial–neuronal 
communication, the release of TNF by astrocytes. The released TNF by astrocytes in turn induces an 
increase in synaptic strength of the post-synaptic neuron; which helps to maintain neuronal activity 
(synaptic scaling) and promote learning and memory functions. Adapted from McAfoose & Baune, 2009. 
 
As shown by Baune and others (2008a), the presence of TNF, in mice, during 
physiological conditions is essential for normal functions of memory and learning. 
Subsequent research by McAfoose et al (2008), showed that although the initial 
absence of TNF in transgenic knockout mice (TNF-/-) is cognitively detrimental, with 
age TNF deficiency appears to be cognitively beneficial. Although the biological 
mechanisms underlying this change in cognitive profile remain to be determined, the 
behavioural results alone suggest a possible role for TNF in neurocognitive aging. 
Indeed, in healthy elderly humans it was reported (Baune et al., 2008b) that genetic 
variants of TNF may have protective effects in cognitive function. In transgenic mice 
the over-expression of TNF is detrimental, with both pathological changes in brain 
and cognitive impairment demonstrated (Aloe et al., 1999; Campbell et al., 1997).  
 
1.5.2 Neurodegenerative Properties 
Within the brain inflammatory factors can exert physiological, protective and 
neurodegenerative properties (see Figure 6). Indeed, chronic inflammation has been 
widely characterized in neurodegenerative diseases, however, some debate remains 
as to whether these inflammatory processes play a causal, bystander or beneficial 
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role in disease (Wyss-Coray, 2006). What is known is that with age levels of 
inflammatory factors, such as pro-inflammatory cytokines (IL-1, IL-6 and TNF) and 
chemokines, increase resulting in chronic low-grade inflammation. In particular, glial-
mediated chronic inflammation can exert neurotoxicity, promote the production and 
aggregation of abnormal proteins, disrupt neurogenesis and impair synaptic 
plasticity. Moreover, microglial senescence and associated chronic inflammation, can 
profoundly impair brain function and contribute to cognitive decline and the 
development of neurodegenerative diseases (Streit, 2006; Streit et al., 2008). Toxic 
soluble and aggregated proteins associated with neurodegenerative diseases, such 
as beta-amyloid (Aβ), tau, alpha-synuclein and prion protein can activate glia cells 
and induce neuroinflammation and brain pathology. 
In Alzheimer’s disease, for example, oligomeric forms of Aβ can activate the innate 
immune system and trigger inflammatory responses in microglia and astrocytes that 
can lead to further Aβ accumulation, tau phosphorylation, neurotoxicity, oxidative 
stress and synaptic dysfunction (Salminen et al., 2009).  In particular, cytokines IL-1, 
TNF and IFN-γ can modulate γ-secretase activity and the production of Aβ via JNK-
dependent MAPK pathway (Liao et al., 2004). In transgenic mice harboring the 
Swedish mutation, TNF and IFN-γ regulate Aβ deposition and β-secretase (BACE1) 
expression (Yamamoto et al., 2007). NFκB-mediated pathways and peroxisome 
proliferated activated receptor-γ (PPARγ) serve an important role in pro-inflammatory 
cytokine modulation of BACE1 activity and expression (Sastre et al., 2008). Similarly, 
research by Medeiros and colleagues (2007) demonstrated in mice that both 
pharmacological (anti-TNF antibody and aminoguanidine) and genetic (knockout 
mice) blockage of TNF and iNOS reduced cognitive deficits evoked by Aβ. In support 
of such findings, He et al. (2007) demonstrated that the deletion of TNF R1 gene in 
APP23 transgenic mice (APP23/TNFR1-/-) inhibits Aβ generation and prevents 
memory deficits.  
Given the role of cytokines in synaptic plasticity and learning and memory processes 
(Di Filippo et al., 2008; McAfoose et al., 2009), it is not surprising that increased 
cytokine levels in the brain have been shown to disrupt synaptic plasticity and 
cognitive functioning (Butler et al., 2004; Goshen et al., 2007). In Alzheimer’s 
disease, evidence indicates that TNF mediates Aβ induced suppression of long-term 
potentiation (LTP) (Wang et al., 2005). In support of these findings it was recently 
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demonstrated by Rowan and colleagues (2007) that neutralizing TNF using 
infliximab, thalidomide and a TNF peptide antagonist prevented Aβ induced inhibition 
of LTP.  It was also shown by these authors that mice deficient in TNF receptor 1 
(TNF R1 knockout mice) do not display any Aβ inhibitory effects on LTP induction; 
suggesting a key role of TNF R1 in TNF-mediated inhibition of LTP. It is also thought 
that prolonged Aβ induced suppression of synaptic activity can lead to excessive 
release of TNF by astrocytes, resulting in synaptic dysregulation (Small, 2008; 
Tobinick, 2008). Interestingly, this would suggest that a physiological function of TNF 
(synaptic scaling) and not an inflammatory or pathophysiological process of TNF, 
might be contributing to AD pathology and cognitive dysfunction. Although this 
remains to be fully clarified, cognitive-behavioural data obtained from mice indicated 
that anti-TNF treatment using thalidomide prevents Aβ induced memory impairment 
(Alkam et al., 2008). Moreover, it was demonstrated in a recent study by Tobinick 
and others (Tobinick et al., 2008) , that once weekly perispinal injection of etanercept 
(a TNF antagonist) resulted in rapid cognitive improvement in a late-onset AD patient.   
 
	  
Figure 6. Schematic showing neurodegenerative, neuroprotective and physiological properties of 
cytokines and chemokines, within the central nervous system. During pathological conditions activated 
microglial and reactive astrocytes release ‘pro-inflammatory’ cytokines, such as, IL-1, IL-6 and TNF, that 
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interact with neurons and other glial cells, to induce a neuroinflammatory response that leads to the 
production of reactive oxygen species and lowered neurotrophic factors levels (i.e. NGF, BDNF and 
GDNF). Collectively, these inflammatory processes alter the normal balance and physiological function 
of neurons resulting in synaptic dysfunction, excitotoxicity and cell death. In Alzheimer’s disease it is 
believed that an up-regulation of cytokines can exacerbate or facilitate the production of amyloid beta 
peptides, their fibrillization, and amyloid deposition. This positive feedback loop leads to further 
activation of glial cells and further up-regulation of cytokines. These same cytokines can also exert 
neuroprotective properties within the CNS; although typically such properties are attributed to the 
release of ‘anti-inflammatory’ cytokines, such as, IL-4 and IL-10. Moreover, during normal physiological 
conditions the release of IL-1, IL-6 and TNF  participate in several forms of synaptic plasticity thought to 
facilitate learning and memory. 
 
1.6 Brain-immune interactions in the protection against neurodegeneration 
Brain-immune functions are governed by complex bi-directional communication 
pathways between the immune and central nervous system and specialized 
mechanisms for the tight control of immune responses. While there is no equivalent 
to lymphatic vessels in the brain, evidence indicates that cerebrospinal fluid (CSF) 
flow and periarterial interstitial fluid (ISF) drainage pathways connect the CNS to the 
lymphatic system; thus facilitating CNS immune surveillance (Engelhardt et al., 2005; 
Johnston et al., 2004; Ransohoff et al 2003; Schwartz et al., 2010). Clearance of 
soluble proteins, especially toxic misfolded proteins, from ISF drainage pathways to 
lymph nodes may represent one pathway by which antigenic material from the brain 
parenchyma can access lymphoid tissue and induce antigen-specific responses by 
naïve or memory B and T cells (Ransohoff et al 2003).  Immune surveillance of the 
CNS parenchyma maybe further facilitated by T lymphocyte trafficking in and out of 
CSF-filled ventricle, subarachnoid and perivacular spaces where contact with antigen 
presenting cells of the CNS (subarachnoid-space macrophages and pericytes 
embedded in the basal membranes of CNS microvasculature) can take place 
(Engelhardt and Ransohoff, 2005). The blood brain barrier (BBB) serves, therefore, a 
fundamental role in regulating brain-immune processes (Banks et al., 2010) and 
protecting the brain against the detrimental effects of brain-reactive autoantibodies 
and cytotoxic T cells that might otherwise lead to autoimmune-associated 
neurological and neuropsychiatric diseases, such as those known in multiple 
sclerosis, paraneoplastic syndromes, neuromyelitis optica, limbic encephalitis, 
Guillian-Barré syndrome, systemic lupus erythematosus (Bhat et al., 2009; Diamond 
et al., 2009). 
On the other hand, both T- and B-cells together with phagocyte functions of brain-
resident microglia against misfolded protein antigens can protect neurons from 
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degeneration. Accumulating evidence suggests roles for naturally-occurring 
antibodies in the delay - or the prevention of – clinically overt neurodegenerative 
disease (Diamond et al., 2009; Neff et al., 2008; Rodriguez et al., 2009; Schwartz et 
al., 2008a; Schwartz et al., 2008b; Szabo et al., 2008). Protective immunity could be 
mediated by conformation-specific antibodies reacting with pathologic misfolded 
protein oligomers, neutralizing their toxic properties, accelerating their microglia-
mediated clearance, or preventing their growth.  
Indeed, the presence of auto-antibodies against Abeta, alpha-synuclein and PrP 
have been documented in the blood and CSF of healthy individuals and patients 
(Geylis et al., 2005; Papachroni et al., 2007). These auto-antibodies can bind, and 
neutralize, conformation-specific epitopes of misfolded proteins, inhibit fibrillization 
and aggregation, block oligomeric induced neurotoxicity, facilitate microglia-mediated 
phagocytosis and promote neuroprotection (Szabo et al 2008; Neff et al., 2008, 
Kellner et al., 2009). Although previous findings have been controversial over the 
years, with earlier papers reporting either no decline or an increase in autoantibodies 
in AD patients, recent studies provide more conclusive evidence.  
Recent work by Britschgi and colleagues (2009), in particular, provides convincing 
evidence that autoantibodies against a broad range of amyloidogenic peptides are 
naturally present in human plasma and CSF and that these autoantibodies display 
conformational-specific reactivity to misfolded proteins with neurotoxic properties. 
The authors also elegantly demonstrate that these autoantibodies display 
neuroprotective properties, with naturally occurring antibodies against Aβ protecting 
primary neurons against Aβ toxicity and that immunization with full-length Aβ can 
induce an enhanced cross-reactive autoantibody response against not only other Aβ 
species but also other toxic amyloidogenic peptides. In support of these findings, it 
was shown that autoantibodies levels decrease with age with even further reductions 
being described in AD patients. Kellner et al (2009) have also reported on the effects 
of auto-antibodies against Abeta on beta-amyloid plaque removal in non-immunized 
AD patients and age-matched non-demented controls. In this study, AD patients with 
high IgG-labeled neuritic beta-amyloid plaques demonstrated reduced beta-amyloid 
plaque load along with signs of increased phagocytic microglia; suggesting that the 
presence of anti-Abeta antibodies may be a naturally occurring protective factor 
against beta-amyloid pathology in AD. Indeed, in comparison to non-demented 
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healthy elderly subjects, AD patients exhibit lower serum titers levels of naturally 
occurring anti-Abeta antibodies (Du et al., 2001; Weksler et al., 2002). Catalytic IgM 
antibodies against Abeta have been additionally found in human sera and show high 
specific anti-Abeta activity but low capacity to clear the BBB compared to IgG anti-
Abeta antibodies; raising the possibility that IgM anti-Abeta antibodies might prove to 
be therapeutically effective in the blood (Szabo et al., 2008). As recently reported by 
Marcello and colleagues (2011), reduced plasma levels of IgM autoantibodies 
against N-truncated pyroglutamate Abeta were found in AD patients compared to 
healthy controls, along with a significant correlation between levels of these IgM 
autoantibodies and cognitive status in MCI patients.  
The presence of brain reactive antibodies in human sera may represent two aspects 
of immune response: a destructive autoimmune response that contributes to disease 
pathology resulting in antibody-mediated brain dysfunction, or alternatively, a 
protective autoimmune response that serves a protective role against disease 
processes resulting in antibody-mediated neuroprotection. Understanding the 
protective and detrimental aspects of brain reactive auto-antibodies, the mechanisms 
mediating their entry into the brain and their consequences on brain development 
and function during health and disease, will provide new insight into the pathogenesis 
and treatment of several neurodegenerative diseases. The advent of molecular 
imaging technology together with therapeutic immunization strategies targeting 
neurotoxic misfolded proteins provides new aspects for the treatment and prevention 
of neurodegenerative diseases including AD, prion disease, PD and ALS.  
 
1.7 Immune-modulatory strategies for Alzheimer’s disease 
Rejuvenating and harnessing the aged immune system is of therapeutic importance 
and the subject of considerable investigation (Dorshkind et al., 2009; Popovich et al., 
2008; Ron-Harel et al., 2009). Indeed, the last decade has seen tremendous 
advancement in the development of immune-based treatment intervention for 
neurodegenerative diseases. To-date, several anti-amyloid immunotherapy 
strategies have been developed for the treatment of Alzheimer’s disease (Citron, 
2010; Lemere et al., 2010), with many currently under extensive pre-clinical and 
clinical testing. In addition to these therapeutic initiatives, new therapies are being 
investigated that target cytokines (Chadwick et al., 2008; Tweedie et al., 2007) and 
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other inflammatory processes in Alzheimer’s disease that result in neuronal injury, 
neurodegeneration and cognitive dysfunction. 
In a pilot study, Tobinick and others (2006) demonstrated that once weekly perispinal 
injection of etanercept (a TNF antagonist) in 15 mild-to-severe AD patients resulted in 
significant improvement in cognitive function at 6 months follow-up. In a subsequent 
study (Tobinick et al., 2008), the same authors demonstrated that perispinal anti-TNF 
treatment results in rapid cognitive improvement in a late-onset AD patient. Based on 
the reported rapid improvement in cognitive function following treatment and the 
known involvement of TNF in synaptic plasticity, it has been suggested that perispinal 
administration of etanercept might ‘reverse’ the synaptic dysregulation caused by 
TNF over-expression (Griffin, 2008; Tobinick, 2008; Tobinick, 2009).  Alternatively, 
etanercept might be a combined TNFalpha neutralizing/“passive immunization” agent 
with rapid efficacy due to its anti-TNF properties and long-term efficacy resulting from 
engagement of Fc receptor-mediated effector functions (Griffin, 2008). Future 
research should therefore seek to identify the biological mechanisms underling the 
‘rapid’ and ‘long-term’ therapeutic efficacy of etanercept treatment. Ideally such 
research should utilize mouse models in which the expression of TNF (and other 
cytokines) can be characterized throughout aging (wildtype mice), disease 
progression (transgenic AD mouse models) and following therapeutic intervention, 
especially in relation to cognitive function (cognitive-behavioural testing), 
neurobiological processes (synaptic scaling) and disease pathology (Aβ formation 
and deposition). Such findings are particularly important, as other research (Taoufik 
et al., 2008), investigating the therapeutic efficacy of anti-TNF treatment in MS 
patients, indicated that the net outcome of TNF neutralization is harmful. 
Furthermore, it has been reported that following anti-TNF treatment for rheumatoid 
arthritis, patients have been shown to develop neurological problems and 
demyelinating lesions (Richez et al., 2005; Sicotte et al., 2001). Animal research 
(Aloe et al., 1999; Baune et al., 2008a, McAfoose et al., 2008) has additionally 
demonstrated that both the absence and overexpression of TNF in mice is 
associated with cognitive dysfunction and disease pathology; thus highlighting the 
physiological, neuroprotective and neurodegenerative properties of TNF.  
As mentioned earlier, microglia activation and microglia-mediated neuroinflammation 
are important factors in AD pathophysiology that can result in neuroprotection and 
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the clearance of Ab (phagocytosis) or neuronal damage. Developing treatment 
approaches that successfully control microglia activation and pro-inflammatory 
cytokine expression while promoting neuronal protection are therefore of therapeutic 
significance and currently under extensive investigation (Landreth et al., 2008; Shie 
et al., 2009).  Of particular importance here is the recent discovery that 1) 
peroxisome proliferator-activated receptor gamma (PPARγ) activation inhibits 
microglia activation promotes anti-inflammation and induces Aβ clearance (Camacho 
et al., 2004) and 2) PPARγ agonists (pioglitazone and rosiglitazone) might serve as 
useful therapeutics for the treatment of AD (see for Landreth et al., 2008; Shie et al., 
2009 a review). In transgenic AD mouse models it has been shown that treatment 
with risoglitazone results in improved learning and memory (Escribano et al., 2009; 
Pedersen et al., 2006) and a restoration of LTP (Loane et al., 2007).  In humans, it 
has also been reported, in two clinical trial studies, that AD patients receiving 
rosiglitazone treatment showed improved cognitive function at 6 month follow-up 
(Risner et al., 2006; Watson et al., 2005). Although the exact mechanisms remain to 
be fully characterized evidence (Loane et al., 2007) suggests that IL-4 mediates the 
anti-inflammatory and neuroprotective effects of rosiglitazone.  
Another therapeutic approach, alpha-lipoic acid (LA), has been shown to be 
beneficial in the treatment of AD. Indeed, a 48 month study conducted by Hager et al. 
(2007) showed that treatment with LA slowed the rate of disease progression 
(cognitive decline) in mildly demented AD patients. These therapeutic effects have 
been contributed to LA ability to exert anti-inflammatory and neuroprotective 
properties. Other metal chelator and anti-oxidant treatment approaches, such as M-
30 and HLA-20 (Mandel et al., 2007), have demonstrated therapeutic efficacy in AD 
patients.  
Evidence (Nizri et al., 2006) suggests that in addition to their known ability to 
enhance cholinergic production, acetylcholinesterase inhibitors (AChEIs) can also 
exert anti-inflammatory effects, both peripherally and within the CNS. More 
specifically, it has been shown that peripheral administration of galantamine reduces 
serum TNF levels and that these effects are mediated via the vagus nerve signalling 
“cholinergic anti-inflammatory pathway” (Pavlov et al., 2009). These authors further 
demonstrated (Parrish et al., 2008; Pavlov et al., 2009) that this anti-inflammatory 
process (vagus nerve-based cholinergic anti-inflammatory pathway) is mediated by 
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the alpha7 subunit-containing nicotinic acetylcholine receptor (α7nAChR). Such 
findings raise the possibility that at least some of the therapeutic effects of AChEIs 
might be due to their anti-inflammatory properties.  
 
1.8 Amyloid-lowering immunotherapeutic strategies for Alzheimer’s disease 
Based on the effective clearance of beta-amyloid from brain upon repeated Abeta 
immunization in mouse models for AD, along with restoration of neuronal morphology 
and behavioural functions, clinical trials in humans were initiated (for review see: 
Brody et al., 2008; Lemere et al., 2010). More than one dozen clinical trials testing 
both passive immunotherapy and active vaccination strategies are currently 
underway.  
Clinical trials of active immunization were first done with aggregated Abeta42 
combined with the adjuvant QS-21 (Elan/Wyeth AN1792 trial) (Bayer et al., 2005; 
Gilman et al., 2005). During the later stages of the phase I trial, the emulsifier 
polysorbate 80 was added to the active vaccine formulation after which the observed 
immune responses shifted from a predominantly Th2 biased response to a 
proinflammatory Th1 response (Pride et al., 2008). This change in formulation was 
associated with the occurrence of a case with aseptic meningoencephalitis in phase I 
(Nicoll et al., 2003), and further 18 patients in the phase II trial corresponding to 6% 
of the patients treated with the active vaccine (Orgogozo et al., 2003). Unrelated to 
the T-cell mediated side-effect of meningoencephalitis, patients with AD responded to 
the active vaccination by generation of highly specific antibodies against beta-
amyloid plaques (Hock et al., 2002; Gilman et al., 2005), along with better memory 
performance in a cohorts of patients with high antibody titers (Hock et al., 2003). 
Long-term follow-up of the actively immunized AN1792 cohort of patients revealed 
reduced cognitive decline in immunization responders with increased antibody titers 
up to 5 years after the initial immunizations (Vellas et al., 2009). Autopsy analyses 
consistently showed signs of clearance of beta-amyloid from brain (Ferrer et al., 
2004; Masliah et al., 2005) and the magnitude of beta-amyloid clearance apparently 
was correlated serum titers of antibodies against beta-amyloid (Holmes et al., 2008). 
In addition, increased titers of antibodies against beta-amyloid was associated with 
decreased CSF levels of the intraneuronal protein tau, possibly as an indication of 
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slowed neuronal disintegration following attenuated neurodegeneration (Gilman et 
al., 2005). 
Whether clearance of beta-amyloid from brain in patients with AD will be associated 
with sufficient clinical benefits over time may depend largely on the disease stage at 
which the treatment is initiated, as implied by recent reports on individual AD patients 
who received active vaccination (Holmes et al., 2008; Vellas et al., 2009). If these 
initial findings hold true in larger patient populations, it may turn out that Abeta 
immunotherapy is most effectively applied in non-demented subjects with preclinical 
brain beta-amyloidosis, referred to as primary progressive brain amyloidosis. 
Emerging longitudinal imaging studies of brain beta-amyloid with PET indicate that 
67% of amyloid-positive non-demented subjects with mild cognitive impairment (MCI) 
converted to AD within 5 years, as compared to 0% of amyloid-negative non-
demented subjects with MCI (Nordberg, ICAD2009). Taken together, this population 
of elderly subjects with primary progressive brain amyloidosis may turn out to be a 
prime target population for secondary prevention of AD by using Abeta 
immunotherapy.  
 
1.9 Aims of thesis 
1.9.1 Anti-TNF project 
This project was designed to test the following Working Hypothesis, that anti-TNF 
therapy can lower amyloid pathology, ameliorate neuroinflammatory responses and 
rescue cognitive deficits in 12 month old arcAb transgenic mice.  
Specific Aims:  
1. To identify the effects TNF deficiency (TNF ko models) on AD pathology in arcAb 
mice. 
2. To determine if anti-TNF therapy (etanercept) will rescue cognitive deficits in arcAb 
mouse. 
3. To determine the therapeutic outcome of icv vs. ip administration of etanercept. 
4. To determine the underlying therapeutic mechanisms of etanercept anti-TNF 
therapy on amyloid pathology and neuroinflammation (astrocytosis and microgliosis). 
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1.9.2 DARPin project 
This project was designed to test the following Working Hypothesis, that selected 
DARPins with Abeta-binding properties could be used as a therapeutic approach to 
lower amyloid pathology and rescue cognitive deficits in 12 month old transgenic 
mouse models of Alzheimer’s disease.  
Specific Aims:  
1. To determine if DARPin therapy will rescue cognitive deficits in Swedish and arcAb 
mouse. 
2. To determine the underlying therapeutic mechanisms of DARPin therapy on 
amyloid pathology and neuroinflammation (astrocytosis and microgliosis). 
 
1.9.3 Delta project 
This project was designed to test the following Working Hypothesis, that the 
specific conformational change induced by the E22Δ mutation causes the formation 
of soluble oligomeric derivatives with synaptotoxic activities that cause cognitive 
decline in the absence of amyloid plaque formation and deposition.  
The Specific Aims of this project are: 
1. To determine the effects of E22Δ Aβ on cognitive performance in E22Δ transgenic 
mice expressing the mutation, as compared to arcAb and Swedish (tg2576) mice. 
2. To determine the histological and biochemical properties of E22Δ Aβ-pathology 
overtime, as compared to arcAb and Swedish mutations. 
3. To elucidate the aggregation propensity of E22Δ Abeta species, as compared to 
arcAb and wildtype Abeta species.  
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Abstract  
Alzheimer’s disease (AD) is a neurodegenerative disease associated with the 
accumulation of misfolded Abeta-amyloid aggregates and glia-mediated 
neuroinflammatory processes. The overexpression of tumor necrosis factor alpha 
(TNF), in particular, may promote amyloid plaque deposition and mediate Abeta-
related  synaptotoxicity. The use of Etanercept anti-TNF therapy for the treatment of 
AD is therefore currently under Phase II clinical trial investigation. In this study we 
investigated the intracerebroventricular (icv) infusion of Etanercept, Infliximab and 
PBS for 28 days via using ALZET osmotic minipumps, and 4 weekly intraperitoneal 
(ip) injections of Etancercept, Infliximab and PBS, with an additional 15 non-treated 
transgenic and wildtype mice as a further controls. All mice (n=120) underwent 
general health and neurological examination, as well as, cognitive assessment 
before they were sacrificed for further biochemical and histological analyses. 
ArcAβ/TNF knock out mice were also generated to investigate the long-term effects 
of TNF deficiency on amyloid pathology. ArcAβ/TNF knock out mice and control 
littermates were tested at 12 months of age for cognitive-behavioral changes and 
differences in underlying pathology. Immunohistochemical analyses confirmed 
ventricular placement of the brain infusion cannula and the ubiquitious distrubtion of 
Etanercept throughout the brain for intracerebroventricular, with CNS entry of 
peripherally administered Etanercept via leakage in the blood brain barrier. 
Cognitive-behavioral assessment of mice demonstrated a treatment dependent 
improvement in cognitive performance in two hippocampus-dependent cognitive 
tests. Results from the biochemical analyses indicate that the improvement in 
cognition was not associated with changes in soluble brain Abeta levels but rather a 
decrease in Formic acid insoluble Abeta levels. Thioflavin S histological analysis 
demonstrated a treatment-induced lowering of Abeta plaque number and percentage 
area covered by plaques. Results further demonstrated an increase clearance of 
Abeta plaques towards the vasculature, as shown by higher relative area covered by 
CAA. Immunohistochemical staining against GFAP and Iba1 demonstrated reduced 
astrocytosis but increased microglia activation. Our results indicate that TNF-directed 
immunotherapy may successfully reverse Abeta-related cognitive deficits in a 
transgenic mouse model of AD.  
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2.1 Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that leads to 
serve cognitive impairment and behavioural disturbances. Neuropathologically, AD is 
characterized by extracellular accumulation of β-amyloid protein (Aβ), intracellular 
neurofibrallary tangles (NFT), cerebral amyloid angiopathy, granulovacular 
degeneration, Hirano bodies, neuropil threads and activated glial cells (chronic, 
localized non-immune mediated inflammation). Although the pathogenesis of AD 
remains to be fully clarified, current evidence suggests that Aβ plays a central role in 
the complex and multifactoral mechanisms that underlie AD; the so-called amyloid 
cascade hypothesis. Although the pathways controlling production and aggregation 
of Aβ are well studied, the mechanisms that drive the spread of neurodegeneration in 
the brain are unclear. One possible mechanism that is gaining wide acceptance is 
that Alzheimer’s disease involves an orchestrated cytokine and/or ‘inflammatory’ 
process that culminates in neuronal injury and destruction (Rojo et al., 2008). 
 
In particular, there is now substantial and accumulating, basic science, and clinical 
evidence that excess TNF is centrally involved in the pathogenesis of dementia and 
other neuropsychiatric conditions. In Alzheimer’s disease it is thought that the over-
expression of TNF may give rise to the development of amyloid plaques and 
subsequently mediate amyloid interference with memory (He et al., 2007; Rowan et 
al., 2007; Wang et al., 2005). Findings by Medeiros and colleagues (2007) has 
demonstrated that TNF signaling pathways and iNOS act as central mediators of Aβ 
action in a mouse model of AD. Their research demonstrated that both 
pharmacological (anti-TNF antibody and aminoguanidine) and genetic (knockout 
mice) blockage of TNF and iNOS reduced cognitive deficits evoked by Aβ. In support 
of these findings, He et al. (2007) demonstrated that the deletion of TNF R1 gene in 
APP23 transgenic mice (APP23/TNFR1-/-) inhibits Aβ generation and prevents 
memory deficits. Moreover, it has recently been suggested that the progression of AD 
might be the consequence of exaggerated TNF-mediated synaptic scaling during 
prolonged neuronal inactivity caused by Aβ (Small, 2008). The concept of TNF-
alpha-inhibition for the treatment of AD has, therefore, been recently reviewed 
(Tweedie et al., 2007; Tobinick, 2008). In a pilot study, Tobinick and others (2006) 
demonstrated that once weekly perispinal injection of etanercept (a TNF antagonist) 
in 15 mild-to-severe AD patients resulted in significant improvement in cognitive 
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function at 6 months follow-up. In a subsequent study (2008), the same authors 
demonstrated that perispinal anti-TNF treatment results in rapid cognitive 
improvement in a late-onset AD patient. Given TNFs involvement in synaptic 
plasticity (Beattie et al., 2002; Stellwagen et al., 2005; Stellwagen et al., 2006) it is 
thought that this rapid improvement in cognition results from ‘reversed’ excess TNF-
mediated synaptic plasticity dysregulation (Griffin, 2008; Tobinick, 2008; Tobinick, 
2009). Alternatively, etanercept might be a combined TNFalpha neutralizing/“passive 
immunization” agent with rapid efficacy due to its anti-TNF properties and long-term 
efficacy resulting from engagement of Fc receptor-mediated effector functions 
(Griffin, 2008). Animal research (Aloe et al., 1999; Baune et al., 2008a, McAfoose et 
al., 2008) has additionally demonstrated that both the absence and overexpression of 
TNF in mice is associated with cognitive dysfunction. Such findings highlight the 
physiological, neuroprotective and neurodegenerative properties of TNF.  
 
The aim of the study was to investigate, in a preclinical study, the efficacy of directly 
infused and systemically administered etanercept anti-TNF therapy using ArcAβ 
transgenic mice as an AD mouse model. A primary outcome of this study was to 
assess the effects of anti-TNF treatment on cognitive performance and patho-
biological measures suggestive of a disease-modifying mechanism, in particular the 
effects of anti-TNF treatment on Aβ levels, as well as, plaque deposition, astrocytosis 
and microglia activation. The long-term effects TNF deficiency on amyloid pathology 
was investigated using ArcAβ/TNF ko transgenic mice. 
 
2.2 Materials and Methods 
2.2.1 Animals 
This study used a recently published (Knobloch et at., 2008) AD transgenic mouse 
model expressing human APP with the combined Swedish and Arctic mutations 
(arcAβ) that develop Abeta plaque pathology between the ages of 9 to 12 months of 
age. As part of this study, arcAβ mice were crossed with TNF knockout mice to 
generate both arcAβ/TNF knockout mice (arcAβ/TNF-/-), arcAβ/TNF +/- mice and 
arcAβ/TNF +/+ control littermates. Mice were bred, held and kept at the 
Neurodegenerative and Biobehavioral Research (NBR) Facility of the Division of 
Psychiatry Research under specific pathogen free (SPF) conditions, temperature 
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controlled (22 °C±1 °C), 3 to 5 animals per cage, with sawdust as bedding and tissue 
as nesting material. All housing boxes were under individual air ventilation. A 12 hour 
light–dark cycle beginning at 7:00 h was maintained in the housing room and except 
for the time of testing, water and food was provided ad libitum.  Cognitive-behavioral 
testing was performed in a separate room within the NBR Facility specifically 
designed for cognitive-behavioural investigations (minimal stress, quite room, 
controlled lighting, etc.). Experiments were approved by the veterinary office of the 
Cantonal Health Department and efforts were made to minimize the number and 
suffering of the animals in these experiments. 
 
2.2.2 Cognitive-behavioural testing  
A battery of well-validated and carefully controlled tests were used to behaviorally 
assess mice for motoric and cognitive performance (Crawley, 2007). At the time of 
testing, mice were weighed and examined for general health measures to ensure that 
the mice were physically able to conduct the cognitive-behavioral test and to rule out 
any adverse side effects due to the surgical procedure or anti-TNF treatment; 
supplementary material.  
 
Grip Strength Analysis  
Grip strength was measured using a Grip strength Meter apparatus that measures 
the gripping strength of mice. The system is supplied with a grid which connects to 
the sensor. Animals were lowered down until the paws grasped the gird and then 
gently pulled back until the grip was released. The maximal force achieved by the 
animal was recorded electronically over three trials.  
 
Paw grip endurance test (PaGE) Using a stainless steel mesh grid, mice were 
suspended upside down over a foam landing pad for 120s and the longest latency to 
fall over three trials is recorded. 
 
Extension reflex 
Extension of the hindlimbs is normally observed when a mouse is suspended in the 
air by its tail. However, in mice with motoneuron disease, retraction of the hindlimb is 
more commonly seen. A score of 0 indicates normal extension reflex of both 
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hindpaws, whereas, a score of 1 corresponds with extension reflex of only one 
hindpaw, and 2 is the absence of any hindlimb extension. 
 
Rotarod test 
In the rotarod test a mouse has to keep its balance on a horizontal rotating rod 
(diameter 3 cm). A trial starts when the mouse is placed on the rotating rod, and 
stops when the mouse falls down. Five mice are simultaneously placed on the 
rotarod apparatus with the rod rotating at 4 rpm (rotations/minute) during the first 
minute, with an increase in rotation speed every 30 seconds thereafter. A trial ends 
for a mouse when it falls down or when 5 minutes are complete.  
 
Locomotor Activity 
Open Field Test: According to published procedures (Crawley, 2007) mice are placed 
in the center of a brightly lit white Plexiglas box (50x50cm), and their movements 
(distance traveled and average speed) were tracked using ANY-maze video tracking 
software (Stoelting Co., USA) for 5 min.   
 
Y-maze 
Spatial working memory was assessed in mice using the Y-maze (Y-shaped plastic 
maze, with 40 cm x 20 cm x 10 cm arm sizes). During a 5 minute trial, the sequence 
of arm entries was recorded using the ANY-maze Video Tracking System (Stoelting 
Co., USA). The percent alternation was calculated as the ratio of actual to possible 
alternations (defined as the total number of arm entries -2) x 100%.  
 
Novel Object Recognition  
The Novel Object Recognition task is undertaken in accordance to published 
protocols (Winters et al., 2008). In brief, following a habituation period, mice are 
exposed to two novel objects placed within the open-field box, then after a 5 minute 
delay, one of the familiar objects is replaced with a new novel object, and the time 
spent exploring each object is recorded electronically. A preference index, or time 
spent exploring the novel object over the time spent exploring the familiar object, is 
used to measure recognition memory. 
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2.2.3 Biochemical and Immunohistochemical analyses 
Mice were deeply anesthetized and blood collected from the right ventricle using a 
syringe with EDTA and samples were centrifuged at 8’000 rpm for 8 minutes at 4C 
and plasma extracted using a sterile pipette and stored at -80C for later batch 
analysis. Following the collection of blood, mice were transcardially perfused with 
PBS and their brains rapidly removed. Brains were dissected in two hemispheres 
with the left hemisphere being placed in 4% PFA and post-fixed overnight at 4C° and 
then transferred to 30% sucrose for 72 hours (cyroprotection) for later histological 
analysis.  PFA-fixed and cryoprotected hemibrains were cut in 35 µm thick coronal 
slices at -80C using a microtome (Leica Jung HN40) and kept at -20C in an anti-
freeze solution (phosphate buffer 0.50 M in MilliQ water: ethyleneglycol: glycerol = 
1.3:1:1) until staining was performed. The right hemibrain was dissected for 
biochemical purposes and immediately frozen in liquid nitrogen and stored at -80C°. 
Brain tissue was later homogenized using a sequential extraction protocol in which 
tissue was homogenized using a glass-Teflon homogenizer (20 strokes, 315 rpm) in 
RIPA buffer containing complete protease inhibitor tables (Sigma-Aldrich), 
centrifuged at 100,000 x g (53,000 rpm) at 4C for 1 hour and supernatant extracted 
and stored at -80C for later biochemical batch analysis. The remaining pellet was 
frozen on dry ice, resuspended in 70% formic acid, sonicated for 30s at 30% power, 
ultracentrifuged (100,000 x g @ 4C for 30 minutes), supernatant extracted, 
lyophilized, reconstituted in RIPA buffer and stored at -80C for later batch analysis.  
 
Beta-amyloid analysis.  
Abeta levels were measured in plasma and brain homogenates using a MSD 3plex 
multi-SPOT Abeta human kit (MesoScale Discovery, USA) for Aβ38, Aβ40 and Aβ42, in 
accordance to manufacturer’s instructions. MSD SECTOR Imager 6000 reader was 
used for analysis and the MSD DISCOVERY WORKBENCH software (Version 
3.0.17) with Data Analysis Toolbox was used to calculate sample concentrations by 
comparing them against a standard curve (five-parameter logistic curve).  
 
Immunohistochemistry.  
All immunohistochemical stainings were executed using the free-floating method. 
Washing steps were carried out between all incubations using washing buffer (TBS 
pH 7.4 containing 0.2%Triton X-100) at RT. Slices were blocked for 1 hour at RT 
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using blocking buffer (5.0% goat serum 5.0% donkey serum in washing buffer). 
Blocked slices were incubated overnight at 4C with slight agitation in primary 
antibody incubation buffer (2.5% goat serum and 2.5% donkey serum in washing 
buffer) containing the primary antibody/antibodies. Primary antibodies were: rabbit 
anti- Iba1 (Wako Chemicals, Osaka, Japan) and goat anti-GFAP (Advanced 
ImmunoChemical Inc.). Subsequently, secondary antibody incubations were carried 
out for 2 hours at RT using fluorophor-conjugated antibodies. Slices were washed in 
washing buffer, mounted on chrom-gelatin-coated microscopy slides (Super-frost-
plus, Menzel, Braunschweig, Germany) and glass-covered using Hydromount® 
(National Diagnostics, Hull, UK). Thioflavin S staining was done according to 
standard protocol. In short, floating sections were washed in KPBS and mounted on 
chrom-gelatin coated glass slides before being processed. After treatment for 20 min 
with 0.25% potassium permanganate, sections were washed in d.d. H2O and 
incubated in 2% potassium disulfide and 1% oxalic acid until they appeared white. 
Sections were then floated 3 seconds in 0.25% acetic acid, washed in d.d. H2O and 
stained for 5 min with a solution of 0.015% Thio-S in 50% ethanol. Finally, sections 
were washed in 50% ethanol and in d.d. H2O, then dried, and glass-covered using 
Hydromount® (National Diagnostics, Hull, UK). For detection of micro-hemorrhages 
Prussian Blue staining was performed in which sections were incubated in a mixture 
of equal volumes of 10% potassium ferrocyanide (K4Fe(CN)6 trihydrate) in d.d. H2O 
and 20% hydrochloric acid (HCl) in d.d. H2O for 30 min. Brain sections were 
subsequently washed with d.d. H2O, counterstained with nuclear fast red solution for 
10 min and washed with d.d. H2O, then dried, and glass-covered using Hydromount® 
(National Diagnostics, Hull, UK).  All chemicals were purchased from Sigma-Aldrich, 
Switzerland. 
 
2.2.4 Treatment and Surgical Implantation of Alzet® osmotic minipumps 
Twelve-month-old arcAβ mice were deeply anaesthetized 
(fentanyl/midazolam/medetomidin), a small midline incision was made to expose the 
skull, and a subcutaneous pocket was prepared in the midscapular area of the back 
of the mice so that a sterile Alzet® minipump (model 2004, 3.0 cm. in length, 0.7 cm. 
in diameter and weighing 1.1 g empty weight) filled with antibody solution or vehicle 
could be inserted. Mice were then head fixed within a stereotaxic apparatus and the 
bone suture junction bregma was used as a reference point to drill a hole in the skull 
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and lower an Alzet Brain infusion kit 3 cannula into the left lateral ventricle; 
coordinates according to bregma; AP, -0.2 mm; ML, 0.9 mm; and DV, 2.5 mm. 
Following the placement of the cannula, two small screws were placed within the 
skull and dental cement applied to firmly attach to the skull. Naloxon, 
flumazenill/atipamezol and metacam was given subcutaneously as an antidote and 
post-operative analgesic, with further metacam and buprenorphine / phenylbutazon / 
aminophenazon / benzylpenicillin / dihydrostreptomycin provided within the drinking 
water for 2 weeks as an analgesic /antibiotic. Post-operatively, mice were housed for 
three days on heat pads and moist food placed at the floor of the cage to promote 
recovery and to reduce drop-outs. Groups of 15 transgenic arcAβ mice were used 
per treatment condition, with mice either receiving icv-infusion over 28 days (10mg/ml 
concentration, ∼26.4 µg per day; 740 µg over 28 days infusion) or weekly 
intraperitoneal injections of 5 mg/kg for 4 weeks of anti-TNF therapy (Etanercept), 
anti-TNF control (Infliximab) or PBS control. Additionally, non-treated transgenic and 
wildtype littermates were included as controls. 
 
2.2.5 Image analysis  
Immunohistochemical quantification was performed using ImageJ software 
(http://rsb.info.nih.gov/ij/), in which all images were first converted into grayscale 
images (8-bit). Subsequently, all images were further adjusted to a defined grayscale 
threshold. For each investigation, the grayscale threshold was held constant for all 
groups to allow comparison between images. Quantification of plaque load and CAA 
(ThioS), astrocytosis (GFAP) and activated microglia (Iba1) was reported as the area 
positive for the staining in a determined area of the cortex (% area). 
 
2.2.6 Statistical analysis 
Data analysis was performed using the Statistica 10.0 statistical software. Tests for 
normal distribution were performed before statistical testing, according to the results 
of the Shapiro-Wilk- and the Kolmogorov-Smirnov-Test for normality, either T- or 
Mann-Whitney-U-Test for 2 sample groups or one-way ANOVA was performed 
(followed by post-hoc Fischer LSD analysis). For NORT a Wilcoxon-Test was 
performed to test if the ratio differed significantly from 1, +P < 0.05. A p-value < 0.05 
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was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001 indicate 
significantly different performances. Error bars are SEM.  
 
 
2.3 Results 
2.3.1 Cognitive-behavioural assessment 
There were no differences in general health measures across all experimental 
groups, with both i.c.v. treated, i.p. treated and non-treated arcAβ mice displaying 
similar, general health measures, healthy appearance of fur, appropriate social 
behaviors and handling responses, auditory-visual sensory integrity, comparable grip 
strength, intact righting and extension reflexes (see supplementary material, Table 1). 
All groups were further monitored for possible treatment-induced side effects, drop 
outs, or specific technical failures, with no treatment group specific differences being 
reported (see supplementary material, Table 2). Assessment of body weight, 
demonstrated equivalent body weights across all experimental groups, for both 
males and females. Locomotor examination using the open field test demonstrated 
comparable locomotor activity across all groups, including total distance travelled, 
maximum speed and time immobile (data not shown). Similarly, all experimental 
groups exhibited comparable performance on the rotarod, grip strength and paw grip 
endurance (data not shown). 
 
Cognitive assessment in the Y-maze demonstrated that both etanercept icv- and ip- 
treated mice displayed a significant increase in the percentage of spatial alternations, 
compared to PBS treated mice (p<.05, see Figure 1 B). Results further demonstrate 
that treated mice performed better than non-treated transgenic mice comparable of 
wildtype performance, indicating a treatment-induced improvement in spatial working 
memory (Figure 1 B). The increase in spatial alternations could not be attributed to 
an increase in exploration, as the number of total arm entries and distance travelled 
did not differ between groups (data not shown). ArcAβ/TNF -/- mice (t(16)=1.554, 
p=0.069; Figure 1 A) and arcAβ/TNF -/+ (t(12)=1.613, p=0.066; Figure 1 A) also 
showed non-significant trends towards better cognitive performance than arcAβ mice, 
with similar performance compared to wildtype mice. Novel object recognition 
(NORT) assessment demonstrated non-significant improvements in performance for 
both icv- and ip-treated etanercept mice compared to Infliximab and PBS treated 
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mice and non-treated controls (Figure 1 B). Similar results were shown for 
arcAβ/TNF -/- and arcAβ/TNF -/+ mice, as compared to arcAβ controls (Figure 1 D). 
Collectively, these results suggest an improvement in performance comparable to 
wildtype mice.  
 
	  
 
Figure 1. TNF deficiency and Etanercept Anti-TNF therapy improves cognitive performance in arcAb 
transgenic mice. A. ArcAβ transgenic mice on TNF deficient background (arcAβ/TNFko) demonstrate 
comparable spatial alternations on Ymaze as wildtype mice, whereas, arcAb control mice show 
decreased spatial alternation. B. ArcAβ/TNFko mice perform similar to wildtype mice on the NORT, 
with a higher preference index for the novel object than the familiar object, whereas, arcAβ controls 
show nearly an equal preference for novel and familiar objects. C. Etanercept icv-treated and ip-
treated mice display comparable spatial alternation performance as wildtype mice, whereas, Infliximab 
and PBS icv-treated and ip-treated controls display similar spatial alternation performance as non-
treated arcAβ control mice. D. Etanercept icv-treated and ip-treated mice show higher preferences for 
the novel object than familiar objects comparable to wildtype mice, whereas, Infliximab and PBS icv-
treated and ip-treated controls show decreased preference for the novel object. n = 12-15 per group. 
 
 
2.3.2 Histological analysis for cannula placement, mIgG and distribution of 
anti-TNF biologics 
To confirm the correct stereotactic surgical placement of the brain cannulas into left 
lateral ventricle, the brains of all icv-treated mice were microscopic analyzed (Figure 
2 A) and mice identified with misplaced cannula were excluded from further analyses 
(see supplementary material, Table 2). As a further control measure, we investigated 
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the distribution of icv-infused etanercept in all treated mice. Results from anti-hIgG 
immunohistological analysis demonstrated a diffused expression of etanercept anti-
TNF biologic, extending from the site of infusion throughout the brain of icv-treated 
mice (Figure 2 B). These findings confirm sufficient distribution of therapeutic biologic 
throughout the brain and exclude failure to continually infuse biologic over the 28 
days of the osmotic minipumps. To confirm whether peripherally administered 
etanercept would remain systemically or potentially cross the blood brain barrier 
(BBB), anti-hIG stainings were additionally carried out on ip-treated mice. Anti-hIgG 
stainings in ip-treated arcAβ mice revealed entry of biologic into the CNS via 
leakages in the blood brain barrier, as compared to ip-injected wildtype controls in 
which the biologic remained within the vasculature (Figure 2 C). Anti-mIgG 
immunohistological analysis revealed no difference in mIgG presence between 
treatment groups and PBS treated controls (Figure 2 D), suggesting no MAHA 
response to the treatment biologic.   
 
 
 
Figure 2. Histological analysis of brain cannula placement, biologic distribution, entry into CNS and 
MAHA response.  A. Placement of the brain cannula within the lateral ventricle was confirmed 
histologically. B and C. Representative microphotographs of sections stained for anti-human IgG to 
measure the distribution of biologic throughout the brain in icv-treated mice (B) and ip-treated mice 
(C). D. The lack of mIgGs in brains of both etanercept icv and ip-treated as compared to PBS controls, 
suggests that there was no MAHA responses generated by treated mice.  Scale bars: 1 mm (A, B and 
D) and 250 µm (C).        
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2.3.3 Histological analysis for amyloid plaques, CAA and micro-bleeds 
Histological analysis of fibrillar Aβ and CAA demonstrated that arcAβ mice on TNF 
deficient backgrounds (arcAβ/TNFko), as compared to arcAβ controls, showed a 
significant decrease in plaque number (t(94)=-2.028, p=0.023; data not shown), but 
comparable percentage plaque load (t(94)=-0.014, p=0.494; Supplementary Figure 1). 
Further analysis demonstrated a significant increase in CAA in arcAβ TNF deficient 
mice, as compared to arcAβ mice (t(94)=-2.004, p=0.025; Supplementary Figure 1). 
Thioflavin S histological analysis also demonstrated a treatment-induced significant 
lowering in the number of Abeta plaques (f(3,131)=11.665, p<0.001), with etanercept 
icv-treated mice as compared to infliximab and PBS treated mice, as well as, non-
treated transgenic controls (all p’s<0.001) showing significantly lower number of 
plaques (Figure 3 A). Fischer LSD post-hoc analysis showed no significant difference 
between infliximab and PBS icv-treated mice, or non-treated transgenic mice. Further 
investigation demonstrated a significant difference in percentage area covered by 
plaques (f(3,131)=2.643, p=0.05), with reduced plaque area for etanercept icv- treated 
mice as compared to infliximab icv- treated mice (p=0.034), PBS icv-treated mice 
(p=0.045) and non-treated transgenic mice (p=0.009). No other significant 
differences were found between treatment groups (Figure 3 A). Quantification of the 
percentage CAA revealed a significant difference (f(3,131)=12.449, p<0.001), with 
etanercept icv-treated mice showing higher percentage CAA as compared to all other 
treatment groups (all p’s <0.001) (Figure 3 A and B). Post-hoc analysis further 
demonstrated a significant difference between both infliximab icv-treated and non-
treated mice and PBS icv-treated mice (p=0.037 and p=0.039, respectively), but no 
significant difference between infliximab icv-treated mice and non-treated transgenic 
controls. Histological analysis further demonstrated a significant reduction in plaque 
number for etanercept ip-treated mice (t(86)=-3.869, p<0.001) in comparison to PBS 
controls, as well as lower percentage plaque area (t(88)=-1.798, p=0.037; data not 
shown). Prussian Blue staining combined with Thioflavin S co-staining revealed 
plaque- and CAA-related micro-bleeds in both etanercept and PBS icv-treated mice, 
as well as, non-treated transgenic controls (Figure 3 C). Further analysis under 
higher magnification showed that micro-bleeds were not associated with all CAA and 
did not present in higher frequencies for etanercept icv-treated mice.  
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Figure 3. Anti-TNF therapy and genetic deletion leads to lower amyloid plaques but higher CAA. A. 
ArcAβ/TNFko mice show less number of plaques as compared to arcAβ controls but higher over all 
plaque load, suggesting the development of larger plaques. These mice also display higher amounts 
of CAA then arcAβ control mice, suggesting an increased tendency for vascular deposition of amyloid. 
B. Etanercept icv-treatment results in significantly reduced number of plaques and overall plaque load, 
as compared to Infliximab and PBS icv-treated mice, as well as, non-treated transgenic controls. 
Etanercept icv-treated mice further display increased CAA as compared to controls, suggesting a 
redistribution of parenchymal plaques towards the vasculature. C. Representative photomicrographs 
demonstrating the increased CAA in Etanercept icv-treated mice, as compared to controls. D. 
Histological analysis demonstrated plaque- and CAA- associated micro-bleeds in both PBS and 
Etanercept-treated mice. The frequency and severity of micro-bleeds was not correlated with 
increased CAA in Etanercept icv-treated mice, with many CAA pathologies not being associated with 
micro-bleeds, suggesting an amyloid-induced risk for micro-bleeds and not a treatment-induced risk 
for micro-bleeds, despite increased CAA in treated mice. Scale bars: 1 mm (B) and 250 µm (C). 
 
2.3.4 Brain homogenate and plasma Abeta peptide anaylsis 
Biochemical analysis of Abeta levels in brain homogenates from icv- and ip-treated 
mice showed a non-significant increase in RIPA soluble Abeta 40 levels, as 
compared to both icv- and ip-PBS treated mice and non-treated transgenic controls 
(Figure 4 A). No other changes were shown in RIPA solube Abeta 38 or 42 levels in 
icv- and ip-treated mice, as compared to icv- and ip-PBS and non-treated controls 
(Figure 4 A). Icv-treated mice did however demonstrate a significant reduction in the 
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formic acid fraction of Abeta 38, 40 and 42, as compared to icv-PBS treated mice and 
non-treated transgenic controls (Figure 4 B, p<0.05). Ip-treated mice showed similar 
Abeta patterns in the formic acid fraction with a significant reduction in Abeta 38 
levels and non-significant reductions in Abeta 40 and 42 levels, as compared to both 
ip PBS treated mice and non-treated controls (Figure 4 B). No significant difference 
where seen in the plasma Abeta levels amongst all treatment groups (data not 
shown).  
 
 
 
Figure 4. Anti-TNF therapy results in reduced formic acid Abeta levels. A. Biochemical analysis using 
MSD 3-plex Abeta plates revealed no significant difference in RIPA soluble Abeta 38, 40 or 42 levels 
across all experimental groups. There was however, a slight trend towards increased RIPA soluble 
Abeta 40 levels in both Etanercept icv- and ip-treated mice.  B. Etanercept icv- and ip- treatment did 
however result in significantly lower Abeta 38, 40 and 42 levels in the formic acid insoluble fraction.  
n = 6-8 per group. 
 
2.3.5 Microglia and Astrocyte analysis 
Immunohistochemical staining against GFAP and Iba1 demonstrated strong 
astrocytosis and microgliosis in all transgenic mice, whereas age-matched wt mice 
were almost devoid of any reactive astrocyte or activated microglia (data not shown). 
ArcAβ mice on a TNF knockout background (arcAβ/TNFko) did however show a 
slight but non-significant reduction in astrocytosis and a non-significant trend towards 
increased microglia activation, as compared to arcAβ mice (Figure 5 B and E). 
Etanercept icv-treated mice did, however, show significantly lower astrocytosis, as 
compared to PBS icv-treated mice ((t(70)=-2.43, p=0.002; Figure 5 C), and a non-
significant trend towards lower astrocytosis, as compared to Infiximab icv-treated 
mice (Figure 5 C). Histological analysis of Iba1 demonstrated a significantly higher 
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relative increase in activated microglia in Etanercept icv-treated mice, as compared 
to Infliximab icv-treated ((t(70)=2.271, p=0.026; Figure 5 F) and PBS icv-treated mice 
(t(70)=2.354, p=0.021; Figure 5 F). 
 
 
 
Figure 5. Anti-TNF therapy leads to reduced astrocytosis and increased microgliosis. A. 
Representative photomicrograph of GFAP staining in Etanercept and PBS icv-treated mice. B. ArcAβ 
mice on TNF deficient backgrounds display lower astrocytosis than arcAβ controls. C. Etanercept icv-
treated mice display significantly lower levels of astrocytosis, as compared to Infliximab and PBS icv-
treated controls. D. Representative photomicrograph of Iba1 staining in Etanercept and PBS icv-
treated mice. E. ArcAβ mice on TNF deficient backgrounds show a non-significant trend towards 
increased activated microglia. F. Etanercept icv-treated mice have significantly increased levels of 
activated microglia, as compared to both Infliximab and PBS icv-treated mice. Scale bars: 500 µm (A 
and D).        
 
 
2.4 Discussion 
Our findings demonstrate, in a preclinical study, that anti-TNF etanercept therapy, 
administered intracerebroventricularly (28 days infusion) or intraperitoneally (4 
weekly ip injections) can rescue cognitive deficits, as well as, reduce amyloid plaque 
deposition in 12 month old arcAβ mice. Here we sought to differentiate the 
therapeutic efficacy of direct modulation of TNF-mediated responses within the 
central nervous system (CNS) versus systemic TNF-mediated inflammatory or brain-
immune communication mechanisms. As such, we either administered anti-TNF 
therapy directly into the CNS via icv-infusion or systemically through weekly ip-
injections. As a control, therefore, all icv-treated mice included in this study were 
examined both macro and microscopically to confirm correct cannula placement 
	  39	  
	  
within the left ventricle and that following 28 days infusion there was wide distribution 
of the biologic throughout the entire brain of treated animals. Similarly, it was 
demonstrated that ip-treated mice showed diffusion of the biologic within the brain at 
sites of impaired blood-brain-barrier (BBB); a widely reported characteristic of arcAβ 
mice (Knobloch et al., 2007; Merlini et al., 2011). The entry of peripherally 
administered etanercept within the brain excluded any restricted systemic effect of 
anti-TNF treatment and lends support towards a CNS-delivered therapeutic 
approach, as originally demonstrated by Tobinick et al (2006 and 2008) in which the 
authors treated Alzheimer’s disease patients with once weekly perispinal injection of 
etanercept. However, with Phase II clinical trials underway to investigate the 
therapeutic potential of subcutaneously administered etanercept in Alzheimer’s 
disease patients, it will be possible to determine in human subjects if systemic anti-
TNF therapy may have beneficial effects as well.  
 
All mice tolerated treatment and surgery well, with no aversive side effects observed 
and no signs towards a MAHA response against the treatment biologic.  Cognitive 
assessment within the Y-maze and Novel Object Recognition Task (NORT) 
demonstrated improvements for both icv- and ip- treated mice, as compared to 
controls. These treated mice showed performance levels comparable to wildtype 
mice, suggesting a complete rescue in cognitive deficits following treatment. Such 
findings support previous studies in mice, as well as, the cognitive improvements 
demonstrated in Alzheimer’s disease patient following weekly perispinal injections 
(Tobinick et al., 2006; Tobinick et al., 2008). Given the short duration of treatment (1 
month), our findings also support the rapid cognitive rescue observed in human 
following etanercept anti-TNF treatment (Tobinick et al., 2008). Similarly, it was 
shown that arcAβ mice deficient in TNF (ArcAβ/TNF-/- mice) displayed better 
cognitive performance than arcAβ transgenic mice, suggesting long-term benefits of 
TNF modulation.  
 
These behavioral findings were supported by histological reductions in the number of 
plaques, as well as, lower percentage area covered by plaques in icv- and ip-treated 
mice, as compared to controls. Upon further histological investigations, etanercept 
icv-treated mice were further shown to display increased CAA as compared to 
controls, suggesting a redistribution of parenchymal plaques towards the vasculature. 
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As micro-bleeds have been widely described to occur at sites of extensive CAA it 
was anticipated that the redistribution of amyloid to the vessels in icv-treated 
etanercept mice would lead to increased occurrence of micro-bleeds. However, 
histological analysis indicated that micro-bleeds were associated with plaque- and 
CAA-pathology irrespective of treatment, with frequency and severity of micro-bleeds 
showing no correlation with increased CAA in etanercept icv-treated mice. In 
particular, it was shown that many areas of heavy CAA deposition in etanercept icv-
treated mice did not show signs of micro-bleeds, suggesting an amyloid-induced risk 
for micro-bleeds and not a treatment-induced risk for micro-bleeds, despite increased 
CAA in treated mice. However, it could be that these micro-bleed free areas of heavy 
CAA deposition might reflect newly formed CAA following anti-TNF treatment induced 
redistribution of amyloid towards the vasculature and that with time, if not cleared 
efficiently, these vessels might deteriorate, lose their integrity and begin to bleed. 
 
As a next step, we used MSD analysis to determine Aβ levels in two sequentially 
extracted protein fractions from hemi brain tissue. In agreement with our histological 
findings, icv- and ip-treated etanercept mice showed a significant reduction of Aβ in 
the detergent insoluble formic acid fraction, as compared to control mice. Collectively, 
these findings provide evidence that anti-TNF etanercept treatment may successfully 
reverse Aβ-mediated cognitive deficits in a transgenic mouse model of brain 
amyloidosis and that the continuous infusion of etanercept may have a modulatory 
effect on brain Aβ levels, as well as, amyloid deposition. Indeed, it has been widely 
shown that TNF over-expression may promote amyloid plaque deposition, as well as, 
mediate amyloid induced cognitive dysfunction (He et al., 2007; Rowan et al., 2007; 
Wang et al., 2005). Medeiros and colleagues (2007) demonstrated that TNF 
signaling pathways and iNOS act as central mediators of Aβ with both 
pharmacological and genetic blockage of TNF and iNOS improving cognitive deficits 
evoked by Aβ. Other evidence supports the role of TNF-mediated synaptic 
dysfunction in the progression of AD following prolonged Aβ-induced neuronal 
inactivity (Small, 2008). 
 
Our histological findings demonstrated that icv-treatment was able to lower 
astrocytosis, as compared to control mice. These results were similarly shown in 
ArcAβ mice on a TNF knockout background. Such findings suggest a normalization 
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of reactive astrocytes towards physiological conditions and lend support for an anti-
TNF therapy mediated reversal of TNF-mediated synaptic dysfunction. Microglia 
investigations showed a treatment-induced increase in active microgliosis, with 
similar founding in ArcAβ TNF knockout mice. These findings suggest that excessive 
TNF expression might interfere with microglia activation and the potential clearance 
of amyloid plaque by microglia. Combined, our results indicate that anti-TNF therapy 
may restore physiological astrocyte functions, promote microglia activation, reduce 
amyloid burden and successfully reverse abeta-induced cognitive deficits in 12 
month old arcAβ transgenic mice.  
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2.6 Supplementary Material 
General health, sensory-motor and mini-neurological examination. Mice were 
weighed and their coat appearance, handling responses and home cage social 
behavior registered. More specifically, coat appearance was assessed for matted, 
discolored fur, bald patches, missing whiskers, scarring, or wounds, which might 
otherwise indicate poor health, insufficient grooming, overgrooming and fighting.  
Unusual responses to handling including, extreme jumping, vocalizations, and 
attempts to bite the human handler may indicate poor health and were regarded as 
poor handling responses. Nesting patterns, sleeping in a huddle, allogrooming and 
normal social interaction behaviors were considered as good home cage social 
behaviors, whereas, social withdrawal or isolation, excessive fighting, over grooming 
was regarded as inappropriate home cage social behaviors. Any deviations from 
good coat appearance and appropriate handling responses and home cage social 
behavior would be regarded as poor health and scored as a fail, thus excluding the 
mouse from cognitive-behavioral testing.  Successful righting reflex was recorded if 
the mouse was able to right itself when placed on its back and/or since mice able to 
right themselves often can't be placed on their backs, the inability to place the mouse 
on its back was considered successful righting as well. Grip strength was determined 
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by placing the mouse on a grid and gently inverting the grid and observing whether or 
not the mouse was able to hold on will suspended upside down. The visual forepaw 
test involved holding the mouse by its tail at a height of about 15cm above a flat 
surface and noting the limbs held close to the body. As the mouse was gradually 
lowered to the surface, successful visual forepaw response was considered if the 
mouse extended its forepaws for a “soft landing” on the horizontal surface before or 
without the whiskers or nose touching. Acoustic startle reflex provides a good 
measure of gross hearing ability and was considered successful if the mouse 
displayed a flinch response to a loud hand clap. All abovementioned assessments 
were measured as a pass-or-fail or yes-or-no response by the human observer. 
 
 
 
 
Supplementary Table 1. General health, sensory-motor and mini-neurological examination. All 
experimental groups had normal coat appearances, appropriate handling responses and home 
cage behavior, intact visual-auditory function and normal basic reflexes, including visual forepaw 
response, acoustic startle and righting reflexes.  
 
Experiment 
group Administration 
Coat 
appearance 
Handling 
response 
Home cage 
behavior 
Visual 
forepaw 
Acoustic 
startle Grip test 
Extension 
reflex 
Righting 
reflex 
Etanercept  
icv Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
ip Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Infliximab  
icv Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
ip Good (14/14) 
Good 
(14/14) 
Good 
(14/14) 
Pass 
(14/14) 
Pass 
(14/14) 
Good 
(14/14) 
Pass 
(14/14) 
Pass 
(14/14) 
PBS 
icv Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
ip Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Non-treated  none Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Wildtype  none Good (15/15) 
Good 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
Good 
(15/15) 
Pass 
(15/15) 
Pass 
(15/15) 
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Supplementary Table 2. Drop-outs and technical failures including, cannula misplacement 
or dislodgement, incorrect ip injections or wrongful genotyping. 
 
Experiment group Administration Start Drop-out Technical Failures Finished 
Etanercept  icv 15 3 2 10 
ip 15 0 1 14 
Infliximab  icv 15 1 3 11 
ip 14 0 0 14 
PBS 
icv 15 1 1 13 
ip 15 1 1 13 
Non-treated  none 15 2 0 13 
Wildtype  none 15 0 0 15 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	  44	  
	  
3  
 
 
Aβ-specific DARPins as a novel class of therapeutics for 
Alzheimer’s disease   
 
 
Michael Hanenberg, Jordan McAfoose, Luka Kulic, Tobias Welt, Fabian Wirth, Petra 
Parizek, Lisa Strobel, Susann Cattepoel, Claudia Späni, Rebecca Derungs, Marcel 
Maier, Andreas Plückthun & Roger M. Nitsch 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  45	  
	  
 
Abstract  
With the advent of recombinant protein expression and efficient in vitro selection 
technologies, a novel class of designed ankyrin repeat proteins (DARPins) are 
beginning to present attractive opportunities for both diagnostic and therapeutic use. 
DARPins are small and highly stable proteins with a compact modular architecture 
ideal for high-affinity protein-protein interactions. In this report we describe the 
selection of Aβ-specific DARPins, determination of their affinities, Aβ epitope 
recognition and binding kinetics. We further showed their in vitro ability to delay Aβ 
aggregation and prevent Aβ-mediated neurotoxicity. To demonstrate their in vivo 
therapeutic potential mono- and trivalent Aβ-specific DARPins (D23 and 3xD23) were 
infused intracerebroventricularly into brains of 11 months old Tg2576 mice over four 
weeks. Both D23 and 3xD23 treatment were shown to result in improved cognitive 
performance and reduced soluble Aβ levels. These findings demonstrate the 
therapeutic potential of Aβ-specific DARPins for the treatment of Alzheimer’s 
disease.   
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3.1 Introduction 
The accumulation of misfolded aggregation-prone proteins as intracellular inclusion 
bodies and extracellular plaques within the brain is a common pathological feature of 
many neurodegenerative diseases. In contrast to their physiological precursors, 
these misfolded proteins often acquire β-sheet structural changes that promote and 
stabilize oligomeric and fibril aggregate formation, as well as, the resistance to 
natural degradation processes and ultimately the gain of toxic properties that lead to 
neurodegeneration. Other shared mechanisms include the cell-to-cell propagation of 
these misfolded proteins (Aguzzi et al., 2009; Lee et al., 2010). From a therapeutic 
point of view, these emerging concepts strongly support the use of 
immunotherapeutic strategies with antibodies that can bind, neutralize, and prevent 
the aggregation and propagation of misfolded proteins throughout the brain. 
 
Based on the effective clearance of β-amyloid from the brains of mouse models of 
brain amyloidosis upon repeated Aβ immunization (Schenk et al., 1999; Morgan et 
al., 2000), numerous immunotherapy clinical trials in humans have subsequently 
been initiated (Rinne et al., 2010; Siemers et al., 2010; Relkin et al., 2009). To-date, 
more than one dozen anti-amyloid immunotherapy clinical trials testing both passive 
immunotherapy and active vaccination strategies are currently underway for the 
treatment of AD (Delrieu et al., 2012). Apart from relatively high costs associated with 
immunoglobulin production and challenges in quality assurance, complex 
glycosylation patterns, the inability to reach intracellular targets and the sensitivity to 
reducing environments may place serious constraints on the use of antibody-based 
immunotherapies. As an alternative, designed ankyrin repeat proteins (DARPins), 
which can be effectively selected in vitro for binding affinities against a broad variety 
of target proteins have begun to provide new therapeutic opportunities (Stumpp et 
al., 2008). 
 
DARPins are built by several ankyrin repeat (AR) modules that are tightly packed and 
capped by terminating capping repeats that shield the hydrophobic core (Binz et al., 
2003). Moreover, DARPins can be conveniently produced in E. coli and the lack of 
cysteines in their primary amino acid sequence provides them with stability in harsh 
intracellular conditions, high thermostability and good solubility with low aggregation 
tendency (Binz et al., 2003; Binz et al., 2004). At one-tenth the molecular weight of 
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IgGs, DARPins are likely to exhibit a higher degree of tissue penetration and might 
cross the blood brain barrier (BBB) more efficiently upon peripheral administration. 
Combined with their ability to rapidly diffuse throughout tissue and an accelerated 
serum half-life (Zahnd et al., 2010), DARPins bound to Aβ could be potentially 
removed quickly and efficiently making them ideal amyloid-lowering therapeutics with 
lower risk for immunogenicity, potential aversive immune reactions and the 
production of neutralizing antibodies following repeated administration. 
 
Here we describe the selection of a novel class of Aβ-specific DARPins, their affinity 
determination and binding kinetics, as well as, their ability to prevent Aβ aggregation, 
reduce Aβ-mediated neurotoxicity and in vivo therapeutic potential in Swedish 
(Tg2576) transgenic mice. 
 
3.2 Materials and Methods 
3.2.1 Preparation of the amyloid-β peptides.  
The full length recombinant Aβ1-42 peptide was purchased from rPeptide (Bogart, 
USA). All biotinylated variants (biot.-Aβ1-28, Aβ1-40-biot. and biot.-Aβ1-42) were 
obtained from Anaspec (Fremont, USA). The lyophilized peptide was prepared as 
previously described (Stine et al., 2003; Wood et al., 1996). Briefly, the peptide was 
dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to yield a final concentration of 
1 µg/µL. The peptides were distributed into 10 – 50 µg aliquots and the HFIP 
completely evaporated under a constant stream of nitrogen. The tubes were snap-
frozen in liquid nitrogen and stored at -80°C until further use. For resuspension, the 
Aβ aliquots were thawed on ice and dissolved in 10 mM NaOH under vigorous 
vortexing and sonication (30 s) to yield a final concentration of 10 – 250 µM. From 
these stock solutions, the peptides were finally diluted into the experimental buffer. 
 
3.2.2 Ribosome display selection of DARPins.  
The enrichment of anti-Aβ DARPins was performed using previously described cDNA 
libraries with two randomised repeat units (N2C) flanked by N- and C-terminal 
capping repeats (Binz et al., 2004). As reported previously, the library was subjected 
to a total of four selection cycles with modifications as follows (Zahnd et al., 2007). 
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A microtiter plate (Nunc, Langenselbold, Germany) was coated with 100 µL of a 66 
nM solution (Tris-buffered saline; pH 7.4) of neutravidin overnight at 4°C. 
Subsequently, wells were blocked with 0.5% bovine serum albumin (BSA) in TBS 
and 100 µL of a solution of C-terminally biotinylated Aβ1-28 (250 nM, in TBS) was 
immobilized. From cycle two onwards, the selection was performed in solution and 
ternary complexes were pulled down with 20 µL of streptavidin (SV) coated magnetic 
particles (Roche, Rotkreuz, Switzerland). Prior to the incubation step with the peptide 
target, the DARPin subpool was depleted from unspecific binders by preabsorption to 
empty SV particles. Selection stringency was increased by a decreased amount of 
biotinylated Aβ1-28 (400 nM in cycle 1, 100 nM in cycles 2 to 4), extended washing 
time and a decreasing number of PCR cycles (40, 35, 30, 28) for re-amplification of 
the reverse-transcribed mRNA pool. After cycle 4, the cDNA was subcloned into 
expression vector pQE-30ss (Huber et al., 2007) and transformed into competent 
E.coli XL-1 Blue.  
 
3.2.3 Screening ELISA.  
Individual clones were picked and grown in deep-well microtiter plates (Nunc, 
Langenselbold, Germany) in 1 mL of LB medium containing 100 µg/mL ampicillin. 
DARPin expression and cell lysis were performed as described by Eggel et al (Eggel 
et al., 2009). For the analysis of individual DARPin clones microtiter plates (Corning, 
Amsterdam, The Netherlands) were coated with 66 nM neutravidin (30 µL/well) 
overnight and 250 nM of the target peptides (30 µL of biotinylated Aβ1-28, Aβ1-40 or 
Aβ1-42) were immobilized for 1 h at 4°C. Binding of the crude extracts to wells 
containing the peptides was compared to wells containing biotin-blocked neutravidin 
alone. After extensive washing with TBS-T (TBS supplemented with 0.05% Tween 
20) bound DARPins were detected via an anti-RGS-His6 antibody (Qiagen, dilution 
1:1000) and an anti-mouse-HRP conjugate (GE Healthcare, dilution 1:2000). The 
assay was developed using 20 µL of a mixture of tetramethylbenzidine (TMB) with 30 
mM citric acid (1:20) and stopped with 20 µL of 1 M H2SO4. The absorbance at 450 
nm was recorded against a reference wavelength of 690 nm with a standard ELISA 
reader Sunrise™ (Tecan, Männedorf, Switzerland). 
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3.2.4 Titration ELISA.  
Biotinylated antigens (biotinylated Aβ1-28 or Aβ1-42) were immobilized on 
neutravidin coated plates in triplicates as described before. Purified DARPins were 
serially diluted in TBS and applied to the wells with previously coated antigen. The 
wells were washed three times with TBS-T between every incubation step and 
detection of bound complexes was performed with an anti-RGS-His6 primary 
antibody (Qiagen, 1:1000) and an anti-mouse-HRP conjugate (GE Healthcare, 
1:2000), diluted in TBS-B (TBS supplemented with 0.5% BSA). After addition of the 
TMB substrate, the signal was recorded at 450 nm against a reference wavelength of 
690 nm. The signals were normalized to the highest absorbance and plotted against 
the logarithm of the DARPin concentration. The data were fitted to a sigmoid dose-
response equation using Graph Pad Prism 5 (GraphPad Software, USA) to calculate 
the half-maximal effective concentration (EC50). 
 
3.2.5 Competition ELISA.  
The competition ELISA was performed as originally described by Friguet et al., 
(1985). with the following modifications: a constant concentration of DARPin (10 nM) 
was incubated with various quantities of soluble Aβ1-42 ranging from 0 to 5000 nM in 
TBS150 for 1 h at 4°C in order to achieve equilibrium. A total of 30 µL of these 
DARPin-antigen mixtures was then transferred into the wells of a microtiter plate 
previously coated with Aβ1-28-biotinyl (30 µL per well at 250 nM in TBS150 for 1 h at 
4°C) and incubated for 30 min at 4°C. In order to probe any readjustment of 
equilibrium, the content of each well was transferred to identically coated wells of a 
second microtiter plate, incubated for the same time and processed as the first plate. 
After three washing steps with TBS-T, bound DARPins were detected using an anti-
RGS-His6 antibody (dilution 1:1000) and an anti-mouse-HRP conjugate (GE 
Healthcare, dilution 1:2000). The fractions of DARPins retained in the first wells was 
computed as described by Friguet et al., (1985) (f < 0.2 was considered a still 
acceptable shift in equilibrium). The absorbance was recorded at 450 nm (reference 
690 nm) and plotted versus the concentration of the competitor. 
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3.2.6 Epitope mapping by monoclonal antibodies.  
Biotinylated DARPin D23 was diluted to 500 nM in TBS150 and immobilized on 
neutravidin-coated wells of a 96-well microtiter plate for 1 h at 4°C. Unbound surface 
sites were blocked with 0.5% BSA dissolved in TBS150. A 50 µg aliquot of Aβ1-42 
was dissolved in 10 mM NaOH to yield a final concentration of 100 µM. The sample 
was vigorously vortexed and sonicated for 30 s and diluted in PBS (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.38 mM K2HPO4, pH 7.4) to a final concentration of 
200 nM. The peptide was incubated in the DARPin-coated wells for 1 h at 4°C. The 
bound peptide was probed with varying concentrations from 10 ng/µL to 0.1 ng/µL of 
monoclonal antibody 6E10, 4G8 (Covance, Basel, Switzerland) and 22C4 (in-house). 
These antibodies are known for their differing linear epitopes on the Aβ1-42 peptides 
comprising residues 1-16, 17-24 and 30-42, respectively (Kim et al., 1988; Mohajeri 
et al., 2002). The antibodies were detected with an anti-mouse-IgG-HRP conjugate 
(GE Healthcare, 1:2000) and revealed colourimetrically using TMB diluted in citric 
acid. 
 
3.2.7 Epitope mapping by peptide competition.  
Aβ1-28-biotin (250 nM) was surface-immobilized on a neutravidin layer in a 96-well 
format as described previously. DARPin D23 was diluted to 50 nM in TBS150 and 
pre-incubated with a 50-fold molar excess of the peptide fragments Aβ(-4-6), Aβ (-3-
7), Aβ(-2-8), Aβ(-1-9), Aβ(1-8), Aβ(2-11), Aβ(3-12), Aβ(4-13), Aβ(5-14), Aβ(6-15) 
(peptides&elephants, Potsdam, Germany), Aβ(1-11), Aβ(1-16), Aβ(12-28), Aβ(17-
28), Aβ(29-40), Aβ(31-35), Aβ(33-42), Aβ(1-28), Aβ(1-28) (Bachem, Bubendorf, 
Switzerland) and scrambled Aβ1-42 (rPeptide, Bogart, USA). The lyophilized 
peptides were dissolved in DMSO to a final concentration of 1 mM and stored at -
20°C until further use. Bound DARPin was detected with an anti-hexahistidine 
antibody (dil. 1:1000, Qiagen, Hildesheim, Germany) and a subsequent anti-mouse 
IgG-HRP conjugate (dil. 1:2000, GE Healthcare,). Revelation was done using TMB 
diluted in citric acid as described before. 
 
3.2.8 Aβ aggregation assays.  
The rate of spontaneous aggregation of the monomeric Aβ peptide into fibrillar 
amyloid structures was monitored via thioflavin T (ThT) fluorescence as described 
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previously (Finder et al., 2010). Briefly, the recombinant Aβ1-42 peptide was 
dissolved in 10 mM NaOH under vigorous vortexing and sonification (1 min) to a final 
concentration of 250 µM. The concentration of the Aβ stock solutions was determined 
spectrophotometrically (ε = 1730 M-1cm-1) as described (Finder et al., 2010). The 
stock solutions were kept on ice und used within 24 h of preparation. The 
aggregation kinetics were performed and monitored in stirred fluorescence quartz 
cuvettes (1 mL) at 25°C using a CaryEclipse fluorescence spectrophotometer 
(Varian, Agilent Technologies, Basel, Switzerland) with external temperature control. 
Unless indicated otherwise, the aggregation mixtures consisted of 50 µM Thioflavin 
T, 150 mM NaCl, 10 mM phosphate with a pH of 7.4. In case of inhibition studies, 
equimolar (5 µM) amounts of DARPin D23 or E2_5 were also included in the assay 
mix. As a last step, the monomeric Aβ1-42 peptide was added freshly to the 
tempered mix at a final concentration of 5 µM. The samples were zeroed and 
aggregation kinetics were immediately monitored by exciting the sample at λ1 = 456 
nm and recoding the emission at λ2 = 489 nm every 2 min (optimal wavelengths 
experimentally determined in pre-experiments with amyloid fibres). 
 
3.2.9 Neurotoxicity assays.  
Primary neurons were isolated from the cortex of rat embryos (day E18). Therefore 
the brains were dissected in ice-cold PBS supplemented with 1 mg/mL glucose 
according to standard protocols (Freshney, 2010). Briefly, the cortices were removed 
from the brains and collected in ice-cold PBS/glucose. After removal of the meninges, 
they were minced and incubated in Dispase II (2.4 U/ml, Roche, Mannheim, 
Germany) at 37°C for 10 min. The enzyme was discarded and the tissue was 
washed with DMEM, supplemented with 10% FCS. After thorough trituration, the 
number of living cells was determined via Trypan Blue staining. The cells were 
pelleted (5 min, 1000 rpm), the medium was removed and diluted to the desired 
density in Neurobasal medium (Invitrogen, Basel, Switzerland), supplemented with 
2% B27 and 125 µM L-glutamine (Invitrogen, Zug, Switzerland). The cells were 
seeded in poly-ornithine-coated plates (either 96-well plates or 24-well plates with 12 
mm round coverslips) at 1 x 103 cells/well (96-well plates) or 1 x 105 cells/well (24 
well plates). The cells were kept in culture for 5 days (days in vitro, DIV) at 37°C and 
7% CO2. The cytotoxicity experiments were started on DIV 6. For this purpose, Aβ 
was prepared as previously described and premixed with Neurobasal medium, 
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DARPin D23 or DARPin E2_5, respectively. Half of the cell culture medium was 
removed and the Aβ / DARPin pre-mix was added onto the cells. Controls were 
treated either with vehicle or with scrambled Aβ (both in 10 mM NaOH / Neurobasal 
medium). The plates were incubated for another 48 h before either the cytotoxic 
effect or neuromorphological changes were measured. For toxicity studies, the 
CytoTox-GloTM Cytotoxicity assay (Promega, Madison, USA) was used according to 
the manufacturer’s instructions. Three wells per treatment were measured and the 
assay repeated two more times. Data are given as means ± SEM.  
 
3.2.10 Cloning strategy for multivalent DARPins.  
The DARPin CDS was excised from the expression plasmid pQE30 (Qiagen, 
Hildesheim, Germany) using the restriction enzymes BamHI and HindIII (New 
England Biolabs, Ipswich, USA). The recipient plasmid (pQI-bi-1_1) was opened with 
the same restriction enzymes. DARPins were first inserted into cassette 1 via a 
BamHI/Hind III restriction digestion and in a separate restriction digestion into 
cassette 2 through the compatible restrictions sites for BgLII and BsaI downstream of 
the linker sequence. An MRGSH6 tag located 5' of the first expression cassette 
allowed purification and detection of the fusion constructs. For the construction of 
trivalent DARPins, the bivalent construct was PCR amplified using the primers 
MVD3_forw (5’-AAAGAGGAGAAATTAACTATGAGAGGATC-3’) and QiBi_MVD_rev 
(5’-AAGGATAGGTCTCAAGCTAGAGAGTCATTACCCCAGGCGTTTAAGG-3’). The 
reverse primer has a 5'-overhang with a BsaI restriction site (underlined, overhang 
restriction). The resulting amplificate was digested using BamHI / BsaI and inserted 
into the pQI-bi-1_1 recipient vector via the restriction sites for BgLII and BsaI. The 
vector had previously been modified to already contain a DARPin in the 5'-expression 
cassette. The resulting trivalent DARPin codes for three in-frame monomer units 
connected by two 10-AA-linkers. The cloning strategy introduced an additional 
transcription termination region (TTR) at the 3' of the expression cassettes. 
 
3.2.11 Surface plasmon resonance.  
SPR was recorded with a Biacore T100 instrument (GE Healthcare) similarly to 
previous descriptions (Binz et al., 2004). A streptavidin SA chip (GE Healthcare) was 
coated with 170 RU Aβ1-28-biotinyl or 250 RU Aβ1-42-biotinyl in 10 mM NaOH. For 
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all subsequent experiments a HBS-EP running buffer (10 mM HEPES, 150 mM NaCl, 
3.4 mM EDTA, 0.05% Tween 20, pH 7.4) was used. Association and dissociation 
events were measured at a constant flow rate of 30 µL/min. Analytes were injected at 
increasing concentrations doubling from 0.5 nM to 512 nM for 12 min and the 
dissociation phase was recorded for 30 - 70 min. Wherever possible, concentrations 
were assessed in duplicates and binding stability monitored to exclude target loss. As 
a correction for non-specific binding, the signal of an uncoated reference cell was 
subtracted from all measurements. The kinetic data obtained were evaluated via 
global fit using the BIAevaluation software 2.0.3 (GE Healthcare). 
 
3.2.12 Animals.  
This study used Swedish tg2576 transgenic mice expressing human APP with the 
Swedish mutation. Mice were bred, held and kept at the Division of Psychiatry 
Research mouse facility under specific pathogen free (SPF) conditions, temperature 
controlled (22 °C±1 °C), 3 to 5 animals per cage, with sawdust as bedding and tissue 
as nesting material. All housing boxes were under individual air ventilation. A 12 hour 
light–dark cycle beginning at 7:00 h was maintained in the housing room and except 
for the time of testing, water and food was provided ad libitum.  Cognitive-behavioral 
testing was performed in a separate room within the mouse facility specifically 
designed for cognitive-behavioral investigations. Experiments were approved by the 
veterinary office of the Cantonal Health Department. 
 
3.2.13 Cognitive-behavioural testing.  
At the time of testing, mice were weighed and examined for general health measures 
to ensure that the mice were physically able to conduct the cognitive-behavioral test 
and to rule out any adverse side effects due to the surgical procedure or DARPin 
therapy; supplementary material. Spatial working memory was assessed in mice 
using the Y-maze (Y-shaped plastic maze, with 40 cm x 20 cm x 10 cm arm sizes). 
During a 5 minute trial the sequence of arm entries was recorded using the ANY-
maze Video Tracking System (Stoelting Co., USA). The percent alternation was 
calculated as the ratio of actual to possible alternations (defined as the total number 
of arm entries -2) x 100%.  
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3.2.14 DARPin icv administration via surgical Implantation of Alzet® osmotic 
minipumps.  
Twelve-month-old tg2576 mice were deeply anaesthetized, a small midline incision 
was made to expose the skull, and a subcutaneous pocket was prepared in the 
midscapular area of the back of the mice so that a sterile Alzet® minipump (model 
2004, 3.0 cm. in length, 0.7 cm. in diameter and weighing 1.1 g empty weight) filled 
with DARPin solution or vehicle could be inserted. Subsequently, an Alzet Brain 
infusion kit 3 cannula was lowered into the left lateral ventricle (coordinates according 
to bregma; AP, -0.2 mm; ML, 0.9 mm; and DV, 2.5 mm) and two small screws were 
placed within the skull and dental cement applied to firmly attach to the skull. Post-
operatively, mice were housed for three days on heat pads and moist food placed at 
the floor of the cage to promote recovery and to reduce drop-outs. Groups of 19-23 
mice received icv-infusion over 28 days (equimolar concentration of 50µM) of either 
D23, 3xD23, E2_5 or PBS control. 
 
3.2.15 Biochemical and Immunohistochemical analyses.  
Mice were deeply anesthetized and blood collected from the right ventricle using a 
syringe with EDTA and samples were centrifuged at 8’000 rpm for 8 minutes at 4°C 
and plasma extracted using a sterile pipette and stored at -80°C for later batch 
analysis. Following the collection of blood, mice were transcardially perfused with 
PBS and their brains rapidly removed. Brains were dissected in two hemispheres 
with the left hemisphere being placed in 4% PFA and post-fixed overnight at 4C° and 
then transferred to 30% sucrose for 72 hours (cyroprotection) for later histological 
analysis.  PFA-fixed and cryoprotected hemibrains were cut in 35 µm thick coronal 
slices at -80°C using a microtome (Leica Jung HN40) and kept at -20°C in an anti-
freeze solution (phosphate buffer 0.50 M in MilliQ water: ethyleneglycol : glycerol = 
1.3:1:1) until staining was performed. The right hemibrain was dissected for 
biochemical purposes and immediately frozen in liquid nitrogen and stored at -80°C. 
Brain tissue was later homogenized using a sequential extraction protocol in which 
tissue was homogenized using a glass-Teflon homogenizer (20 strokes, 315 rpm) in 
RIPA buffer containing complete protease inhibitor tables (Sigma-Aldrich, 
Switzerland), centrifuged at 100,000 x g (53,000 rpm) at 4°C for 1 hour and 
supernatant extracted and stored at -80°C for later biochemical batch analysis. The 
remaining pellet was frozen on dry ice, resuspended in 70% formic acid, sonicated 
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for 30s at 30% power, ultracentrifuged (100,000 x g @ 4°C for 30 minutes), 
supernatant extracted, lyophilized, reconstituted in RIPA buffer and stored at -80°C 
for later batch analysis.  
 
3.2.16 Beta-amyloid analysis.  
Aβ fragments were measured in plasma and brain homogenates using a MSD 3plex 
multi-SPOT Abeta human kit (MesoScale Discovery, USA) for Aβx-38, Aβx-40 and 
Aβx-42, in accordance to manufacturer’s instructions. MSD SECTOR Imager 6000 
reader was used for analysis and the MSD DISCOVERY WORKBENCH software 
(Version 3.0.17) with Data Analysis Toolbox was used to calculate sample 
concentrations by comparing them against a standard curve (five-parameter logistic 
curve).  
 
3.2.17 Immunohistochemistry.  
Thioflavin S staining was done according to standard protocol. In short, floating 
sections were washed in KPBS and mounted on chrom-gelatin coated glass slides 
before being processed. After treatment for 10 min with 0.25% potassium 
permanganate, sections were washed in KPBS and incubated in 1% potassium 
metabisulfite and 1% oxalic acid until they appeared white. Sections were then 
floated 3 seconds in 0.25% acetic acid, washed in water and stained for 5 min with a 
solution of 0.015% Thio-S in 50% ethanol. Finally, sections were washed in 50% 
ethanol and in water, then dried and coverslipped with Hydromount® (National 
Diagnostics, Hull, UK). All chemicals were from Sigma (St. Louis, MO). 
 
3.2.18 Statistical analysis. 
Data analysis was performed using the Statistica 10.0, SPSS 19.0 statistical software 
and GraphPad Prism 4.03 software. Tests for normal distribution were performed 
before statistical testing, according to the results of the Shapiro-Wilk and the 
Kolmogorov-Smirnov Test for normality, either Student’s t Test or Mann-Whitney U 
Test for 2 sample groups or ANOVA was performed (followed by post-hoc Fischer 
LSD analysis or Tukey’s test). A p-value < 0.05 was considered statistically 
significant. Error bars are SEM. 
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3.3 Results 
3.3.1 DARPin D23 specifically binds to soluble monomeric Aβ.  
Ribosome display was used to enrich specific DARPins against the Aβ peptide. A 
cDNA library with two randomized repeat units (N2C) was subjected to surfaces 
coated with C-terminally biotinylated Aβ1-28. This truncated Aβ variant was chosen 
over Aβ1-42 for its reduced propensity to form aggregates. In every round, the 
selection pressure was increased through a decrease in the amount of target 
peptide, increased washing stringency and a reduced number of PCR cycles to re-
amplify the selected subpool. An alternate use of neutravidin and streptavidin 
excluded the erroneous selection against scaffolding proteins. From cycle 2 onwards, 
selection was performed in solution to drive the selection of DARPins recognizing 
soluble Aβ species (Figure 1 A). After four cycles, a screening ELISA revealed 30 out 
of 96 clones as positive (~ 31%) with negligible reactivity to control proteins 
(Supplementary Figure 1). DNA sequence analysis of twenty randomly selected Aβ 
binders confirmed differences mainly at the variable interaction residues and with 
lower frequency also in the N-terminal cap. Due to best performance in a series of 
competition experiments, the DARPin termed D23 was selected as a lead candidate 
for further characterization. A titration ELISA (Figure 1 B) demonstrated that the 
selected clone also recognizes the pathologically relevant variant Aβ1-42 with a 
comparable EC50 in the nanomolar range (17 nM for Aβ1-28 and 31 nM for Aβ1-42). 
The binding of DARPin D23 to surface-immobilized Aβ was specifically competed 
using a molar excess of soluble Aβ1-42 with a 50% drop in binding signal at a 
competitor concentration of approximately 50 nM suggesting that D23 specifically 
binds soluble Aβ1-42 in the low nanomolar range (Figure 1 C). 
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Figure 1. A specific anti-Aβ DARPin was selected in vitro through ribosome display. (a) A DARPin 
N2C library was selected against decreasing amounts of the biotinylated Aβ1-28 peptide via ribosome 
display in four selection cycles. Peptides were presented via neutravidin (cycle 1) or recovered from 
solution through streptavidin-coated particles in all subsequent rounds.  DNA was re-amplified at the 
end of each cycle with decreasing numbers of PCR cycles (arrow numbers). After four cycles, 
individual clones were analyzed for Aβ binding activity through ELISA. (b) DARPin D23 showed a 
superior binding profile as compared to other clones and bound both Aβ1-28 and Aβ1-42 in the 
nanomolar range with an EC50 of 17 nM (Aβ1-28) and 31 nM (Aβ1-42). A non-selected library 
member, E2_5, did not bind Aβ1-42 at any concentration. (c) DARPin D23 binding to immobilized Aβ1-
28-biotin can be inhibited by increasing concentrations of the soluble peptide Aβ1-42. The competition 
shows half-maximal inhibition at approximately 50 nM Aβ1-42. Data represented as means ± SD. 
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3.3.2 D23 binds a conformational Aβ epitope involving the free N-terminus.  
D23 bound three C-terminally biotinylated variants (Aβ1-28, Aβ1-40 and Aβ1-42) with 
similar affinities, but did not recognize N-terminally biotinylated Aβ1-42 in ELISA 
(Supplementary Figure 2). We utilized the three monoclonal antibodies 6E10 (N-
terminus), 4G8 (central domain) and 22c4 (C-terminus) with known epitopes on the 
Aβ peptide to thoroughly analyze the DARPin-bound epitope. The addition of these 
antibodies to a DARPin-immobilized Aβ coat revealed that the DARPin-Aβ interaction 
strongly interfered with peptide recognition by antibody 6E10 and to a lesser extent 
by 4G8 suggesting that the N-terminal Aβ stretch was already bound by DARPin D23 
(Figure 2 A). The use of truncated Aβ1-28 during ribosome display selections 
precluded the interference of DARPin D23 with the C-terminal antibody 22c4 and 
served as maximal readout control for this assay. To dissect the DARPin-Aβ 
interaction more closely, a peptide scanning approach with soluble short Aβ 
fragments was used to compete the DARPin-Aβ1-28 interaction (Figure 2 B). A 50-
fold molar excess of partially overlapping peptide fragments was used for competition 
and only signals above those of scrambled Aβ1-42 were regarded as specific 
inhibition. Not only was the importance of the N-terminal aspartate residue confirmed 
for high affinity binding, but also we observed that longer peptide fragments (Aβ1-16, 
Aβ1-38) inhibited the interaction more effectively than shorter ones suggesting that 
the N-terminal stretch is part of a conformational, rather than a linear epitope. The 
binding mode of D23 is probably different from that of previously mentioned 
monoclonal antibodies that recognize a linear stretch of the Aβ peptide and also 
cross-react to APP (Tampellini et al., 2007) (at least 6E10 and 4G8). This particular 
DARPin binding modality is advantageous as the conformation of the monomeric Aβ 
peptide is most likely different from the one in its parental protein and also limits 
cross-reactivity to APP (data not shown). In an immunohistochemical analysis of 
brain sections from APP transgenic mice, we observed the specific staining of 
parenchymal and vascular amyloid deposits through D23 but not by E2_5 (Figure 2 
C). Importantly, D23 does not cross-react to other brain structures in wild-type mice 
(WT). 
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Figure 2. DARPin D23 recognizes a conformational Aβ epitope and binds amyloid deposits in ex vivo 
murine brain tissue. (a) In a direct ELISA with immobilized DARPin D23, the accessibility of bound 
Aβ1-42 was probed with monoclonal anti-Aβ antibodies directed against the N-terminus (6E10), 
central part (4G8) or C-terminus (22c4) of the peptide. Binding of the N-terminus specific antibody 
6E10 to the Aβ peptide was impaired most. (b) To further determine the Aβ epitope recognized by 
D23, a 50-fold molar excess of Aβ-derived peptide fragments was used to compete DARPin binding to 
immobilized Aβ1-28 peptide and ELISA signals normalized to a non-competed control. Inhibition was 
considered specific if signals were below the one of scrambled Aβ1-42 control (dotted line). A free N-
terminus aspartate residue was required for efficient inhibition, whereas central or C-terminal 
fragments did not show any inhibitory effect. Competition with longer fragments involving a free N-
terminus (Aβ1-16, Aβ1-28, Aβ1-38) showed best inhibition of up to 80%. (c) GFP-fused DARPin D23 
specifically recognizes amyloid-β plaques in brain slices from transgenic ArcAβ mice. The specificity of 
plaque binding by the selected DARPin D23 was confirmed by applying DARPins C-terminally fused to 
superfolder GFP (sfGFP) onto brain sections from wildtype mice (A-C) and ArcAβ (D-F) transgenic 
mice and. D23 recognized vascular and parenchymal amyloid deposits without cross-reactivity to WT 
brain structures. The control DARPin E2_5 did not show any binding activity. First row: DARPin 
binding (GFP channel); middle row: α-Aβ antibody binding (Cy3 channel); bottom row: merge of GFP- 
and Cy3-channel. 
 
 
	  60	  
	  
3.3.3 D23 prevents Aβ aggregation and –mediated neurotoxicity  
To study the DARPin’s functional effect on Aβ aggregation, equimolar concentrations 
of Aβ1-42 were incubated under constant agitation either alone or with DARPins D23 
and E2_5, and thioflavin T (ThT) fluorescence signals were recorded over time 
(Figure 3 A). Whereas a 5 µM preparation of monomeric Aβ1-42 readily aggregates 
into fibrils, the addition of equimolar amounts of D23 – but not E2_5 – is able to 
significantly delay both the lag time and steepness of the aggregation curve. We 
hypothesize that D23 stabilizes the monomeric form of Aβ peptide and sequesters it 
from the dynamic aggregation equilibrium. This idea is underscored by the 
observation that D23 does not interfere with the Aβ aggregation process if added 
during log-phase or after the plateau has been reached, but delays the aggregation 
process if supplemented in substoichiometric amounts at the beginning of the assay 
(data not shown). To analyze the DARPin’s effect on toxicity mediated by soluble Aβ 
species, we determined a 48 hours incubation of 5 µM Aβ as most toxic to a culture 
of rat primary cortical neurons, whereas a preparation of similarly composed 
scrambled Aβ did not induce any toxicity (Supplementary Figure 3). Aβ-mediated 
neurotoxicity was quantified either alone or in equimolar combination with DARPin 
D23 or its control version E2_5. The latter did not show any effect on neurotoxicity, 
while the anti-Aβ DARPin could reduce toxicity by about 40% (Figure 3 B).  
 
 
 
Figure 3. Aβ aggregation and -mediated neurotoxicity can be inhibited through D23 addition. (a) The 
inhibitory effect of DARPin D23 on Aβ1-42 aggregation was monitored by thioflavin T fluorescence 
(ThT). Equimolar concentrations of Aβ1-42 and DARPins D23 or E2_5 were co-incubated and ThT 
fluorescence monitored for 3 hours at 489 nm. DARPin D23 delays Aβ aggregation, whereas E2_5 
has no effect on the Aβ1-42 aggregation profile. The assays were performed in triplicates in stirred 
cuvettes. Data presented as means ± SD. (b) Primary rat neurons (day in vitro 5) were co-incubated 
with equimolar amounts of recombinant Aβ1-42 and DARPins D23 or E2_5 (all components 5 µM). 
After 48 hours the level of Aβ1-42-mediated toxicity was assessed by luminescence emitted from 
released neuronal protease activity. D23 is able to significantly decrease Aβ1-42-mediated cytotoxicity 
as compared to controls (mean ± SEM; * p < 0.05; One-way ANOVA, followed by Tukey's test). 
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3.3.4 Multivalent DARPins improve binding kinetics for immobilized Aβ1-42. 
To further optimize Aβ binding, we constructed bi- and trivalent DARPins that were 
connected by flexible amino acid linkers. DARPins were genetically engineered as 
end-to-head fusions and expressed in a single open reading frame (ORF) as 
previously described (Zahnd et al., 2010). As for the monovalent DARPin D23, 
multivalent constructs were efficiently expressed and purified in a single IMAC-
procedure from bacterial crude cell lysates (Figure 4 A, inlay). Size exclusion 
chromatograms (SEC) confirmed that all constructs eluted as single peaks with 
apparent molecular weights of 12 kDa (D23), 30.4 kDa (2xD23) and 44.3 kDa 
(3xD23) from a SEC column (Figure 4 A). Only minor differences in their 
corresponding EC50 values were observed, when comparing Aβ binding in ELISA 
(Supplementary Figure 4), but a separate kinetic analysis of the association and 
dissociation phases via surface plasmon resonance, revealed substantial differences 
in the on- and off-rates of the individual constructs (Figure 4 B-D). While the 
monovalent DARPin D23 (Figure 4 B) showed a very fast on-rate (kon = 1.26 x 106 M-
1s-1), the association kinetics were decreased by a factor of 40 for the bivalent 
DARPin 2xD23 (kon1 = 3.72 x 104 M-1s-1, kon2 = 4.19 x 10-5 M-1s-1), but only three times 
for the trivalent construct 3xD23 (kon1 = 4.03 x 105 M-1s-1, kon2 = 8.02 x 10-4 M-1s-1; 
Figure 4 C,D). This suggests that DARPin association kinetics are influenced by the 
sterical accessibility to the Aβ peptide rather than by a limited diffusion due to the 
increased molecular weight of the multivalent constructs. The high off-rates of D23 
(koff = 7.3 x 10-2 s-1) indicate that the monovalent DARPin dissociates from its target 
in proportion to its association velocity limiting its affinity to a two-digit nanomolar 
range. An apparent increase in overall affinity of the multivalent constructs 2xD23 
(koff1 = 2.8 x 10-3 s-1, koff2 = 6.3 x 10-4 s-1) and 3xD23 (koff1 = 1.3 x 10-3 s-1, koff2 = 2.0 x 
10-3 s-1) is due to their built-in avidity allowing frequent re-binding to the sensor-
surface. Kinetic data suggest that the construction of the trimeric derivative 3xD23 
best combined a slightly decreased on-rate with a strongly improved off-rate, even 
though this effect can only be exploited in polymeric Aβ species such as oligomers or 
fibrils. Motivated by the promising in vitro features of the selected DARPins, we 
investigated the long-term stability of D23 under physiological conditions 
(Supplementary Figure 5) and were reinforced to investigate the effect of 
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intracerebroventricular infusions of mono- and trivalent DARPin constructs in 
SweAPP transgenic mice. 
 
 
 
 
 
Figure 4. Multivalent DARPin constructs are stable and show improved binding to immobilized Aβ1-42. 
(a) Multivalent DARPin variants of D23 were constructed by fusing monovalent units by 10 AA long 
linkers. These constructs were well expressed and eluted as monomeric peaks from size exclusion 
chromatography with apparent molecular weights of 12 kDa (VE=1.86 mL, D23), 30.4 kDa (VE= 1.57 
mL, 2xD23) and 44.3 kDa (VE=1.45 mL, 3xD23). (b), (c) and (d) Surface plasmon resonance kinetics 
of mono-, bi- and trivalent DARPins on surface-immobilized Aβ1-42. (b) The C-terminally biotinylated 
peptide Aβ1-42 was immobilized on a streptavidin sensor chip and monovalent DARPin D23 was 
injected in duplicates at increasing concentrations of 1 to 128 nM. Association and dissociation phases 
were recorded and the kinetic rate constants kon and koff obtained by global fitting (red dotted lines) of 
the sensorgrams to a 1:1 binding model. The monovalent construct showed very fast on- and off-rates. 
Monovalent D23: kon = 1.26 x 106 M-1 s-1, koff = 7.3 x 10-2 s-1, KD = 5.81 x 10-6 M.  (c) Binding kinetics 
were similarly recorded 2xD23, but fitted to a bivalent binding model. Both on- and off-rates were 
decreased as compared to the monovalent construct. Bivalent 2xD23: kon1 = 3.72 x 104 M-1 s-1, kon2 = 
4.19 x 10-5, koff1 = 2.8 x 10-3 s-1, koff2 = 6.3 x 10-4 s-1. (d) The trivalent construct 3xD23 displayed a 
comparable on-rate to D23 and a decreased off-rate. Trivalent 3xD23: kon1 = 4.03 x 105 M-1 s-1, kon2 = 
8.02 x 10-4, koff1 = 1.3 x 10-3 s-1, koff2 = 2.0 x 10-3 s-1. 
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3.3.5 DARPin therapy improves cognition and lowers amyloid pathology 
Two weeks after surgery, all mice underwent behavioral-testing. No differences in 
general health measures or any treatment-induced side effects were observed across 
all experimental groups (Supplementary Figures 6 and 7). Cognitive assessment in 
the Y-maze revealed a significant improvement in memory function upon treatment 
with both mono- and trivalent anti-Aβ DARPins, as compared to E2_5 and PBS 
treated control mice (p<0.05, Figure 5 A). The increase in spatial alternations could 
not be attributed to an increase in exploration, as the number of total arm entries and 
distance travelled did not differ between groups (data not shown).   
 
Thioflavin S immunohistochemical analysis of brain sections revealed a treatment-
induced trend towards less plaque deposition and size in both D23 and 3xD23 mice, 
as compared to E2_5 and PBS treated mice (Figure 5 B). Since Tg2576 mice only 
begin to deposit plaques at 11 months of age, these results provided the first 
evidence to investigate biochemically the effects of DARPins on amyloid levels in 
both soluble and insoluble fractions.  
 
As a next step, we used MSD analysis to determine Aβ levels in two sequentially 
extracted protein fractions from hemi brain tissue (Figure 5 C-H). In agreement with 
our histological findings, D23 and 3xD23 treated mice showed a significant reduction 
of Aβ in the detergent soluble (RIPA soluble, Figure 5 C-E) protein fraction, as 
compared to E2_5 and PBS control mice. This trend was mirrored in the detergent 
insoluble (formic acid soluble, Figure 5 F-H) Aβ pool, though the effect was less 
pronounced.  
 
These findings provide the first in vivo evidence that DARPins may successfully 
reverse Aβ-mediated cognitive deficits in a transgenic mouse model of brain 
amyloidosis and that the continuous infusion of DARPins can have a modulatory 
effect on brain Aβ levels. 
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Figure 5. DARPin treatment restores memory deficits in APPSwe transgenic mice and influences 
soluble brain Aβ levels. (a) Two weeks after continuous intracerebroventricular infusion of mono- 
(fasciated) and trivalent (black) DARPins Tg2576 mice were cognitively assessed in a Y-maze 
experiment. Animals receiving anti-Aβ therapy performed significantly better than those animals 
receiving a non-specific DARPin (E2_5, grey) or PBS (white).  (b) After four weeks of anti-Aβ therapy, 
animals were sacrificed and the brain cortical area covered by amyloid deposits determined. DARPin 
treatment appears to influence amyloid deposition, but does not reach significance.  (c)-(h) Total levels 
of both soluble (RIPA, c-e) and insoluble (formic acid, f-h) brain Aβ1-38, Aβ1-40 and Aβ1-42 levels 
were measured. Levels of soluble Aβ1-38 in the CNS are significantly decreased for both the mono- 
and the trivalent DARPin and for Aβ1-40 and Aβ1-42 in case of the monovalent variant. Animals per 
group n = 10-12. Data shown as mean ± SEM. Statistical analysis by Mann Whitney U test; * p<0.05; # 
trend p<0.10. 
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3.4 Discussion 
Ribosome display of combinatorial DARPin cDNA libraries have been utilized to 
select for DARPin binders against a diverse set of target proteins with characteristic 
three-dimensional folds, but not against peptide antigens (Baumann et al., 2010; 
Milovnik et al., 2009; Zahnd et al., 2007; DeMattos et al., 2001). In this study we were 
able to select, for the first time, a DARPin binder, termed D23, with nanomolar 
affinities for the Aβ peptide that showed superior binding characteristics in both direct 
and competition ELISA assays. D23 was, therefore, identified as the lead candidate 
for further characterization and to demonstrate the therapeutic potential of DARPins 
administered in vivo for the treatment of brain amyloidosis in APP transgenic mice.  
 
Although the binding of D23 to surface-immobilized Aβ1-28 and Aβ1-42 was shown 
to be in the low nanomolar range, the physiologically more relevant specific binding 
to Aβ in solution needed to be clarified. Indeed, it has been shown that Aβ-binding 
macromolecules can display varying specificities for the quaternary structure of the 
peptide, ranging from soluble monomers (DeMattos et al, 2001), oligomeric 
intermediates (Kayed et al., 2003) to fibrillar states (O’Nuallain et al., 2002). A 
competition assay using freshly dissolved monomeric Aβ1-42 as competitor 
confirmed the observations made with surface-immobilized Aβ and suggested a KI 
value of approximately 50 nM. This inhibition was specific, as the use of scrambled 
Aβ1-42 did not significantly reduce D23 binding to the surface-immobilized target 
(Figure 2 B). We had noticed that C-terminal amino acid extensions (longer than the 
28 residues used for selection) resulted in slightly decreased affinities, but had no 
major influences on the binding properties of D23 to Aβ (Supplementary Figure 2). 
However, modifications at the peptide’s N-terminus, such as the attachment of a 
biotin moiety, resulted in abrogation of the binding. Although we could not entirely 
exclude that this N-terminal modification had any influence on the structure of the Aβ 
monomer, the results likely indicate that the free N-terminus of the peptide must be 
involved in D23 binding. This was confirmed by an epitope mapping approach in 
which three monoclonal antibodies with distinct Aβ specificities were used to 
compete with D23 binding for Aβ. The strongest inhibition was demonstrated for 
6E10, a monoclonal IgG recognizing Aβ residues 1-16, with less interference shown 
for 4G8, an antibody directed against the central domain of Aβ, thus suggesting D23 
binding involves the N-terminus, as well as, parts of the central domain. These 
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findings were directly comparable as both the antibody concentrations and their 
affinities for the Aβ peptide were in similar order of magnitude (Ramakrishnan et al., 
2009). More precise epitope mapping for D23 was investigated using a peptide 
scanning approach, which confirmed the N-terminus binding. However, not all 
fragments with a functional N-terminus displayed equal inhibition, with the highest 
inhibition observed when longer peptide variants were used such as Aβ1-16, Aβ1-28 
and Aβ1-38, suggesting the recognition of a discontinuous rather than linear epitope. 
This observation is in accordance with previous findings that DARPins preferentially 
recognize three-dimensional, structural epitopes due to their intrinsic rigid scaffold 
that displays a relatively shallow and elongated binding interface (Binz et al., 2004; 
Schweizer et al., 2007; Stumpp et al., 2007). 
 
To determine the binding characteristics of D23 ex vivo, we performed GFP-fused 
DARPin immunohistochemical analyses on brain tissue from a mouse model of AD 
(ArcAβ, Figure 2 C). The staining of amyloid deposits by D23 indicates that the 
missense mutation in the Arctic Aβ sequence did not markedly influence D23 binding. 
Moreover, when compared to anti-Aβ antibody stainings, D23 was found to bind 
preferentially the cross-β pleated dense central cores of the amyloid deposits. Such 
findings underscore D23’s recognition of discontinuous amino acid stretches on both 
the N-terminal and central domain of the Aβ peptide that still exist in both the 
monomeric and aggregated form. Non-specific adherence of the hydrophobic internal 
DARPin scaffold to the ‘sticky’ amyloid plaques could be excluded as no tissue 
reactivity was observed with the non-specific E2_5 control DARPin. These findings 
suggest that the binding mode of D23 is fundamentally different from most 
monoclonal antibodies that recognize a linear stretch of both the Aβ peptide and 
APP. The absence of cross-reactivity to APP (data not shown) thus might prove 
advantageous for DARPin-based therapeutic purposes, as peripheral APP would be 
a scavenger that captures the majority of exogenously applied anti-Aβ DARPins. 
 
As a first proof-of-principle, we were able to demonstrate in vitro using Thioflavin T 
(ThT) aggregation assays that D23 could delay Aβ aggregation in both a stirred 
cuvette-based (Figure 3 A) and quiescent microtiter plate assay (data not shown). As 
Thioflavin T only has limited affinity for β-sheets (Hudson et al., 2009; LeVine, 1993), 
we excluded that the addition of other exogenous compounds with higher affinities, 
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such as the DARPin scaffold, leads to a dissociation of the fibril-bound dye. The 
addition of D23 during log phase or after complete fibrillization did not lead to any 
decrease in ThT signal. We did however observe a dose-dependent inhibition of the 
aggregation process, when D23 was added during the lag phase of the ThT assay 
before a seeding of the aggregation process had occurred. This likely indicates that 
D23 binds to and stabilizes monomeric Aβ, thus excluding it from the aggregation 
process. As a further proof-of-principle, we were able to demonstrate that D23, but 
not E2_5 control DARPin, when administered into the medium of rat primary cortical 
neuron cultures could reduce Aβ-mediated neurotoxicity and preserve neuronal 
morphology (Figure 3 B). To optimize D23 binding behavior for potential therapeutic 
use, bi- and trivalent D23 DARPins were engineered by fusing two and three 
monovalent units of D23 into one continuous open reading frame. While these 
multivalent D23 DARPins showed similar structural integrity and binding to the Aβ 
peptide (Figure 4 A, Supplementary Figure 4), surface plasmon resonance kinetic 
analysis revealed differences in on- and off-rates for each individual construct. In 
particular, these findings suggest that the association kinetics of multivalent DARPins 
might be influenced by the sterical accessibility to the Aβ peptide rather than by their 
increased molecular weight and therefore limited diffusion. This is in contrast to 
previous publications where multivalent DARPin constructs did not show altered on-
rates, presumably due to the use of a bulkier protein target that better enabled multi-
unit DARPin recruitment (Eggel et al., 2009).The high off-rates of D23 indicate that 
the DARPin dissociates from its target in proportion to its association velocity limiting 
its affinity to a two-digit nanomolar range (Figure 4 B). An apparent increase of 
2xD23 and 3xD23 in overall affinity is due to their built-in avidity allowing frequent re-
binding to the sensor-surface. Overall, 3xD23 with its slightly decreased on-rate and 
strongly improved off-rate kinetics was identified as a lead candidate for targeting 
polymeric Aβ species such as oligomers or fibrils.  
 
Finally, as a direct proof of therapeutic benefit, we were able to demonstrate the in 
vivo therapeutic potential of D23 and 3xD23 in Tg2576 mice. Following the direct 
intracerebroventricular infusion of mono- and trivalent DARPin constructs over 28 
days treatment, D23 and 3xD23 treated mice showed improved cognitive 
performance, compared to E2_5 non-specific DARPin and PBS treated mice. These 
results were supported by immunohistochemical analyses with trends towards less 
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plaque deposition in both D23 and 3xD23 mice (Figure 5 B). However, as we infused 
anti-Aβ DARPins in Tg2576 mice at 11 months of age, the majority of the amyloid 
burden is still present in soluble Aβ forms explaining the limited number of amyloid 
deposits in the cortices of treated animals. This secondary preventative treatment 
paradigm was underscored by a biochemical analysis that showed further reductions 
of brain Aβ levels for both D23 and 3xD23 treated mice with the most pronounced 
modulatory effects on the soluble Aβ pool (Figure 5 C-E).  
 
Our findings demonstrate the therapeutic potential of Aβ-specific DARPins for the 
treatment of Alzheimer’s disease. With the advent of recombinant protein expression 
and efficient in vitro selection technologies, this novel class of engineered protein 
scaffolds present attractive opportunities for both diagnostic and therapeutic use.  
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3.6 Supplementary Material 
General health, sensory-motor and mini-neurological examination. Mice were 
weighed and their coat appearance, handling responses and home cage social 
behavior registered. More specifically, coat appearance was assessed for matted, 
discolored fur, bald patches, missing whiskers, scarring, or wounds, which might 
otherwise indicate poor health, insufficient grooming, overgrooming and fighting.  
Unusual responses to handling including, extreme jumping, vocalizations, and 
attempts to bite the human handler may indicate poor health and were regarded as 
poor handling responses. Nesting patterns, sleeping in a huddle, allogrooming and 
normal social interaction behaviors were considered as good home cage social 
behaviors, whereas, social withdrawal or isolation, excessive fighting, over grooming 
was regarded as inappropriate home cage social behaviors. Any deviations from 
good coat appearance and appropriate handling responses and home cage social 
behavior would be regarded as poor health and scored as a fail, thus excluding the 
mouse from cognitive-behavioral testing.  Successful righting reflex was recorded if 
the mouse was able to right itself when placed on its back and/or since mice able to 
right themselves often can't be placed on their backs, the inability to place the mouse 
on its back was considered successful righting as well. Grip strength was determined 
by placing the mouse on a grid and gently inverting the grid and observing whether 
or not the mouse was able to hold on will suspended upside down. The visual 
forepaw test involved holding the mouse by its tail at a height of about 15cm above a 
flat surface and noting the limbs held close to the body. As the mouse was gradually 
lowered to the surface, successful visual forepaw response was considered if the 
mouse extended its forepaws for a “soft landing” on the horizontal surface before or 
without the whiskers or nose touching. Acoustic startle reflex provides a good 
measure of gross hearing ability and was considered successful if the mouse 
displayed a flinch response to a loud hand clap. All abovementioned assessments 
were measured as a pass-or-fail or yes-or-no response by the human observer. 
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Supplementary figures 
 
Supplementary figure 1 Results of post-selection screening ELISA. Lysates from several hundred 
clones were probed against Aβ peptides that either were directly immobilized on a microtiter plate 
(Aβ1-42) or bound on a previously coated neutravidin-layer (Aβ1-28-biotin). The thirty best binding 
signals are depicted. Bound DARPins were detected via an anti-RGS-hexahistidine antibody. Clones 
were subdivided into groups that showed a signal-to-noise ratio (S/N)<100 (a) or >100 (b). 
Conformationally-insensitive Aβ1-42 immobilization (black bars) resulted in absence of DARPin 
binding to the plates. The monoclonal anti-Aβ antibody 6E10, used as positive control, does not 
differentiate between the immobilized Aβ species. 
 
 
 
 
Supplementary figure 2 Influence of tag positions on the DARPin-Aβ interaction. Different Aβ 
species with biotin moieties at the N- or C-terminus of the peptide were immobilized via neutravidin on 
microtiter wells. D23 binding was probed at increasing concentrations on the different peptide coats. 
Bound DARPin was detected via an antibody directed against the N-terminal hexahistidine tag. The 
selected DARPin D23 binds longer peptide variants with slightly decreased affinity and shows total 
abrogation of the binding reaction if the biotin moiety is attached to the N-terminus of the peptide. 
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Supplementary figure 3 Determination of neurotoxic Aβ concentrations on primary neuronal 
cultures. Primary cortical neurons from rat embryos were taken into culture and incubated with 
increasing concentrations of recombinant Aβ1-42 or recombinant scrambled Aβ1-42 at DIV5 for 48 
hours. The toxic effect of the peptides was determined by detecting protease activity released from 
damaged cells. Released proteases cleave a substrate that is subsequently used by a luciferase 
enzyme to emit light. Luminescence from vehicle-treated wells was subtracted as background 
correction. A dose-dependent neurotoxic effect for recombinant Aβ1-42 is observed, whereas the 
same concentration of scrambled Aβ1-42 does not produce any toxic effect above background. 
 
 
 
Supplementary figure 4 Multivalent DARPin constructs show minor improvements in anti-Aβ ELISA. 
The mono-, bi-, and trivalent variants of D23 were serially diluted and assessed for Aβ-binding affinity 
via ELISA. All D23 variants show activity in the nanomolar range as determined by a sigmoid dose-
response curve fit (solid and dotted lines). The multivalent variants show a slightly decreased (2xD23) 
and a slightly increased (3xD23) affinity for immobilized Aβ, respectively, but a decreased maximal 
plateau. 
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Supplementary figure 5 Long-term stability of selected DARPins in human serum and saline 
solution. (a) DARPins D23 and 3xD23 were incubated at 25 µM in PBS150 at 37°C and 5% CO2 for 3 
weeks. Samples were drawn at 1 hour, 1 day, 1 week, 2 weeks, and 3 weeks after incubation start 
and compared to freshly prepared samples. After mixing equivolumetric amounts of DARPin with 
loading buffer, the samples were subjected to SDS-PAGE and subsequently stained with Commassie 
Brilliant Blue. The molecular weight standard is shown in kDa. No degradation products can be 
detected. (b) Stability analysis of the DARPin D23 under native conditions using size exclusion 
chromatography. The samples were diluted to 2.5 µM in PBS and injected onto a gel filtration column. 
The respective peak heights and AUCs were compared to chromatograms of freshly prepared 
samples and showed less than 10% degradation during the observation time of three weeks. (c) 
Identical stability testing for the trimeric version 3xD23. (d) Functional analysis of D23 after stability 
challenge in human serum. The DARPin was diluted to 25 µM in 50 % human serum/PBS150 and 
incubated as described before. At each timepoint, the remaining DARPin activity, as measured in an 
anti-Aβ-binding ELISA, was quantified by performing a dilution series (1000, 100 and 10 nM) of the 
DARPin in triplicates. No significant loss of activity was observed even after 3 weeks serum 
incubation. (e) Same analysis as in d for the trimeric version 3xD23. 
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Supplementary Figure 6. General health, sensory-motor and mini-neurological examination. All 
experimental groups had normal coat appearances, appropriate handling responses and home cage 
behavior, intact visual-auditory function and normal basic reflexes, including visual forepaw response, 
acoustic startle and righting reflexes.  
 
 
Supplementary Figure 7. Drop-outs and technical failures including, cannula misplacement or 
dislodgement or wrongful genotyping. 
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Abstract  
Pathogenic APP mutations clustered around position 693 of APP – position 22 of the 
Aß sequence – are commonly associated with congophilic amyloid angiopathy (CAA) 
and intracerebral hemorrhages. In contrast, the “Osaka” (E693Δ) intra-Aß APP 
mutation shows a recessive pattern of inheritance that leads to AD-like dementia 
despite low brain amyloid on in vivo PET imaging. Here, we investigated the effects 
of the “Osaka” APP mutation on Aß accumulation and deposition in vivo using a 
newly generated APP transgenic mouse model (E22ΔAβ) expressing the “Osaka” 
mutation together with the “Swedish” (K670N/M671L) double mutation. E22ΔAβ mice 
exhibited reduced α-processing of APP and early accumulation of intraneuronal 
fibrillar Aβ oligomers associated with cognitive deficits. In line with our in vitro 
findings, aged E22ΔAβ mice showed extracellular CAA deposits in leptomeningeal 
cerebellar and cortical vessels. In vitro results from Thioflavin T aggregation assays 
with recombinant Aβ peptides revealed a yet unknown anti-amyloidogenic property 
of the E693Δ mutation in the heterozygous state and an inhibitory effect of E22Δ 
Aβ42 on E22Δ Aβ40 fibrillogenesis. Moreover, E22Δ Aβ42 showed a unique 
aggregation kinetics lacking exponential fibril growth and poor seeding effects on 
wildtype Aβ aggregation. These results provide a possible explanation for the 
recessive trait of inheritance of the “Osaka” APP mutation and the apparent lack of 
amyloid deposition in E693Δ mutation carriers.  
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4.1 Introduction 
Extracellular deposition of fibrillar amyloid-beta (Aβ) peptide as amyloid plaques and 
congophilic amyloid angiopathy (CAA) is considered a cardinal neuropathological 
feature of Alzheimer’s disease (AD) (Thal et al., 2004; Thal et al., 2008). According 
to the “amyloid cascade hypothesis” soluble and fibrillar Aβ species play a central 
role in the pathogenesis of AD and start to accumulate in brain years before 
cognitive decline and dementia symptoms are observed (Hardy et al., 2002). 
Evidence supporting the “amyloid cascade hypothesis” comes from several sources 
including genetic studies of familial AD cases carrying mutations in the amyloid-beta 
peptide precursor (APP) gene and the presenilin genes (Hardy et al., 2002; Tanzi et 
al., 2005). Pathogenic mutations in the APP gene have been shown to influence the 
metabolism of the Aβ peptide in various ways. The “Swedish” double mutation 
(K670N/M671L), for example, located upstream of the Aβ N-terminus adjacent to the 
β-cleavage site, results in an increased production of both Aβ40 and Aβ42 species 
(Citron et al., 1992; Haass et al., 1995; Mullan et al., 1992), whereas mutations 
located at the γ-cleavage site of APP cause an increase of the Aβ42/Aβ40 ratio and, 
as a consequence of this, result in increased Aβ aggregation and deposition (Bugiani 
et al., 2010; Chartier-Harlin et al., 1991; Eckman et al., 1997; Goate et al., 1991; 
Murrell et al., 1991). The recently discovered E693Δ “Osaka” mutation in a Japanese 
pedigree (Tomiyama et al., 2008) is one of the six so-called “intra-Aβ” mutations 
clustered around the hydrophobic core of the Aβ sequence. Position 693 seems to 
be a critical site involved in pathogenic aggregate formation since mutations at or 
(±1) around this site including the “Dutch” (E693Q) (Levy et al., 1990), “Flemish” 
(E692G) (Hendriks et al., 1992), “Italian” (E693K) (Bugiani et al., 2010), “Iowa” 
(D694N) (Grabowski et al., 2001) and “Arctic” (E693G) (Nilsberth et al., 2001) 
mutations have been reported to result in an increase in total Aβ production (Haass 
et al., 1994) and – with the exception of the “Flemish” mutation – enhance Aβ 
aggregation and toxicity (Fraser et al., 1992; Murakami et al., 2003). Interestingly, all 
currently known intra-Aβ APP mutations – with the exception of E693Δ – have 
previously been shown to be “vasculotropic” and are characterized 
neuropathologically by prominent vascular amyloid deposition (Kumar-Singh et al., 
2009). 
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Although neuropathological data have not been reported to date, homozygous 
carriers of the recessive “Osaka” APP mutation are believed to develop an AD-like 
clinical phenotype in the absence of relevant extracellular amyloid deposition as 
revealed by a very low signal on amyloid PET imaging (Tomiyama et al., 2008). In 
vitro experiments demonstrated enhanced oligomerization but no fibrillization of 
synthetic E22Δ Aβ40 and E22Δ Aβ42 preparations, suggesting that AD-like 
symptoms may be caused by the presence of synaptotoxic Aβ oligomers, rather than 
fibrillar Aβ, in the affected patients (Tomiyama et al., 2008). Consistent with these 
findings, synthetic E22Δ Aβ42 potently inhibited hippocampal long-term potentiation 
(LTP) (Tomiyama et al., 2008; Takuma et al., 2008) and induced synapse loss in 
mouse hippocampal slices (Suzuki et al., 2010). Further cell culture experiments and 
results from the recently reported E693Δ transgenic mouse model revealed 
enhanced accumulation of intraneuronal Aβ oligomers as a prominent feature of the 
“Osaka” APP mutation (Nishitsuji et al., 2009; Tomiyama et al., 2010; Umeda et al., 
2011). E693Δ transgenic mice start to accumulate intraneuronal Aβ aggregates at an 
age of eight months and are completely devoid of extracellular amyloid deposits up 
to an age of 24 months (Tomiyama et al., 2010). The apparent lack of extracellular 
amyloid deposition in these mice has been suggested to be in line with the initial in 
vitro findings with synthetic Aβ preparations that E22Δ-mutated Aβ peptides do not 
form amyloid fibrils (Tomiyama et al., 2008).  
 
Follow-up studies, however, revealed with recombinant Aβ preparations that both 
E22Δ Aβ40 and E22Δ Aβ42 readily formed amyloid fibrils in vitro (Suzuki et al., 
2010; Inayathullah et al., 2011; Ovchinnikova et al., 2011). Based on these findings, 
we hypothesized that E22Δ-mutated Aβ may, in principle, also form amyloid fibrils in 
vivo and generated a novel APP transgenic mouse line (E22ΔAβ) to investigate the 
effects of the E693Δ mutation on amyloid accumulation and deposition in vivo. In line 
with our recent in vitro findings (Ovchinnikova et al., 2011), E22ΔAβ mice were 
characterized by a late but prominent extracellular amyloid deposition in the 
leptomeningeal vasculature at 24 months of age, which was preceded by an early 
accumulation of intracellular oligomeric Aβ species already at an age of three 
months. The results of this study provide strong evidence that E22Δ-mutated Aβ 
species are fibrillogenic, thus placing the E693Δ “Osaka” mutation on the list of other 
“vasculotropic” intra-Aβ APP mutations.  
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4.2 Materials and Methods 
4.2.1 Animals  
The newly generated E22ΔAβ mice express the human APP695 isoform containing 
the “Swedish” (K670N+M671L) and “Osaka” (E693Δ) mutations. The mutations were 
generated by site directed mutagenesis of pGEM-9zf(-)-huAPP695. The cDNA was 
inserted into pMoPrP-Xho (Borchelt et al., 1996), and the construct was sequenced. 
After removal of the vector sequence, the linear construct was injected into pronuclei 
of fertilized zygotes of B6D2F1 mice. Founders were screened for transgene 
expression by tail PCR and Western blot analysis, and the line used in this project 
was expanded on the hybrid background of C57Bl/6 and DBA/2 (B6D2). For all 
behavioral, biochemical and histological analyses offspring from the B6D2 
generation backcrossed once with pure C57Bl/6 was used. Mice were kept on a 12 
hour light/dark cycle at 22°C. Food pellets and water were available ad libitum.  
For histological and Western blot analyses, mice at different ages were anesthetized 
and transcardially perfused with ice-cold PBS. One hemibrain was dissected into 
cortex and hippocampus, frozen in liquid nitrogen, and stored at –80°C. The other 
hemibrain was postfixed in 4 % (w/v) paraformaldehyde in PBS overnight at 4°C and 
embedded in paraffin.  
All animal experiments were performed in compliance with Swiss national guidelines 
and were approved by the veterinarian authorities of the Canton of Zurich.  
 
4.2.2 Protein extracts and Western blotting  
Brain tissues were homogenized with a glass teflon homogenizer in a sixfold wet 
weight amount of “buffer A” containing 100 mM Tris-HCl, 150 mM NaCl, Complete 
Protease Inhibitor Cocktail (Roche Diagnostics) and Phosphatase Inhibitor Cocktails 
1 + 2 (Sigma-Aldrich). After centrifugation at 100’000 g for 1 h supernatants were 
collected (=”Tris fraction”) and pellets were rehomogenized in buffer A containing 1 
% Triton X-100. Centrifugation at 100’000 g was repeated and supernatants were 
again collected (=”Triton fraction”). The remaining pellets were rehomogenized in 
buffer A containing 2 % SDS. After an additional centrifugation step and collection of 
the supernatants (=“SDS fraction”) the resulting pellets were eventually dissolved in 
70% formic acid (FA), sonicated for 30 sec at 30 % power, ultracentrifuged, 
supernatants extracted, lyophilized and reconstituted in buffer A containing 2 % SDS 
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for further analysis. Total protein concentrations were measured with the DC protein 
assay (BioRad Labs). Extracts were separated by SDS–PAGE, blotted onto 
nitrocellulose, boiled for 5 min in PBS, and blocked in TBS containing 5 % milk for 
one hour at room temperature. Primary antibodies were incubated overnight at 4°C 
(6E10 1:500; anti-C-terminal APP (Sigma) 1:2000) and visualized by peroxidase-
conjugated antibodies and ECL reactions (Amersham Biosciences). Monoclonal anti-
β-actin antibody (Abcam, 1:2000) was used as internal loading control and for 
normalization of densitometric analyses of the immunoreactive bands. Quantification 
of the immunoreactive bands was carried out by densitometry of the scanned films 
under conditions of non-saturated signal using the Image J software.  
 
4.2.3 MSD analysis 
Aβ fragments were measured in above mentioned brain homogenate fractions using 
an MSD 3plex multi-SPOT Aβ human kit (MesoScale Discovery, USA) for Aβ38, Aβ40 
and Aβ42, in accordance to manufacturer’s instructions. Human sAPPα levels were 
determined using an MSD 2plex kit, and human Swedish sAPPβ levels were 
determined using an MSD 1plex kit, in accordance to manufacturer’s instructions. 
MSD SECTOR Imager 6000 reader was used for analysis and the MSD 
DISCOVERY WORKBENCH software (Version 3.0.17) with Data Analysis Toolbox 
was used to calculate sample concentrations by comparing them against a standard 
curve (five-parameter logistic curve).  
 
4.2.4 Histological analysis 
Histological stainings were done on 5 µm paraffin brain sections by using standard 
published procedures. For the immunohistochemical detection of intraneuronal Aβ 
deposits, sections were boiled in 10 mM Sodium Citrate Buffer pH 6.0, followed by 
antigen retrieval with 95 % formic acid for five minutes. The following antibodies 
were used for immunohistochemistry: 6E10 (Signet, 1:500 dilution) and β-Amyloid 
Antibody (Cell Signaling, 1:200 dilution) were used for the detection of pan-Aβ. Anti-
β-Amyloid Protein (1-40) antibody (Sigma, 1:100) and BA27 (Wako, Amyloid β-
Protein Immunohistostain Kit) were used to specifically detect Aβ40. Beta Amyloid 
42 Polyclonal Antibody (Signet, 1:100) and BC05 (Wako, Amyloid β-Protein 
Immunohistostain Kit) were used to specifically detect Aβ42. Polyclonal antibodies 
	  80	  
	  
A11 and OC (C. Glabe, both 1:100) were used for the detection of prefibrillar and 
fibrillar Aβ oligomers, respectively. 11A1 (IBL Japan, 1:100) was used to detect Aβ 
with a conformational turn epitope between positions 22 and 23 of the Aβ sequence 
(Murakami et al., 2010). Anti-Amyloid Precursor Protein, C-Terminal antibody 
(Sigma, 1:200) was used for the detection of full length APP and APP C-terminal 
fragments. Secondary antibodies were obtained from Vector Laboratories 
(Vectastain ABC kits PK-6101 and PK-6102) for peroxidase-diaminobenzidine 
stainings, and from Jackson Immunoresearch Laboratories (West Grove, PA) for 
immunofluorescence. 
 
Thioflavin S staining and Congo red stainings were performed according to standard 
protocols as previously described (Knobloch et al., 2007).  
 
4.2.5 Recombinant Aβ production  
Production of recombinant Aβ peptides (wildtype Aβ40 and Aβ42, E22Δ Aβ40 and 
Aβ42, and E22G Aβ40 and Aβ42) was performed as previously described (Finder et 
al., 2010). In brief, recombinant Aβ peptides were expressed under the control of the 
T7 promoter/lac operator in E. coli BL21 (DE3) as fusion proteins to the peptide 
sequence (NANP)19 with an N-terminal hexahistidine tag. Mutagenesis at codon 22 
in both Aβ1–40 and Aβ1–42 was performed with the QuikChange site directed 
mutagenesis kit (Stratagene). The correct genetic sequences of the constructs were 
verified by DNA sequencing. Cleavage of the fusion proteins (100 µM) with 7.5 µM 
tobacco etch virus protease (TEV) was performed in 10 mM Tris–HCl (pH 8.0), 0.5 
mM ethylenediaminetetraacetic acid, and 1 mM DTT for 1 h at room temperature, 
followed by incubation at 4 °C overnight. The cleaved Aβ peptides precipitated 
during the cleavage reactions and were pelleted by centrifugation (4500 g, 20 min, 4 
°C), dissolved in 6M guanidinium chloride–HCl (pH 2.0), and purified via reversed-
phase high-performance liquid chromatography. Peptides were eluted with CAN, 
aliquoted in Protein LoBind Eppendorf tubes (Vaudaux-Eppendorf), lyophilized, and 
stored at −80 °C. The high purity and identity of the peptides were verified by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry using sinapinic 
acid as matrix. 
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4.2.6 Thioflavin T aggregation assays 
Preparation of Aβ solutions and Thioflavin T aggregation assays were performed as 
described earlier (Finder et al., 2010; Ovchinnikova et al., 2011). In brief, Aβ variants 
were dissolved in 10 mM NaOH to concentrations of 100–150 µM. Aβ concentrations 
were determined via the absorbance of Aβ at 280 nm in 10 mM NaOH (extinction 
coefficient at 280 nm and pH 12 corresponding to a single tyrosine residue: 1730 M−1 
cm−1). Stock solutions were kept on ice and were used for aggregation experiments 
within 6 h. Aggregation reactions were performed at 37 °C with 2.5 or 5  µM Aβ (final 
concentration) in 10 mM H3PO4–NaOH (pH 7.4), 100 mM NaCl, and 35 µM 
Thioflavin T in a volume of 1000 µl in stirred quartz fluorescence cuvettes (1 cm—0.4 
cm). The Thioflavin T concentration was determined via its extinction coefficient of 
36,000 M−1cm−1 at 412 nm. Aggregation reactions were started by a dilution of the 
Aβ stock solution in 10 mM NaOH (prepared and ultracentrifuged immediately before 
use) with an aggregation buffer mix, resulting in pH 7.4 and the final concentrations 
indicated above. Thioflavin T fluorescence emission at 482 nm (excitation at 440 nm; 
excitation and emission slit: 1.6 nm) was monitored on a Quantamaster (QM-7/2003) 
fluorescence spectrometer (Photon Technology International).  
 
4.2.7 Cognitive-behavioral testing  
A battery of well-validated and carefully controlled tests was used to behaviorally 
assess mice for motoric and cognitive performance (Crawley, 2007). At the time of 
testing, mice were weighed and examined for general health measures to ensure 
that the mice were physically able to conduct the cognitive-behavioral test. 
 
Locomotor activity in the Open Field Test 
According to published procedures mice were placed in the center of a brightly lit 
white Plexiglas box (50x50cm), and their movements (distance traveled and average 
speed) were tracked using ANY-maze video tracking software (Stoelting Co., USA) 
for 5 min.   
 
Y-Maze 
Spatial working memory was assessed in mice using the Y-Maze (Y-shaped plastic 
maze, with 40 cm x 20 cm x 10 cm arm sizes). During a five-minute trial, the 
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sequence of arm entries was recorded using the ANY-maze Video Tracking System 
(Stoelting Co., USA). The percentage alternation was calculated as the ratio of 
actual to possible alternations (defined as the total number of arm entries -2) x 
100%.  
 
Barnes Maze 
The Barnes Maze was used to assess hippocampus-dependent spatial learning and 
memory (Paul et al., 2009). The Barnes Maze consists of a grey, acrylic, circular disk 
91 cm in diameter with 20 equally spaced holes (5-cm diameter) located 1.5 cm from 
the edge, and elevated 90 cm above the floor. The platform was illuminated by a 100 
W electric bulb located 110 cm above the center of the maze (150 Lux), thus 
providing motivation for the animals to avoid the open surface and escape into a 
small dark recessed chamber (escape box) located under the platform. The inclusion 
of false boxes that look the same as the target escape box but are too small to be 
entered, were used to remove visual cues that might allow the mouse to discriminate 
the location of the escape hole from the other holes. A cylindrical plastic start 
chamber (10.5 cm diameter, 9.5cm height) was used to hold mice in the middle of 
the maze at the start of each trial. A web camera (Logitech) was placed 1.2 m above 
the center of the maze to record trials using the ANY-maze Video Tracking System 
(Stoelting Co., USA). Distinct spatial cues placed in a constant location around the 
maze served as a reference point to learn the position of the escape hole. 
Mice completed four days of acquisition training with four trials per day with an inter-
trial interval of 10-15 minutes. For each trial, mice were placed in the start chamber 
in the middle of the maze and after 10 seconds, the start chamber was raised to start 
the trial and the mouse was allowed to explore the maze for three minutes. During 
these three minutes the latency to enter the escape box, distance travelled, speed, 
time spent immobile and search strategy used was measured, among other 
parameters. The trial ended when the mouse successfully entered the escape box or 
after the three minutes had elapsed. If a mouse did not successfully enter the 
escape box during the three minutes it was placed back at the start position and 
gently guided to the escape hole, where the mouse remained in the escape box for 
one minute. At the end of each trial, mice were returned to their holding cage until 
the next trial. To reduce intra-maze odor cues, the maze surface and escape box 
were cleaned with 70% ethanol after each trial. Search strategies were determined 
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by examining individual track plots for each mouse per day and classifying their 
ability to find the escape location as either; 1) random search strategy – search 
patterns that cross through the center of the maze in a completely random fashion, 
2) serial search strategy – in which mice search every hole or every other hole in a 
clockwise or counterclockwise systematic fashion, or 3) spatial search strategy – in 
which the mice were able to locate the escape box directly plus or minus two 
adjacent holes within the target quadrant only. 
 
4.2.8 Statistical analysis 
Data analysis was performed using the Statistica 10.0 and SPSS 19.0 statistical 
software. Tests for normal distribution were performed before statistical testing, 
according to the results of the Shapiro-Wilk and the Kolmogorov-Smirnov Test for 
normality, either Student’s t Test or Mann-Whitney U Test for 2 sample groups or 
ANOVA was performed (followed by post-hoc Fischer LSD analysis). A p-value < 
0.05 was considered statistically significant. Error bars are SEM. 
 
4.3 Results 
4.3.1 Transgene expression and APP processing  
The newly generated E22ΔAβ mice overexpress the human APP695 isoform 
containing the “Swedish” (K670N + M671L) and “Osaka” (E693Δ) mutations. The 
“Swedish” double mutation was introduced to increase the amount of total secreted 
Aβ without affecting the Aβ42/Aβ40 ratio. Several transgenic founder lines were 
analyzed for brain expression of the full length human APP transgene, and a line 
expressing comparable transgene levels to our APP transgenic arcAβ mouse model 
(overexpression of the “Swedish” and “Arctic” (E693G) mutations) and the widely 
established Tg2576 AD mouse model (overexpression of the “Swedish” mutation 
alone) was chosen for further analysis (Figure 1 A). Western blot analysis of SDS 
extracts revealed similar full length APP and β-stub (C99) levels in the E22ΔAβ, 
arcAβ and Tg2576 mice (Figure 1 A). α-stub (C83) levels, however, were 
significantly reduced in both E22ΔAβ and arcAβ mice as compared to Tg2576 mice 
(Figure 1 A). MSD analysis of soluble APP levels from SDS brain extracts revealed a 
two- to threefold reduction in sAPPα levels in the E22ΔAβ and arcAβ mice. In 
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contrast, sAPPβ levels were comparable to the Tg2576 mice (Figure 1 B). These 
findings indicate that both intra-Aβ APP mutations at position 22 of the Aβ sequence 
specifically interfere with the α-secretase processing of APP in vivo. 
 
	  
Figure 1. Transgene expression and APP processing. A, Western blot analysis of cortical SDS 
extracts from three month-old E22ΔAβ mice in comparison with age-matched Tg2576 and arcAβ 
mice. A C-terminal specific APP antibody (Sigma) was used for the detection of full length APP and 
APP C-terminal fragments (C99 and C83). Values were quantified and normalized to the loading 
control (β-actin). Quantification reveals no significant differences in full length APP and β-stub (C99) 
levels among the three mouse lines. α-stub (C83) levels, however, are significantly reduced and the 
C99/C83 ratio is increased in the E22ΔAβ and arcAβ mice as compared to the Tg2576 mice. * p < 
0.05 E22ΔAβ and arcAβ versus Tg2576 (Mann-Whitney U Test). n = 4 per group. B, MSD analysis of 
sAPPα and sAPPβ levels in cortical samples extracted with Tris buffer containing 2 % SDS. In 
accordance with the results of the APP CTF analysis, sAPPβ levels were not significantly different 
among the three APP transgenic mouse lines, whereas sAPPα was reduced almost threefold in the 
E22ΔAβ and arcAβ mice as compared to the Tg2576 mice. * p = 0.001 E22ΔAβ and arcAβ versus 
Tg2576 (Mann-Whitney U Test). n = 6-8 per group. 
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4.3.2 Age-dependent changes in Aβ levels 
As a next step, we used MSD and Western blot analysis to determine Aβ levels in 
four sequentially extracted protein fractions from cortical brain tissue (Figure 2). In 
agreement with previous findings (Hsiao et al., 1996; Kawarabayashi et al., 2001; 
Knobloch et al., 2007), Tg2576 and arcAβ mice showed an age-dependent 
exponential accumulation of Aβ in detergent insoluble (formic acid soluble) protein 
fractions (Figure 2 E-K) that accompanied the occurrence of parenchymal amyloid 
deposits in these mouse models (data not shown). Aβ accumulation occurred earlier 
and was more pronounced in the arcAβ mice as compared to age-matched Tg2576 
mice (Figure 2 E-K), as previously reported in immunohistological findings (Hsiao et 
al., 1996; Knobloch et al., 2007). In contrast, most of the Aβ in the E22ΔAβ mice 
accumulated in the SDS (detergent-soluble) protein fraction up to the age of 15 
months (Figure 2 A-C). MSD analysis of Tris buffer and Triton X-100 (mild detergent) 
extracts in the E22ΔAβ mice revealed only very low Aβ levels as compared to the 
Tg2576 mice (Figure 2 A-C). In addition, E22ΔAβ mice (similar to the arcAβ mice) 
showed four- to fivefold lower plasma Aβ levels than the Tg2576 mice 
(Supplementary Figure 1). These results indicate that the lack of accumulation of 
detergent insoluble (formic acid soluble) Aβ in the E22ΔAβ mice up to the age of 15 
months was not accompanied by a relative increase in “soluble” brain or peripheral 
(plasma) Aβ levels. Western blot analysis of the four protein fractions at 15 months 
further confirmed the MSD findings (Supplementary Figure 2). At 24 months of age, 
however, a substantial increase in detergent insoluble (formic acid soluble) Aβ was 
observed in the E22ΔAβ mice (Figure 2 D). This change in Aβ solubility provided the 
first biochemical evidence for a substantial accumulation of fibrillar amyloid deposits 
in aged E22ΔAβ mice. 
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Figure 2. MSD analysis of Aβ38 (black column), Aβ40 (grey column) and Aβ42 (white column) in 
cortical samples serially extracted with Tris buffer, Tris buffer containing 1 % Triton, Tris buffer 
containing 2 % SDS and formic acid (FA). A-D, In E22ΔAβ mice most of the Aβ can be detected in the 
SDS soluble protein fraction up to the age of 15 months whereas Tris buffer soluble, Triton soluble 
and FA soluble Aβ levels are comparatively low. In 24 month-old E22ΔAβ mice, however, detergent 
insoluble FA Aβ   D-F, In contrast, Tg2576 mice show higher (Tris and Triton) soluble Aβ levels and a 
prominent age-dependent Aβ accumulation in the detergent insoluble FA fraction at 15 months. G-I, 
Three month-old arcAβ mice show intermediate Tris and Triton soluble Aβ levels (as compared to 
age-matched E22ΔAβ and Tg2576 mice) and early accumulation of FA Aβ (already at the age of six 
months). n = 6-9 per group. 
 
4.3.3 Absence of amyloid plaque deposition and late congophilic amyloid 
angiopathy (CAA) 
Immunostainings of paraffin-embedded brain sections from aged E22ΔAβ mice with 
Aβ-specific antibodies showed no evidence of extracellular parenchymal amyloid 
deposition up to an age of 15 months (Figure 3 A,B). At 24 months of age, however, 
prominent vascular amyloid deposits were observed in cortical and – more 
pronounced – cerebellar leptomeningeal vessels (Figure 4).  Vascular amyloid 
deposits were Thioflavin S (Figure 4 C-E) and Congo red positive (Figure 4 F,G) and 
were immunostained with several Aβ-specific antibodies (Figure 4 A,B,H,I). 
Immunostainings with Aβ40- and Aβ42-specific monoclonal antibodies revealed that 
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Aβ40 was the dominant Aβ species deposited in the vessel walls of the E22ΔAβ 
mice (Figure 4 H,I). 
 
 
Figure 3. Lack of amyloid deposition in 15 month-old E22ΔAβ mice. A-D, Immunostaining with 
antibody 6E10 reveals a complete absence of extracellular amyloid deposits in 15 month-old E22ΔAβ 
mice (A: cortex; B: hippocampus). In contrast, arcAβ mice show a massive extracellular amyloid 
deposition at that age (C: cortex; D: hippocampus). Scale bars: 250 mm (A-D). 
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Figure 4. Aged E22ΔAβ mice develop congophilic amyloid angiopathy (CAA) at 24 months. A+B, 
Immunostaining of amyloid-laden leptomeningeal vessels with polyclonal anti-amyloid antibody 
directed against human pan-Aβ in the cortex (A) and cerebellum (B) of a 24 month-old E22ΔAβ 
mouse. C+D, Vascular amyloid deposits are Thioflavin S (C) and Congo red positive (D). Note the 
classical apple-green birefringence of Congo red stained vessels under polarized light (D). E+F, 
Immunostainings with Aβ40-specific monoclonal antibody BA27 (E) and Aβ42-specific monoclonal 
antibody BC05 (F) reveal that Aβ40 is the dominant Aβ species deposited in the vessel walls. Scale 
bars: 125 mm (A+B), 40 mm (C-F). 
 
4.3.4 Early accumulation of intracellular Aβ oligomers  
Although extracellular (vascular) amyloid deposits were detectable in the E22ΔAβ 
mice only as late as at the age of 24 months, immunostaining of paraffin-embedded 
brain sections with the monoclonal antibody 6E10 revealed prominent intraneuronal 
accumulation of dot-like aggregates mainly in hippocampal CA1 (Supplementary 
Figure 3 A) and cortical (Supplementary Figure 3 B) neurons that were observed 
already at the age of three months (data not shown). Double immunostaining with a 
polyclonal antibody directed against the APP C-terminus (Supplementary Figure 3 
C,D) showed little colocalization of 6E10 and APP immunoreactivity in the cortex and 
hippocampus (Supplementary Figure 3 E,F) thus excluding 6E10-positive 
aggregates as full length APP or APP C-terminal fragments. Immunostaining with 
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Aβ-specific antibodies directed against the C-terminus of Aβ40 and Aβ42 confirmed 
that the intraneuronal deposits indeed corresponded to Aβ aggregates 
(Supplementary Figure 3 G-K). Interestingly, immunostaining with the Aβ40-specific 
antibody led to a more diffuse staining of both dot-like aggregates and neuronal cell 
bodies and processes (Supplementary Figure 3 G,H) whereas the Aβ42-specific 
specifically stained compact intraneuronal aggregates (Supplementary Figure 3 I,K). 
 
Further characterization of the intraneuronal Aβ aggregates in the E22ΔAβ mice with 
several oligomer-specific (conformation-dependent) antibodies revealed that the dot-
like Aβ deposits were strongly stained by the polyclonal OC antibody directed 
against fibrillar Aβ oligomers (Kayed et al., 2007) (Figure 5 A-D), but not the A11 
antibody directed against prefibrillar oligomers (Kayed et al., 2003) (data not shown). 
OC-immunoreactive intraneuronal deposits were observed in CA1 hippocampal and 
cortical neurons as early as three months of age and appeared to grow and become 
more compact as the mice aged (Figure 5 A-D). Strikingly, the intraneuronal 
oligomeric Aβ deposits were also recognized by 11A1 (Figure 5 E,F), a novel 
conformation-dependent monoclonal antibody specifically designed against the turn 
between positions 22 and 23 of the Aβ sequence. 11A1 has recently been shown to 
stain intraneuronal Aβ aggregates in brains of AD patients but not APP transgenic 
mice (Murakami et al., 2010).  
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Figure 5. Intraneuronal Aβ consists of fibrillar oligomers bearing a “toxic turn” conformation. A-D, 
Immunostaining with polyclonal OC antibody directed against fibrillar Aβ oligomers reveals age-
dependent accumulation of intracellular oligomeric deposits in cortical (A,B) and CA1 hippocampal 
neurons (C,D). Note the temporal change of intraneuronal oligomers from rather diffuse and smaller 
dot-like aggregates at three months of age (A,C) to bigger and more compact deposits at 15 months 
of age (B,D). E,F, Conformation-dependent monoclonal antibody 11A1 directed against the turn 
between positions 22 and 23 of the Aβ sequence stains hippocampal (E) and cortical (F) 
intraneuronal aggregates (representative immunostaining in a 15 month-old E22ΔAβ mouse). Scale 
bar: 40 mm (A-F).   
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4.3.5 Early cognitive deficits in transgenic E22ΔAβ mice  
Based on our previous findings in the arcAβ mouse model in which intracellular Aβ 
deposits occurred concomitantly with robust cognitive deficits, we hypothesized that 
the early accumulation of intraneuronal oligomeric Aβ deposits particularly in 
hippocampal brain regions of the E22ΔAβ mice would also be accompanied by 
significant impairments on several cognitive tasks. Both E22ΔAβ mice and wildtype 
littermates displayed, across all age groups, similar general health measures, 
auditory-visual sensory integrity, comparable grip strength, intact righting and 
extension reflexes (data not shown). Assessment of body weight, demonstrated 
equivalent body weights across all experimental groups, for both males and females 
(data not shown). Locomotor and anxiety examination using the open field test 
demonstrated, the widely published phenotype, that transgenic mice, in comparison 
to wildtype littermates, showed increased locomotor activity and exploratory 
behavior, including increased total distance travelled, less time immobile and more 
time spent in the center zone (data not shown). Cognitive assessment in the Y-maze 
demonstrated a significant decrease in the percentage spatial alternation rate for 
E22ΔAβ mice at three months of age (t(55)=-3.16, p<0.005), six months of age (t(28)=-
1.727, p<0.05) and nine months of age (t(16)=-1.772, p<0.05), as compared to their 
wildtype littermates (Figure 6 A). The Barnes maze was also used at 3 months of 
age as a second hippocampus-dependent cognitive task to assess spatial learning 
and memory. Results demonstrated that both wildtype and transgenic E22ΔAβ mice 
showed successful learning, with significantly lower latencies to escape over the four 
days of training (all p’s<0.05, Figure 6 B). Between genotypes, a significant main 
effect was shown for E22ΔAβ mice (f(1,340)=16.656, p<0.001). Fischer LSD post-hoc 
analysis demonstrated a significantly longer latency to escape for E22ΔAβ mice, as 
compared to wildtype littermates on day three (p=0.01) and day four (p=0.03), with 
similar but non-significant trends on day one (p=0.096) and day two (p=0.095) 
(Figure 6 B). Qualitative assessment of Barnes Maze search strategies revealed a 
decrease in spatial search strategies in three month-old E22ΔAβ mice (Figure 6 D), 
as compared to wildtype control mice (Figure 6 C). 
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Figure 6. Early cognitive deficits in E22ΔAβ mice.  A, Cognitive assessment in the Y-maze 
demonstrates a significant decrease in the percentage spatial alternation rate for E22ΔAβ mice as 
compared to their wildtype littermates at three, six and nine months of age. (all p’s<0.05; Student’s t 
Test). B, Assessment of Barnes Maze spatial learning at the age of three months reveals that both 
wildtype and E22ΔAβ transgenic mice show successful learning over the four days of training. 
However, E22ΔAβ mice, as compared to wildtype littermates, show significantly higher latencies to 
escape on day 3 (p=0.01) and day 4 (p=0.03), with similar but non-significant trends on day 1 
(p=0.096) and day 2 (p=0.095) (ANOVA, followed by post-hoc Fisher LSD analysis). C,D, Qualitative 
assessment of Barnes Maze search strategies reveals a decrease in spatial and relative increase in 
serial search strategies in three month-old E22ΔAβ mice (D) in comparison with wildtype control mice 
(C). n = 22-24 per group.  
 
 
4.3.6 Unique aggregation properties of recombinant E22Δ-mutated Aβ 
peptides 
In agreement with our previous findings that both E22Δ Aβ40 and E22Δ Aβ42 readily 
formed amyloid fibrils in vitro, we observed fibrillar (congophilic) amyloid deposits in 
vivo in aged APP transgenic E22ΔAβ mice. Extracellular amyloid deposition in the 
E22ΔAβ mice, however, only occurred as leptomeningeal CAA at an advanced age 
of 24 months (Figure 4), whereas wildtype Aβ producing Tg2576 mice and E22G 
(“Arctic”) Aβ producing arcAβ mice accumulated fibrillar amyloid deposits at a much 
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earlier age (Figure 2, Figure 3). To further investigate the biophysical basis of the 
E22Δ intra-Aβ mutation leading to early intracellular and very late extracellular 
amyloid deposition in vivo, we conducted in vitro Thioflavin T aggregation assays of 
recombinant E22Δ Aβ40 and E22Δ Aβ42 peptides. E22ΔAβ aggregation curves 
were compared to the aggregation curves of wildtype Aβ40 and Aβ42 and E22G 
(“Arctic”) Aβ40 and Aβ42 (Figure 7). Results demonstrated typical aggregation 
kinetics of wildtype Aβ42 and E22G (“Arctic”) Aβ42 peptides involving a lag phase, 
an exponential growth phase and a plateau phase of saturated fibril growth (Figure 7 
A,B). In contrast, no obvious lag phase and no exponential growth phase were 
observed for E22Δ Aβ42 at 2.5 µM (Figure 7 A) and – more obvious – at 5 µM 
(Figure 7 B). Instead, E22Δ Aβ42 showed a constant non-exponential increase in 
Thioflavin T fluorescence from time point 0’ on and – in contrast to E22G Aβ42 and 
wildtype Aβ42 – formed detergent insoluble high molecular weight (HMW) 
aggregates immediately after reconstitution at pH 7.4 as revealed by Western 
blotting of the recombinant peptide preparations that were used for the Thioflavin T 
analysis (Figure 7 C). Thioflavin T analysis of recombinant Aβ40 peptide variants 
revealed a dramatically accelerated fibril formation for both E22Δ and E22G (“Arctic”) 
Aβ40 in comparison with wildtype Aβ40 (Figure 7 D). In contrast to E22Δ Aβ42, 
E22Δ Aβ40 aggregation was characterized by a lag phase, an exponential growth 
phase and a plateau phase with unusually high absolute Thioflavin T fluorescence 
values indicating increased Thioflavin T binding capacity of the E22Δ Aβ40 peptide 
as previously reported (Ovchinnikova et al., 2011). In summary, Thioflavin T analysis 
of recombinant E22Δ Aβ42 and E22Δ Aβ40 aggregation kinetics confirmed our 
previous findings of a highly increased fibrillogenic property of single preparations of 
the two peptide variants (Ovchinnikova et al., 2011). 
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Figure 7. Unique aggregation kinetics of recombinant E22Δ Aβ peptides in vitro. Fibril formation is 
measured via the absolute increase in Thioflavin T fluorescence at 482 nm during aggregation. 
Aggregation of Aβ peptides (identical total monomer concentrations: 2.5 µM in A+C, 5 µM in B) at 
pH 7.4 and 37 °C is initiated by a 10-fold dilution of Aβ stock solutions in 10 mM NaOH with buffer. 
Average curves of three independent experiments are shown (±SEM). A,B, Thioflavin T analysis of 
E22G (“Arctic”) Aβ42 and wildtype Aβ42 reveals typical aggregation kinetics of the two Aβ peptide 
variants: a lag phase, which is shorter for E22G Aβ42  than wildtype Aβ42, is followed by an 
exponential growth phase that eventually reaches a plateau of saturated beta-sheet formation. In 
contrast, no obvious lag phase and no exponential growth phase are observed for E22Δ Aβ42 at 
2.5 µM (A) and – more obvious – at 5 µM (B). Instead, E22Δ Aβ42 is characterized by slow non-
exponential fibril growth, however, forms detergent insoluble high molecular weight (HMW) 
aggregates immediately after reconstitution at pH 7.4 as revealed by Western blotting of the 
recombinant peptide preparations that were used for the Thioflavin T analysis at time point 0’ and time 
point 60’ of the assay (C). D, In contrast to E22Δ Aβ42, E22Δ Aβ40 – similar to E22G (“Arctic”) Aβ40 
– shows an aggregation kinetics characterized by a lag phase, an exponential growth phase and a 
plateau phase. Note the unusually high Thioflavin T fluorescence values for E22Δ Aβ40 in contrast to 
E22G and wildtype Aβ40 and the remarkably shorter lag phases of the E22 mutated Aβ40 variants in 
comparison with the wildtype peptide. E, In contrast to the Aβ42 analysis, Western blot analysis of 
Aβ40 peptide variants reveals no formation of detergent insoluble HMW aggregates at time point 0’.  
	  95	  
	  
4.3.7 Inhibition of E22Δ Aβ aggregation in the presence of wildtype Aβ  
The E693Δ APP mutation is one of the two currently known familial AD mutations in 
the APP gene with a recessive Mendelian trait of inheritance (Di Fede et al., 2009; 
Tomiyama et al., 2008). The second recessive mutation, A673V, has recently been 
shown to be highly amyloidogenic in the homozygous state, but anti-amyloidogenic 
in the heterozygous state as revealed by an inhibition of Aβ aggregation when 
mutated and wildtype peptides were co-incubated (Di Fede et al., 2009). We 
hypothesized similar effects of wildtype Aβ peptides on the aggregation kinetics of 
the E22Δ mutated Aβ peptides for both co-incubated E22Δ Aβ42 with wildtype Aβ42 
(Figure 8 A) and E22Δ Aβ40 with wildtype Aβ40 (Figure 8 B). Strikingly, co-
aggregation of the E22Δ mutated peptides with the respective wildtype peptides led 
to a significant extension of the lag phase and a delay of the growth phase in 
comparison with the aggregation of the respective Aβ peptide variants alone (Figure 
8 A,B). In contrast, co-aggregation of E22G (“Arctic”) Aβ42 with wildtype Aβ42 
revealed a similar aggregation kinetics as aggregation of E22G Aβ42 alone (see 
Figure 8 A), and co-aggregation of E22G Aβ40 with wildtype Aβ40 only slightly 
delayed fibril formation in comparison with E22G Aβ40 alone (Figure 8 B). 
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Figure 8. Anti-amyloidogenic property of E22Δ Aβ peptides in mixtures of different Aβ peptide 
variants. A,B, Co-aggregation of E22Δ Aβ42 with wildtype Aβ42  (A) or E22Δ Aβ40 with wildtype 
Aβ40 (B) leads to a significant extension of the lag phase and a delay of the growth phase in 
comparison with the aggregation of the respective Aβ peptide variants alone (see Figure 7) (total 
monomer concentrations for each peptide variant: 2.5 µM). In contrast, co-aggregation of 2.5 µM 
E22G (Arctic) Aβ42 with 2.5 µM wildtype Aβ42 (A) results in a similar aggregation curve as with 2.5 or 
5 µM E22G Aβ42 alone (see Figure 7). Co-aggregation of E22G Aβ40 with wildtype Aβ40 (B) only 
slightly delays beta-sheet formation in comparison with E22G Aβ40 alone. C, Co-aggregation of E22Δ 
Aβ40 with E22Δ Aβ42 in a physiological 9:1 ratio (total monomer end concentration in solution: 2.5 
µM) leads to a strong inhibition of E22Δ Aβ40 aggregation. Note the dramatic delay of the growth 
phase and remarkable loss of absolute Thioflavin T fluorescence in comparison with E22Δ Aβ40 
alone (Figure 7). In contrast, 9:1 mixtures of E22G Aβ40 and E22G Aβ42 result in an aggregation 
curve very similar to E22G Aβ40 alone. Average curves of three independent experiments are shown 
(±SEM). 
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4.3.8 Inhibition of E22Δ Aβ40 aggregation in the presence of E22Δ Aβ42  
Based on our results that co-incubation of wildtype Aβ with E22Δ Aβ significantly 
delayed amyloid fibril formation we hypothesized that co-incubation of E22Δ Aβ40 
with E22Δ Aβ42 may have similar anti-fibrillogenic effects. Therefore, recombinant 
E22Δ Aβ40 and E22Δ Aβ42 peptides were co-incubated in a physiological 9:1 ratio 
at 2.5 µM, and the increase in Thioflavin T fluorescence was monitored over time 
(Figure 8 C). We found a dramatic delay of the growth phase and a remarkable loss 
of absolute Thioflavin T fluorescence when we compared the aggregation curve with 
the aggregation curve of E22Δ Aβ40 alone (Figure 7 D, Figure 8 C). Again in 
contrast, 9:1 mixtures of E22G Aβ40 and E22G Aβ42 resulted in an aggregation 
curve very similar to E22G Aβ40 alone (Figure 7 D, Figure 8 C).  
 
4.3.9 Poor seeding of wildtype Aβ42 aggregation by E22Δ Aβ42 fibrils 
Based on the assumption that amyloid formation can be seeded by preformed 
amyloid fibrils we finally addressed the question whether preaggregated E22Δ Aβ42 
fibrils were capable of (a) seeding their own growth and (b) seeding the growth of 
wildtype Aβ42 fibrils. As control experiments, wildtype Aβ42 and E22G (“Arctic”) 
Aβ42 fibrils were incubated with preparations of their respective monomeric peptides 
which resulted in an immediate increase in Thioflavin T fluorescence without a lag 
phase thus indicating good seeding properties (Supplementary Figure 4 A,B). 
Incubation of preaggregated E22Δ Aβ42 fibrils with fresh preparations of E22Δ Aβ42 
peptide also resulted in an immediate increase in Thioflavin T fluorescence that was 
steeper as compared to the aggregation curve of E22Δ Aβ42 in the absence of 
fibrillar seeds (Figure 7 A, Supplementary Figure 4 C). However, when E22Δ Aβ42 
fibrils were used for the seeding of wildtype Aβ42, a significant delay of fibril 
formation was observed which indicated poor seeding properties (Supplementary 
Figure 4 E). In contrast, E22G Aβ42 fibrils appeared only slightly inferior to wildtype 
Aβ42 fibrils in seeding wildtype Aβ42 aggregation (Supplementary Figure 4 D).  
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4.4 Discussion 
Homozygous E693Δ APP mutation carriers develop an AD-like clinical phenotype 
characterized by early memory disturbances, visuospatial deficits and executive 
dysfunction, followed by atypical neurological signs including cerebellar ataxia and 
gait difficulties during later stages of the disease (Shimada et al., 2011; Tomiyama et 
al., 2008). Brain amyloid imaging by PIB PET revealed a very weak signal in E693Δ 
APP mutation carriers with advanced dementia suggesting that AD-like clinical 
symptoms occurred in the absence of relevant amyloid deposition in these patients 
(Shimada et al., 2011; Tomiyama et al., 2008). In vitro experiments with synthetic 
E22Δ Aβ40 and E22Δ Aβ42 peptide preparations demonstrated an enhanced 
oligomerization propensity, but no fibril formation and led to the hypothesis that AD-
like dementia can be caused by the sole presence of synaptotoxic Aβ oligomers 
(Tomiyama et al., 2008). In contrast to these initial in vitro findings, subsequent work, 
including our own recent study with highly pure recombinant peptide preparations, 
demonstrated that both E22Δ Aβ40 and E22Δ Aβ42 readily formed amyloid fibrils in 
vitro (Inayathullah et al., 2011; Ovchinnikova et al., 2011; Suzuki et al., 2010). Based 
on these in vitro findings, we hypothesized that E22Δ Aβ40 and E22Δ Aβ42 would, 
at least in principle, also form amyloid fibrils in vivo. Indeed, aged E22ΔAβ mice 
accumulated detergent insoluble (formic acid soluble) Aβ and showed Thioflavin S 
and Congo red positive amyloid deposits in leptomeningeal cortical and – more 
pronounced – cerebellar vessels; in contrast to the recently published E693Δ mouse 
model, which completely lacked extracellular amyloid deposition even at a very 
advanced age (Tomiyama et al., 2010). E22ΔAβ mice highly overexpress human 
APP at levels comparable to those in the Tg2576 mouse line. Moreover, the 
introduction of the “Swedish” (K670N+M671L) double mutation in the E22ΔAβ mice 
results in an additional increase in total Aβ levels (Haass et al., 1995), which might 
explain the differences between our model and the E693Δ mice. Interestingly, CAA 
deposits in the E22ΔAβ mice were more pronounced in the leptomeningeal 
vasculature of the cerebellum than in cortical vessels (data not shown), which is in 
agreement with recent amyloid PET findings in E693Δ mutation carriers showing a 
relative increase in PIB retention in cerebellar brain regions (Shimada et al., 2011). 
The identification of CAA as a key neuropathological feature of aged E22ΔAβ mice 
adds the “Osaka” E693Δ mutation to the list of vasculotropic intra-Aβ APP mutations 
essentially comprising all of the currently known mutations at or around position 22 
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of the Aβ sequence (for a review Kumar-Singh et al., 2009). Our immunohistological 
analysis of CAA deposits identified Aβ40 as the major E22Δ Aβ species depositing in 
the vessel walls of the E22ΔAβ mice which is in in line with previous findings in 
sporadic and familial AD cases (Kumar-Singh et al., 2008; Kumar-Singh et al., 2002) 
including the “Dutch” E693Q APP mutation (Herzig et al., 2004). Further experiments 
are needed to elucidate the mechanisms underlying the “vasculotropism” of E22Δ-
mutated Aβ and whether similar mechanisms as previously reported for the  “Dutch” 
mutation (i.e. a reduced receptor-mediated clearance across the blood brain barrier) 
play a role (Deane et al., 2004; Monro et al., 2002).  
 
E22ΔAβ mice – similar to our previously reported arcAβ mice (Knobloch et al., 2007) 
– develop intraneuronal Aβ aggregates that coincides the cognitive deficits as early 
as three months of age. Intraneuronal Aβ accumulation is generally believed to be an 
early event in AD pathogenesis although it’s relevance and role in the disease 
process remain a controversial topic (Gouras et al., 2010; Tampellini et al., 2010). 
This may partly be due to technical considerations including the use of non-specific 
antibodies for the detection of intraneuronal Aβ. The intraneuronal Aβ aggregates in 
our E22ΔAβ mouse model only partially colocalized with APP/APP C-terminal 
fragments and were stained by different Aβ C-terminus-specific antibodies, which do 
not cross-react with APP or APP fragments, including BC05 and BA27 (data not 
shown) (Winton et al., 2011). These results therefore indicate that the intraneuronal 
aggregates in the E22ΔAβ mice indeed correspond to Aβ and not accumulating 
APP/APP fragments. Further immunohistological characterization of the deposits 
revealed that the intraneuronal aggregates are strongly stained by OC antibody, 
directed against fibrillar oligomers, but not A11 antibody (data not shown), which 
recognizes prefibrillar oligomers (Kayed et al., 2003; Kayed et al., 2007). 
Interestingly, soluble fibrillar oligomers detected by OC antibody (but not prefibrillar 
oligomers) have recently been shown to be elevated in multiple brain regions of AD 
patients and to correlate with cognitive dysfunction (Tomic et al., 2009). Building on 
the hypothesis that intra-Aβ mutations at or around position 22 of the Aβ increase Aβ 
fibrillogenesis through a facilitation of a “toxic turn” conformation between positions 
22 and 23 of the Aβ sequence, Murakami et al. (2010) developed a novel 
monoclonal antibody (11A1) directed against this specific conformational epitope of 
Aβ42 (Murakami et al., 2010). In human AD brains, 11A1 stained both extracellular 
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and intracellular Aβ deposits, whereas, in APP transgenic Tg2576 mice only 
extracellular deposits were labeled (Murakami et al., 2010). Interestingly, 11A1 
stained intraneuronal Aβ aggregates in the brains of the E22ΔAβ mice, suggesting 
that the oligomeric E22Δ-mutated Aβ deposits contained the abovementioned “toxic 
turn” conformation.  
 
Western blot and MSD analysis of APP cleavage products from cortical brain 
extracts revealed a relative increase in amyloidogenic (beta-secretase-mediated) 
APP processing in the two mouse models bearing the E22 intra-Aβ APP mutations, 
which is in accordance with previous in vitro findings (Nishitsuji et al., 2009; Sahlin et 
al., 2007; Stenh et al., 2002). Since both E22ΔAβ and arcAβ mice overexpress 
similar full length APP, sAPPß and C99 levels, but significantly reduced sAPPα and 
C83 levels, as compared the Tg2576 mice, we concluded that the two intra-Aβ 
mutations specifically interfered with the α-secretase cleavage of APP in vivo. 
Previous in vitro reports in the “Arctic” mutation revealed that E693G APP was not a 
poor substrate to α-secretase, but instead reduced APP levels at the cell surface 
making “Arctic” APP less available for α-secretase cleavage, and increasing Aβ 
levels, especially at intracellular locations (Sahlin et al., 2007). Similar to the “Arctic” 
APP mutation, E693Δ APP overexpression in cell culture was also associated with 
reduced extracellular Aβ levels in vitro (Nishitsuji et al., 2009; Sahlin et al., 2007; 
Stenh et al., 2002). Although these results may imply similar effects of the two intra- 
Aβ mutations on APP processing, we currently cannot exclude E693Δ APP as an 
inferior substrate to α-secretase-mediated cleavage thus leading to the relative 
increase in amyloidogenic APP processing; as shown previously for other intra-Aβ 
APP mutations, including the “Flemish” E692G APP mutation (Lammich et al., 1999).  
 
MSD analysis revealed a marked reduction of buffer and Triton buffer soluble brain 
Aβ as well as peripheral plasma Aβ levels, in particular when E22ΔAβ mice were 
compared to age-matched Tg2576 mice expressing wildtype Aβ. This indicated that 
the absence of extracellular amyloid deposition up to an age of 15 months was not 
associated with a relative increase in soluble or peripheral (plasma) Aβ levels. 
Instead, most of the Aβ accumulated in the SDS soluble protein fraction likely 
corresponding to intraneuronal Aβ pools. These results are in agreement with recent 
in vitro results from cell culture experiments showing increased intracellular Aβ 
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accumulation, but markedly reduced secreted Aβ levels in E693Δ APP-transfected 
cell lines (Tomiyama et al., 2008; Nishitsuji et al., 2009; Umeda et al., 2011). The 
early accumulation of intracellular fibrillar oligomeric Aβ deposits in brains of the 
E22ΔAβ mice is in line with the unique aggregation profiles of the recombinant E22Δ 
Aβ40 and E22Δ Aβ42 peptides showing accelerated beta-sheet formation in 
Thioflavin T aggregation assays as compared to the respective wildtype Aβ peptides 
(this study and Inayathullah et al., 2011; Ovchinnikova et al., 2011; Suzuki et al., 
2011). When aggregation curves of E22Δ, E22G and wildtype Aβ40 and Aβ42 were 
compared, E22Δ Aβ42 showed the highest fibrillogenesis propensity as it 
aggregated without a lag phase and formed SDS-resistant amyloid fibrils 
immediately after reconstitution in solution at pH 7.4. However, E22Δ Aβ42 fibril 
growth after reconstitution in solution occurred only in a slow non-exponential 
fashion in contrast to the other peptides, including E22Δ Aβ40, whose aggregation 
was characterized by an exponential growth phase following lag phase. This slow 
fibril growth and lack of exponential growth in E22Δ Aβ42 may be a crucial factor in 
the prevention of extracellular amyloid deposition in the E22ΔAβ mice.  
 
Apart from A673V, a recently described familial AD APP mutation in an Italian 
pedigree, E693Δ is the second currently known recessive APP mutation that is 
pathogenic only in the homozygous state (Di Fede et al., 2009; Tomiyama et al., 
2008). Similar to the A673V mutation, which is anti-amyloidogenic in the 
heterozygous state (Di Fede et al., 2009), our co-aggregation experiments with 
recombinant E22Δ Aβ peptides variants also revealed an inhibition of Aβ 
aggregation when mutated and wildtype peptides were co-incubated. In contrast, co-
aggregation of E22G (“Arctic”) Aβ peptides with the respective wildtype Aβ peptides 
resulted in aggregation curves very similar to those of the E22G Aβ peptides alone. 
Moreover, E22Δ Aβ42 fibrils, in contrast to wildtype Aβ42 and E22G Aβ42 fibrils, 
only very inefficiently seeded wildtype Aβ42 fibrillogenesis. These results provide a 
possible explanation why heterozygous carriers of the E693Δ mutation do not 
develop the disease whereas heterozygous carriers of the autosomal dominant 
“Arctic” mutation develop dementia.  
 
Hence, we propose the following hypothetical model to explain the phenotype of the 
”Osaka” E693Δ mutation, in which E22Δ Aβ aggregation occurs primarily 
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intracellularly where peptide concentrations are high enough to allow for aggregate 
formation (Supplementary Figure 5). Outside the cell, E22Δ Aβ peptide variants may 
interact with each other – and possibly also other peptides – in a way that results in 
an inhibition of aggregation and amyloid seed formation. Moreover, the E22Δ Aβ42 
peptide shows specific aggregation properties (slow non-exponential growth, lack of 
exponential growth phase) that likely further prevent parenchymal amyloid plaque 
deposition (Supplementary Figure 5). However, late vascular amyloid deposition 
occurs, possibly due to the “vasculotropism” of the E22 mutated Aβ peptide variant 
and age-related changes along perivascular clearing pathways (Supplementary 
Figure 5).  
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4.6 Supplementary material 
 
Supplementary Figure 1. Representative western blot analysis of serially extracted cortical samples 
from a 15 month-old E22ΔAβ mouse and age-matched Tg2576 and arcAβ mice. Immunoblotting with 
monoclonal antibody 6E10 reveals only a very faint monomeric Aβ band in the E22ΔAβ mouse, which 
is most readily detectable in the SDS fraction. In contrast, 15 month-old Tg2576 and arcAβ mice show 
a massive accumulation of both monomeric and oligomeric Aβ species throughout the fractions. The 
prominent band at around 100 kDa corresponds to APP. * corresponds to an unspecific protein band.  
 
 
 
 
Supplementary Figure 2. MSD analysis of Aβ38 (black column), Aβ40 (grey column) and Aβ42 
(white column) in plasma samples of E22ΔAβ, arcAβ and Tg2576 mice at three different ages (three, 
six and 15 months). Plasma Aβ levels are up to four- to fivefold lower in the E22ΔAβ and arcAβ mice 
as compared to the Tg2576 mice. Lowest plasma Aβ levels are detected in the E22ΔAβ mice. n = 6-9 
per group.  
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Supplementary Figure 3. Intraneuronal Aβ deposits and APP. A,B: 6E10 immunoreactive dot like 
deposits are readily detectable within hippocampal CA1 (A) and cortical (B) neurons of a 15 month-
old E22ΔAβ mouse. Double immunostaining with a polyclonal antibody directed against the APP C-
terminus (C,D) reveals only partial colocalization of 6E10 and APP immunoreactivity in the cortex (F) 
and virtually no colocalization in the CA1 region of the hippocampus (E). Scale bar: 40 mm (A-F).   
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Supplementary Figure 4. Further characterization of intraneuronal Aβ deposits using Aβ- and 
oligomer-specific antibodies. A,B, Immunostaining with Aβ40-specific polyclonal antibody (Sigma) 
reveals both dot-like and diffuse (arrow) Aβ immunoreactivity in CA1 hippocampal (A)  and cortical (B) 
neurons of a 15 month-old E22ΔAβ mouse. C,D, In contrast, an Aβ42-specific polyclonal antibody 
(Signet) exclusively stains compact (dot-like) intracellular deposits in hippocampal CA1 (C) and 
cortical neurons (D) of the same mouse. E,F, Similar results are obtained using Aβ40-specific BA27 
(E) and Aβ42-specific BC05 (F) monoclonal antibodies (representative immunostainings of cortical 
brain sections from a 15 month-old E22ΔAβ mouse are shown). G,H, Immunostaining with A11 
antibody directed against prefibrillar oligomers reveals no significant immunoreactivity in CA1 
hippocampal (G)  and cortical (H) neurons of a 15 month-old E22ΔAβ mouse. Scale bar: 40 mm. 
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Supplementary Figure 5. Seeding experiments. Recombinant E22Δ, E22G (“Arctic”) and wildtype 
Aβ42 peptides were reconstituted at 2.5 µM (1 ml buffer solution, pH 7.4) and were incubated at 37 ºC 
under continuous stirring to allow for amyloid fibril formation. After 1000 sec (when all aggregation 
curves had reached the plateau phase) 500 µl of the fibril solution were incubated with an identical 
volume of a solution that contained fresh (monomeric) Aβ42 peptides (total monomer concentration of 
fresh peptide: 2.5 µM). Representative figures of at least three independent experiments are shown. 
A-C, Incubation of wildtype Aβ42 (A), E22G Aβ42 (B) or E22Δ Aβ42 fibrils (C) with preparations of 
their respective monomeric peptides results in an immediate increase in Thioflavin T fluorescence 
without a lag phase which indicates good seeding. D, E22G Aβ42 fibrils are slightly inferior to wildtype 
Aβ42 fibrils in seeding wildtype Aβ42 aggregation (note the slight delay of the increase in Thioflavin T 
fluorescence), whereas E, seeding of wildtype Aβ42 aggregation is relatively delayed when wildtype 
Aβ42 monomers are incubated with E22Δ Aβ42 fibrils. 
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Supplementary Figure 6. Hypothetical model to explain the phenotype of the “Osaka” E693Δ APP 
mutation.  
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5 Conclusion and Outlook 
 
 
5.1 Anti-TNF project 
Tobinick and colleagues (2006), demonstrated, in a Phase I clinical trial, that weekly 
perispinal injections of etanercept anti-TNF therapy for six months could ameliorate 
the cognitive deficits in AD patients, as compared to baseline measurement. 
Subsequently, Tobinick and colleagues (2008) later described the rapid cognitive 
improvement in an AD case study following weekly perispinal injections of 
etanercept. These tantalizing effects raised many questions and lead to the 
suggestion that etanercept anti-TNF therapy might inhibit neuroinflammatory 
responses, stabilize TNF-mediated synaptic dysregulation, or possibly through TNF- 
or Fc-mediated mechanisms lower amyloid pathology. Not surprisingly, etanercept 
anti-TNF therapy has now entered Phase II clinical trail investigations, albeit, the 
underlying therapeutic mechanisms remain to be fully resolved. In Chapter 2, we 
sought to investigate in an AD mouse model the underlying therapeutic mechanisms, 
with particular emphasis on determining if anti-TNF therapy could rescue cognitive 
deficits, lower amyloid pathology and inhibit neuroinflammation.  
Our findings demonstrated that anti-TNF etanercept therapy, administered 
intracerebroventricularly (28 days infusion) or intraperitoneally (4 weekly ip 
injections) could rescue cognitive deficits, as well as, reduce amyloid plaque 
deposition in 12 month old arcAβ mice. Here we choose to use to modes of 
administration (icv infusion and ip injections) in order to differentiate between the 
therapeutic effects of directly modulating TNF-mediated responses within the central 
nervous system, versus systemic TNF-mediated immune/inflammatory processes 
and/or its important role in brain-immune signaling. Our findings showed that similar 
to icv-treated mice with wide distrubtion of the etanercept, ip-treated mice also 
showed diffusion of the biologic within the brain at sites of impaired blood-brain-
barrier (BBB). Indeed, impaired BBB integrity and other vascular changes have been 
widely described in the ArcAβ mice (Knobloch et al., 2007; Merlini et al., 2011), and 
future experiments using an alternative AD mouse model, such as tg2576 mice, 
which lack pronounced vascular pathology might be better able to differentiate 
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between central and peripheral modes of action of anti-TNF therapy. Here, however, 
in our study, the entry of peripherally administered etanercept within the brain 
excludes any restricted systemic effect of anti-TNF treatment and lends support 
towards a CNS-delivered therapeutic approach. However, with Phase II clinical trials 
underway to investigate the therapeutic potential of subcutaneously administered 
etanercept in Alzheimer’s disease patients, it will be possible to determine, in human 
subjects, if systemic anti-TNF therapy may have beneficial effects as well. To 
investigate transient versus long-term effects of TNF inhibition, we also included in 
this study ArcAβ mice backcrossed with TNF knockout mice. These mice allowed us 
to investigate the development of amyloid pathology in the absence of TNF 
expression. The histological and biochemical results from these experiments were in 
line with acute anti-TNF therapy in which we could demonstrate that ArcAβ mice on 
a TNF deficient background showed improved cognitive performance, lower amyloid 
pathology, reduced astrocytosis and increased microglia activation. 
As mentioned above, cognitive assessment in both the Ymaze and NORT 
demonstrated improvements in cognitive performance for both icv- and ip-treated 
mice, as compared to controls. Importantly, the improvement seen in cognitive 
performance was comparable to wildtype mice, suggesting a full rescue in cognitive 
deficits. Moreover, given the short duration of treatment (1 month), our findings 
support the rapid cognitive rescue observed in humans following etanercept anti-
TNF treatment (Tobinick et al., 2008). These behavioral findings were supported by 
histological reductions in the number of plaques, as well as, lower percentage area 
covered by plaques in icv- and ip-treated mice, as compared to controls. Upon 
further histological investigations, etanercept icv-treated mice were shown to display 
increased CAA as compared to controls, suggesting a redistribution of parenchymal 
plaques towards the vasculature. As a potential consequence of this redistribution 
we investigated for a possible increase in micro-bleeds, but found no correlation 
between treatment and the frequency of micro-bleeds. Indeed, our results 
demonstrated that many areas of heavy CAA deposition in etanercept icv-treated 
mice did not show signs of micro-bleeds, suggesting an amyloid-induced risk for 
micro-bleeds and not a treatment-induced risk for micro-bleeds, per se. However, 
one possible explanation for these findings could be that these micro-bleed free 
areas of heavy CAA deposition might reflect newly formed CAA pathology following 
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anti-TNF treatment induced redistribution of amyloid towards the vasculature and 
that with time, if not cleared efficiently, these vessels might deteriorate, lose their 
integrity and begin to bleed. Future experiments should therefore look to identify the 
temporal change in CAA pathology and how these changes over time may or may 
not lead to micro-bleeds. 
We were also able to demonstrate biochemically, using MSD multi-SPOT 
elctrochemiluminesces to measure Aβ levels, that icv- and ip-treated etanercept 
mice showed significant reductions in detergent insoluble formic acid fraction Aβ 
levels, as compared to control mice. Together, these findings provide evidence that 
anti-TNF etanercept treatment may successfully reverse Aβ-mediated cognitive 
deficits in an AD mouse model and that the continuous infusion of etanercept may 
have a modulatory effect on brain Aβ levels, as well as, amyloid deposition. Indeed, 
it has been widely shown that TNF over-expression may promote amyloid plaque 
deposition, as well as, mediate amyloid induced cognitive dysfunction (He et al., 
2007; Rowan et al., 2007; Wang et al., 2005). Medeiros and colleagues (2007) 
demonstrated that TNF signaling pathways and iNOS act as central mediators of Aβ 
with both pharmacological and genetic blockage of TNF and iNOS improving 
cognitive deficits evoked by Aβ. Other evidence supports the role of TNF-mediated 
synaptic dysfunction in the progression of AD following prolonged Aβ-induced 
neuronal inactivity (Small, 2008). 
Histological findings demonstrated in icv-treated mice that anti-TNF treatment 
resulted in the lowering of reactive astrocytosis. Such findings suggest a 
normalization of reactive astrocytes towards physiological conditions and lend 
support for an anti-TNF therapy mediated reversal of TNF-mediated synaptic 
dysfunction. In pilot study (data not shown) we were able to show that acute 
administration of anti-TNF therapy resulted in a partial rescue of LTP deficits in 
ArcAβ transgenic mouse hippocampal slices. Future experiments are planned to look 
at both the genetic and pharmacological inhibition of TNF in ArcAβ transgenic 
hippocampal slices and synaptic activity. Such studies could determine for the first 
time if anti-TNF therapy can restore altered synaptic activity. Similarly, it is possible 
with such experimental methods to decipher the exact cellular mechanisms involved, 
with speculations that astrocytic release of TNF during prolonged neuronal inactivity 
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(synaptic scaling) maybe an early compensatory response in Alzheimer’s disease 
pathogenesis that later leads to synaptic dysregulation. 
Lastly, in this study we were able to show in icv-treated mice and ArcAβ TNF 
knockout mice an increase level of actived microgliosis. It is hypothesized that during 
normal disease progression the overexpression of TNF may interfere with microglia 
activation and that following anti-TNF therapy microglia resume a more activated 
state that promotes effective amyloid plaque clearance. Here, future studies, using 
two-photon microscopy might be able to determine the time dependent activation 
state of microglia before and after anti-TNF treatment and if following treatment 
these activated microglia become more efficient in phagocytizing amyloid plaques. 
Combined, our results indicate that anti-TNF therapy may restore physiological 
astrocyte functions, promote microglia activation, reduce amyloid burden and 
successfully reverse abeta-induced cognitive deficits in 12 month old arcAβ 
transgenic mice.  
 
5.2 DARPin project 
In the last decade numerous amyloid-lowering therapeutic approaches have been 
developed and brought into clinical trial investigations. As an alternative, we 
described in Chapter 3, the selection of a novel class of Aβ-specific DARPins, their 
affinity determination and binding kinetics, as well as, their ability to prevent Aβ 
aggregation, reduce Aβ-mediated neurotoxicity and in vivo therapeutic potential in 
Swedish (Tg2576) transgenic mice. At one-tenth the molecular weight of IgGs, 
DARPins are likely to exhibit a higher degree of tissue penetration and increased 
ability to cross the blood brain barrier (BBB) upon peripheral administration, with 
lower risk for immunogenicity, potential aversive immune reactions and the 
production of neutralizing antibodies following repeated administration. In this study 
we were able to select, for the first time, a DARPin binder, termed D23, with 
nanomolar affinities for the Aβ peptide that showed superior binding characteristics 
in both direct and competition ELISA assays.  
Epitope mapping confirmed that D23 binding involves the N-terminus, as well as, 
parts of the central domain, with evidence to suggest D23’s recognition of a 
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discontinuous rather than linear epitope. This observation is in accordance with 
previous findings that DARPins preferentially recognize three-dimensional, structural 
epitopes due to their intrinsic rigid scaffold that displays a relatively shallow and 
elongated binding interface (Binz et al., 2004; Schweizer et al., 2007; Stumpp et al., 
2007). To determine the binding characteristics of D23 ex vivo, we performed GFP-
fused DARPin immunohistochemical analyses on brain tissue from a mouse model 
of AD. The staining of amyloid deposits by D23 indicates that the missense mutation 
in the Arctic Aβ sequence did not markedly influence D23 binding and that when 
compared to anti-Aβ antibody stainings, D23 was found to bind preferentially the 
cross-β pleated dense central cores of the amyloid deposits. Together these findings 
suggest that the binding mode of D23 is fundamentally different from most 
monoclonal antibodies that recognize a linear stretch of both the Aβ peptide and 
APP. The absence of cross-reactivity to APP might be considered advantageous for 
DARPin-based therapeutic purposes, as peripheral APP would be a scavenger that 
captures the majority of exogenously applied anti-Aβ DARPins.  
Subsequently, we were able to demonstrate in vitro using Thioflavin T (ThT) 
aggregation assays that D23 could delay Aβ aggregation. As a further proof-of-
principle, we were able to demonstrate that D23, but not E2_5 control DARPin, when 
administered into the medium of rat primary cortical neuron cultures could reduce 
Aβ-mediated neurotoxicity and preserve neuronal morphology. To optimize D23 
binding behavior for potential therapeutic use, bi- and trivalent D23 DARPins were 
engineered by fusing two and three monovalent units of D23 into one continuous 
open reading frame. While these multivalent D23 DARPins showed similar structural 
integrity and binding to the Aβ peptide, surface plasmon resonance kinetic analysis 
revealed differences in on- and off-rates for each individual construct.  
Finally, as a direct proof of therapeutic benefit, we were able to demonstrate the in 
vivo therapeutic potential of D23 and 3xD23 in Tg2576 mice. Here we directly 
infused mono- and trivalent DARPin constructs intracerebroventricularly over 28 
days. Following infusion D23 and 3xD23 treated mice demonstrated improved 
cognitive performance, compared to E2_5 non-specific DARPin and PBS treated 
mice. These findings were supported by histological and biochemical analyses with 
trends towards less plaque deposition and significant reductions of brain Aβ levels 
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for both D23 and 3xD23 treated mice; with the most pronounced modulatory effects 
on the soluble Aβ pool.  
 
5.3 Delta project 
In 2008, it was described by Tomiyama and colleagues that a rare mutation in APP 
at site 693 (E693Δ) lead to the development of AD-like dementia in homozygous 
carriers. Interestingly, these patients demonstrated very weak PET PIB signaling, 
suggesting the absence of relevant amyloid deposition in these patients (Shimada et 
al., 2011; Tomiyama et al., 2008). In vitro experiments with synthetic E22Δ Aβ40 and 
E22Δ Aβ42 peptide preparations demonstrated an enhanced oligomerization 
propensity, but no fibril formation and led to the hypothesis that AD-like dementia 
can be caused by the sole presence of synaptotoxic Aβ oligomers (Tomiyama et al., 
2008). In contrast to these initial in vitro findings, subsequent work, including our own 
recent study with highly pure recombinant peptide preparations, demonstrated that 
both E22Δ Aβ40 and E22Δ Aβ42 readily formed amyloid fibrils in vitro (Inayathullah 
et al., 2011; Ovchinnikova et al., 2011; Suzuki et al., 2010). Based on these findings, 
we hypothesized that E22Δ Aβ peptides could indeed form amyloid fibrils in vivo. As 
shown in Chapter 4, E22ΔAβ mice displayed increased levels detergent insoluble 
(formic acid soluble) Aβ in brain homogenates at 24 months of age. Moreover, these 
aged mice demonstrated Thioflavin S and Congo red positive amyloid deposits in 
leptomeningeal cortical and – more pronounced – cerebellar vessels. The 
identification of CAA as a key neuropathological feature of aged E22ΔAβ mice adds 
the E693Δ mutation to the list of vasculotropic intra-Aβ APP mutations essentially 
comprising all of the currently known mutations at or around position 22 of the Aβ 
sequence (for a review Kumar-Singh et al., 2009). However, further experiments are 
needed to elucidate the mechanisms underlying the “vasculotropism” of E22Δ-
mutated Aβ and whether similar mechanisms as previously reported for the  “Dutch” 
mutation (i.e. a reduced receptor-mediated clearance across the blood brain barrier) 
play a role (Deane et al., 2004; Monro et al., 2002).  
We were also able to demonstrate in this study that E22ΔAβ mice – similar to our 
previously reported arcAβ mice (Knobloch et al., 2007) – develop intraneuronal Aβ 
aggregates at a very young age and that these intraneuronal aggregates correlate 
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with cognitive deficits. Immunohistological characterization of the deposits revealed 
that the intraneuronal aggregates were strongly stained by OC antibody, directed 
against fibrillar oligomers, but not A11 antibody, which recognizes prefibrillar 
oligomers (Kayed et al., 2003; Kayed et al., 2007). Building on the hypothesis that 
intra-Aβ mutations at or around position 22 of the Aβ increase Aβ fibrillogenesis 
through a facilitation of a “toxic turn” conformation between positions 22 and 23 of 
the Aβ sequence, Murakami et al. (2010) developed a novel monoclonal antibody 
(11A1) directed against this specific conformational epitope of Aβ42 (Murakami et 
al., 2010). Interestingly, 11A1 stained intraneuronal Aβ aggregates in the brains of 
the E22ΔAβ mice, suggesting that the oligomeric E22Δ-mutated Aβ deposits 
contained the abovementioned “toxic turn” conformation.  
Apart from A673V, a recently described familial AD APP mutation in an Italian 
pedigree, E693Δ is the second currently known recessive APP mutation that is 
pathogenic only in the homozygous state (Di Fede et al., 2009; Tomiyama et al., 
2008). Similar to the A673V mutation, which is anti-amyloidogenic in the 
heterozygous state, our co-aggregation experiments with recombinant E22Δ Aβ 
peptides variants also revealed an inhibition of Aβ aggregation when mutated and 
wildtype peptides were co-incubated. In contrast, co-aggregation of E22G (Arctic) Aβ 
peptides with the respective wildtype Aβ peptides resulted in aggregation curves 
very similar to those of the E22G Aβ peptides alone. Moreover, E22Δ Aβ42 fibrils, in 
contrast to wildtype Aβ42 and E22G Aβ42 fibrils, inefficiently seeded wildtype Aβ42 
fibrillogenesis. These results provide a possible explanation why heterozygous 
carriers of the E693Δ mutation do not develop the disease whereas heterozygous 
carriers of the autosomal dominant Arctic mutation develop dementia.  
Future research is planned to determine the pathological mechanisms of E693Δ 
mutation on tau pathology. For these experiments, we have crossed our E693Δ 
mouse model with Tau P301L transgenic mice. Preliminary findings suggest that, 
unlike arcAβ/Tau P301L double transgenic mice, E693Δ/Tau P301L mice do not 
develop pronounced tau pathology. These findings raise interesting questions as to 
how E22Δ Aβ fibrils exert their toxic effects. 	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